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i Abstract  
Inflammation is a central component of the immune response. In its acute form it aids 
the transition from disease to health via the activation of numerous immune cells, 
enabling them to reach the site of infection/injury and orchestrate themselves to combat 
pathogens, facilitating resolution and repair to restore the host to health. However, 
chronic inflammation is deleterious to the host and differs from the “classical” acute 
inflammatory process in that the inflammation is not necessarily so readily obvious and 
is not self-limiting; rather, the immune system is in a constant state of low-grade 
activation and when challenged by pathogenic or sterile injury the response is 
heightened, resulting in prolonged tissue damage and a failure of efficient resolution 
mechanisms.  
Neutrophils are important mediators of acquired innate immune responses but may also 
contribute to the pathogenesis of chronic inflammatory diseases. Neutrophils are 
heavily involved in antimicrobial defence; their primary role is the localisation and 
elimination of pathogenic microorganisms. This, combined with their relatively short 
lifespan, has resulted in a traditional view of them as limited “kamikaze” cells. 
However, as detailed here, neutrophils have been shown to act with complexity and 
sophistication, orchestrating the immune/inflammatory response but also inadvertently 
contributing to tissue damage in different disease states. This thesis includes the study 
of neutrophil function in acute inflammatory episodes such as gingivitis and more 
chronic long-term health conditions such as obesity,chronic periodontitis and Papillon-
Lefèvre Syndrome. The findings outlined here support the role of neutrophils as 
important contributors to both acute and chronic disease, showing these cells to be far 
more sophisticated than previously regarded. 
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1.1. The neutrophil 
1.1.1. Origin and role in the body 
The human innate immune system is comprised of various cells, their secreted 
proteins/peptides and the complement system, providing an effective defence against 
pathogenic organisms. Neutrophils, along with basophils and eosinophils, are members of the 
granulocyte family of white blood cells, also known as leukocytes (Ehrlich 1880). These 
terminally differentiated phagocytic cells amount to 50-60% of all circulating leukocytes; 
they are short-lived cells with a circulatory lifespan of up to 5.4 days (Pillay et al. 2010). In 
the absence of infection/inflammation, neutrophils in circulation die by a spontaneous 
apoptosis program (Geering & Simon 2011) and apoptotic bodies are cleared by 
macrophages (Bratton & Henson 2011). Neutrophils are approximately 12-14µm in diameter 
and feature a characteristic multi-lobed nucleus which facilitates the elastic nature of the cell, 
allowing it to rapidly leave the blood circulation when required (Dong et al. 1991). Under 
normal physiological conditions neutrophils are generated in the bone marrow at a rate of 
10
11
 cells a day, however this number can increase tenfold upon exposure to injurious agents 
(Cannistra & Griffin 1988). Mature neutrophils differentiate from haematopoietic stem cells 
in the bone marrow by a process known as granulocytopoiesis (Borregaard 2010) and the 
release of neutrophils from the bone marrow is tightly regulated; the small percentage that is 
constitutively present are confined to the vascular capillaries in the absence of 
infection/injury. Stimulation of granulopoiesis is a multi-step process culminating in the 
release of neutrophils into the circulation from the bone marrow and is initiated by the 
production of the cytokines granulocyte-colony stimulating factor (G-CSF) and granulocyte 
macrophage-colony stimulating factor (GM-CSF) by immune cells, such as tissue 
macrophages and mast cells, which become activated upon exposure to an infectious 
challenge such as pathogenic agents or apoptotic host cell material (Stark et al. 2005). 
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Exposure to G-CSF/GM-CSF alters the expression of particular neutrophil cell-surface 
receptors, dictating their confinement or release into the circulation; expression of the 
chemokine receptor CXCR4 ensures neutrophils remain within the bone marrow (Eash et al. 
2009) whereas CXCR2 allows the cells to be released into the circulation, migrating to a 
potential site of injury/inflammation (Theilgaard-Mönch et al. 2005) in a process known as 
transendothelial migration (TEM).  
1.2. Transendothelial migration (TEM) 
Leukocytes can migrate from the circulation to elicit immune responses via two major routes: 
migration into lymph nodes via venules to the lymphatic system and direct movement into 
inflamed sites/tissues. TEM, also known as diapedesis, describes the multistep process by 
which immune cells, including neutrophils, exit the circulatory system to reach the site of 
inflammation (Figure 1.1). This cascade of events is initiated by resident immune cells such 
as macrophages or dendritic cells (DCs) at the site of injury/infection, which detect foreign 
particles such as bacteria, fungi and viruses (and their products) or signals emanating from 
damaged tissues. Exposure to any of these agents results in the secretion of inflammatory 
mediators, such as histamine, cytokines and leukotrienes, which in turn activate endothelial 
cells that line blood vessels (Sadik et al. 2011). The activated endothelial cells subsequently 
release agents known as chemoattractants to attract circulating neutrophils, that under normal 
physiological conditions flow in the centre of the blood stream in a quiescent state, toward 
the vessel wall. Changes in the expression of surface molecules such as the intercellular 
adhesion molecule (ICAM-1/2) and junctional adhesion molecules (JAM-A/B/C) on the 
activated endothelial cell surface attract and capture neutrophils. This facilitates their exit 
from the circulation by ligating complementary receptors such as the integrins leukocyte 
function-associated antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1) on the neutrophil 
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surface, enabling them to adhere and cross the endothelium and enter inflamed/infected 
tissues (Huber et al. 1991; Borregaard 2010). The passage of neutrophils across vascular 
walls occurs only at postcapillary venules, where the vessel wall is thin. Neutrophils can 
cross endothelial cells in two ways: transcellularly, where the cells pass through the 
endothelial cells themselves (Feng et al. 1998), or paracellularly, where cells travel between 
endothelial cells (Marchesi & Florey 1960). Both types of migration rely on homophilic 
interactions between adhesion molecules on neutrophil and endothelial cell surfaces and the 
release of soluble mediators. For example, the release of leukotriene A4 by neutrophils 
induces changes in the actin cytoskeleton of endothelial cells resulting in cell contraction and 
loss of barrier integrity (Colgan et al. 1993). 
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Figure 1.1 Transendothelial migration (TEM) of neutrophils mechanism of action 
1. Neutrophil attachment: occurs via interaction of P- and L-selectins (Buscher et al. 2010) with endothelial ligands expressed as a result of 
activation by stimuli (e.g. pro-inflammatory cytokines) released from nearby inflamed tissues. 2. Rolling: low affinity binding of selectins and their 
receptors results in cell rolling, allowing for sampling of the microenvironment (Steegmaier et al. 1997). 3. Arrest: At the appropriate inflammatory 
cue, e.g. chemotattractant detection, integrins on the neutrophil surface attach to ICAM-1 and ICAM-2 on the endothelial cell causing arrest. 4. 
Crawling: Neutrophil topology studies reveal extensive protrusions and processes on the cells’ surface with embedded integrins which bind to the 
endothelial cell wall, allowing the “flatter” part of the cell to bind and adhere to facilitate transmigration by deciphering an appropriate luminal exit 
point. 5. Transmigration: Exit from vessel occurs para- or transcellularly and neutrophils are guided to inflamed tissues via chemoattractants in a 
gradient-driven manner.  
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Post TEM neutrophils are functionally distinct from those in circulation, giving evidence for 
the existence of different subsets based on expression of specific molecular markers such as  
Olfactomedin 4 (OLFM4) (Liu et al. 2012) and CD177 (Hu et al. 2009). Neutrophils that 
leave the circulation are in an activated state, enabling them to react quickly and effectively 
upon exposure to pathogenic stimuli. Neutrophils have also been shown to revert back into 
the vascular lumen in a process known as reverse transendothelial endothelial migration 
(rTEM) (Mathias et al. 2006). Neutrophils that have undergone rTEM show high expression 
of ICAM-1 and low expression of the CXCR1 chemokine receptor (Buckley et al. 2006). 
rTEM is facilitated through interactions between neutrophils and endothelial cells via JAM-C 
(Woodfin et al. 2011). The identified subpopulations have not been shown to display any 
differences in terms of proneness to undergo apoptosis or ability to phagocytose bacteria, nor 
in their propensity to transmigrate into tissues in response to inflammatory stimuli (Welin et 
al. 2013). A functional difference between the subsets remains to be found. 
1.3.  Neutrophil surface receptors 
1.3.1. Receptors involved in TEM 
The two major groups of neutrophil receptors involved in TEM are selectins and integrins:  
a) Selectins are single-chain glycoproteins that recognise carbohydrate moieties and mediate 
transient interactions between leukocytes and the vessel wall (Sperandio et al. 2009). P-
selectin is expressed on platelets and endothelial cells, E-selectin is expressed on endothelial 
cells during inflammatory responses and L-selectin is expressed on leukocytes. Selectins 
interact with a large number of carbohydrate-containing cell surface molecules including P-
selectin glycoprotein protein ligand 1 (PSGL-1) on leukocytes which act as the counter-
receptor of P- and E-selectins on endothelial cells (Carlow et al. 2009). Selectins and their 
ligands are required for the rolling phase of TEM (Figure 1.1).  
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b) Integrins are heterodimeric transmembrane glycoproteins present on virtually all mammalian 
cells. For neutrophils the most important integrins belong to the β2 integrin family which are 
characterised by the β2 integrin chain and a unique α-chain, such as LFA-1 and Mac-1, which 
both bind to endothelial ICAM-1 and are involved in different phases of TEM (Schymeinsky 
et al. 2007).  
1.3.2. Receptors involved in neutrophil pathogen detection and killing  
The three receptor types involved in neutrophil activation to enable pathogen detection and 
killing include pattern recognition receptors (PRRs), opsonic receptors and G-protein 
coupled-receptors (GPCRs). These are described below (see also Figures 1.2, 1.3 and 1.4). 
a) PRRs recognise pathogen/damage associated molecular patterns (PAMPs/DAMPs) including 
microbe-specific molecules, such as bacterial DNA and bacterial cell wall components, and 
host-derived proteins/peptides, such as necrotic cell matter. DAMPs occur during sterile 
inflammatory episodes such as in burns or hypoxia. Major PRRs that result in ligand 
(pathogenic or host) internalisation are C-type lectin receptors, such as Dectin-1, which 
recognises the fungal cell wall component β-glucan, and upon association with the integrin 
Mac-1, internalises and subsequently eliminates fungal pathogens (Kennedy et al. 2007; X. 
Li et al. 2011). Major non-phagocytic PRRs are known as Toll-like receptors (TLRs) which 
recognise both host-derived and pathogenic molecules including lipids, carbohydrates 
peptides, DNA and RNA (Trinchieri & Sher 2007). In particular, TLR2 and TLR4 can be 
stimulated by bacteria and their products, including the bacterial pathogen Fusobacterium 
nucleatum (Wakelin et al. 2006; Kikkert et al. 2007). Engagement by TLRs activates 
neutrophils, enabling increased cytokine release and a reduction in the rate of apoptosis 
(Parker et al. 2005). Other PRRs include the cytoplasmic nucleotide-binding oligomerisation 
domain (NOD-like) receptors, of which NOD2 is expressed in neutrophils and can detect 
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peptidoglycan-related molecules of bacteria present within the cell cytoplasm, also resulting 
in cytokine release (Ekman & Cardell 2010).  
b) Opsonic receptors are critical for neutrophil-mediated pathogen killing. Engagement of the 
host-derived complement product C3b or IgG coated pathogenic material with its cognate 
high affinity Fc Receptors (FcRs), FCγRIIA/FCγRIIIB and FCγRI respectively, facilitates 
rapid uptake and strong stimulation of neutrophil killing mechanisms (Bruhns 2012).  
c) GPCRs have diverse downstream signalling outcomes and ligands that can bind them 
including bacterial products (such as formyl peptides) and endogenous molecules such as the 
chemokine interleukin-8 (IL-8/CXCL8) and leukotrienes that results in neutrophil 
chemotaxis. Other GPCR signalling results in neutrophil activation which endows the cell 
with the ability to kill invading microbes.  
1.3.3. Receptor-independent neutrophil activation 
The NADPH oxidase complex can be activated by a number of non-physiological agents 
including the calcium ionophore ionomycin and the diester phorbol 12-myristate 13-acetate 
(PMA) (Lundqvist et al. 1996; Dahlgren & Karlsson 1999). During PMA stimulation, an 
assembly of the oxidase occurs not only in the plasma membrane but also in the specific 
granule membrane, giving rise to intracellular oxygen metabolites. Thus reactive oxygen 
species (ROS) production occurs both extracellularly and intracellularly (Karlsson et al. 
2000). 
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Figure 1.2 Toll-like receptor (TLR) activation pathway. 
TLR receptor-ligand pathway results in the activation of the NADPH oxidase complex and subsequent ROS production. Images constructed using 
several sources (Karlsson et al. 2000; Cicchetti et al. 2002; Laroux et al. 2005; Ichikawa et al. 2012; Futosi et al. 2013). 
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Figure 1.3 Fc-gamma activation pathway 
 
Fc-gamma ligand-receptor pathway can result in neutrophil activation characterised by the activation of the NADPH oxidase complex and 
subsequent ROS production. Images constructed using several sources (Karlsson et al. 2000; Cicchetti et al. 2002; Laroux et al. 2005; Ichikawa et al. 
2012; Futosi et al. 2013). 
11 
 
 
 
Figure 1.4 Non-receptor activation pathway 
 
Non-receptor routes can result in neutrophil activation characterised by the activation of the NADPH oxidase complex and subsequent ROS 
production. Images constructed using several sources (Karlsson et al. 2000; Cicchetti et al. 2002; Laroux et al. 2005; Ichikawa et al. 2012 Futosi et 
al. 2013;). 
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1.4. Neutrophil chemotaxis 
Chemotaxis is the process by which cell motility is biased along a concentration gradient of 
soluble factors/extracellular signals known as chemoattractants (Insall 2010). Molecular 
gradients are required to activate intracellular signalling events and establish directional cues 
for migrating cells and chemotaxis exists in a large and diverse number of organisms from 
amoebae to eukaryotes (Van Haastert & Devreotes 2004). For neutrophils, chemotaxis allows 
the cell to migrate to infection sites along a chemoattractive gradient in order to kill invading 
microorganisms. This process involves a number of interacting processes resulting in 
coordinated cell movement including recognition of the chemoattractant, internal signalling 
to activate the cells’ motility centre and gradient detection to influence movement in a 
persistent direction (Levine & Rappel 2013). Neutrophil movement is achieved by producing 
actin-rich pseudopods at the leading edge of the cell whilst retracting in other regions (Friedl 
et al. 2001); the orientation of these protrusions towards a chemoattractant determines the 
direction of migration. In the absence of chemoattractive factors these protrusions occur 
randomly at all edges of the cell. When a chemoattractant is detected however, the 
protrusions are directed towards the source of the chemoattractant thereby determining the 
direction of migration (Andrew & Insall 2007). 
1.4.1. Chemoattractants 
Neutrophil chemoattractants encompass numerous host and foreign molecules as listed in 
Table 1.1 that include leukotriene B4 (LTB4), complement proteins (C5a), cytokine-derived 
chemoattractants (known as chemokines), formylated peptides from bacteria and 
lipopolysaccharide (LPS), an integral component of the outer membrane of Gram negative 
bacteria (Erridge et al. 2002). Chemoattractants have different potencies, forming a chemical 
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hierarchy that serves to recruit neutrophils to the inflammation site. Those that elicit the 
strongest migration are molecules that emerge from the inflammation/infection source, such 
as bacterial N-formly-methionyl-leucyl-phenyalanine (fMLP), one of the strongest 
chemoattractants to induce neutrophil chemotaxis (Showell 1976). Intermediary 
chemoattractants include CXCL8 and LTB4, which are expressed by epithelial and 
endothelial cells during neutrophil recruitment from the circulation (Phillipson & Kubes 
2011).  
 
Table 1.1 Major neutrophil chemoattractants and their receptors 
Adapted from Sadik et al. (2011). BLT1 = leukotriene B4 receptor-1, ENA-78 = epithelial 
neutrophil-activating protein 78, FPR = formylated peptide receptor, GCP = granulocyte 
chemotactic protein 2, GRO = growth-regulated oncogene, HCC = human CC chemokine, 
LTB4 = leukotriene B4, MCP = monocyte chemotactic protein, MIF = macrophage inhibitory 
factor, MIP = macrophage inhibitory protein, NAP-2 = neutrophil-activating peptide-2, PAF 
= platelet activating factor , PGP = proline-glycine-proline, SDF-1α = stromal cell-derived 
factor 1 alpha. 
 
Chemokines 
Receptor Ligand 
CCR1 MIP-1α, RANTES, MIP-3, MCP-3, HCC-2 
CXCR1/2 GROα, GROβ, GROγ, ENA-78, GCP-2, NAP-2, CXCL8 
CXCR4 SDF-1α 
Peptides/cytokines 
C5aR C5a 
C3aR C3a 
FPR1 Formylated peptides (e.g. fMLF) 
CXCR2 PGP 
FPR2 LL-37 
PAFR PAF 
Other 
CXCR2 MIF, Eicosanoids 
BLT1 LTB4 
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The host-derived chemokines specifically attract and recruit populations of immune effector 
cells to sites of injury/infection and thereby shape the development and progression of the 
inflammatory response (Borish & Steinke 2003). Chemokines are divided into four 
structurally similar sub-families (CXC, CX3C, CC and C), split according to the spacing of 
their first two cysteine residues near their amino terminus (Bonecchi et al. 2009). Over 44 
chemokines have been described in humans, several of which can bind to the 21 described 
human chemokine receptors (Esche et al. 2005). Individual neutrophil chemokine receptors 
are GPCRs specific for chemokines, and typically from a single chemokine subfamily (Nibbs 
& Graham 2013). CXC chemokines can be subdivided into two subfamilies; those containing 
the glutamic acid-leucine-arginine (ELR) sequence and those that do not (Zlotnik & Yoshie 
2000). CXC-ELR
+
 chemokines are the main activators of neutrophil recruitment to sites of 
inflammation and include CXCL8 and macrophage inhibitory protein alpha (MIP1α) (Rollins 
1997). Chemokines selectively recruit discrete cell populations into sites of injury and 
thereby effectively regulate leukocyte trafficking (Scapini et al. 2000). During 
infection/inflammation, chemokines secreted by activated endothelial cells can induce rapid 
blood neutrophilia, stimulating neutrophil adhesion and transmigration across the 
endothelium and direct the migration of neutrophils within the tissue to the site of 
inflammation (Furze & Rankin 2008; Williams et al. 2011). Neutrophils are also a source of 
chemokines that are chemotactic for a range of other immune cells including neutrophils 
themselves, monocytes, DCs and natural killer cells (Sadik et al. 2011).   
1.4.2. Chemotactic signaling pathways 
The intracellular events that result in chemotaxis are not fully understood. Chemokines, 
chemotactic complement products, lipid mediators (such as leukotrienes) and the bacterial 
formyl peptides can all be sensed by members of the GPCR family that transduce signals via 
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cytoplasmic G proteins to cytoskeletal proteins which govern the directed movement of 
neutrophils ( Di Gennaro & Haeggström 2012; Sun & Ye 2012; Klos et al. 2013). Figure 
1.5a-d describes the process of neutrophil recruitment to inflamed periodontal tissues. During 
infection bacteria and their products, such as fMLP, penetrate the tissues surrounding the 
tooth and are detected by resident macrophages and epithelial cells that, in turn secrete 
CXCL8. Both CXCL8 and fMLP attract circulating neutrophils into the affected tissues and 
signalling pathways are activated following MIP1α, CXCL8 and fMLP exposure. Figure 1.5e 
describes GPCR resulting in the activation of several of downstream signalling pathways; 
PLC, PI3K, p38 and RHO G proteins (Camps et al. 1992; Stoyanov et al. 1995; Brahmbhatt 
& Klemke 2003; Kim & Haynes 2013) that initiate directional chemotactic neutrophil 
migration (Gambardella & Vermeren 2013). Activation of GPCRs results in internalisation 
and conformational changes to facilitate downstream signalling before being recycled and 
returned to the cell surface or degraded (Forsman et al. 2013). The GPCR subunits, Ga and 
Gβγ, dissociate following internalisation (Gierschik et al. 1989) leading to the consequential 
activation of PI-3K, PLC and activation of small G proteins of the RHO family (RHO, RAC 
and CDC42) to initiate actin polymerisation and direct chemotactic neutrophil migration 
(Camps et al. 1992; Worthen et al. 1994; Stoyanov et al. 1995; Verploegen et al. 2002; 
Gambardella & Vermeren 2013). PI-3K phosphorylation catalyses the formation of 
phosphatidylinositol 3,4,5-triphosphate (PIP3) from phosphatidylinositol 4,5-biphosphate 
(PIP2). PIP3 acts as a second messenger controlling cell adhesion and cytoskeletal 
reorganisation (Toker & Cantley 1997). In a cell responding to a chemoattractant, PIP3 is 
found at the leading edge of the cell (Bagorda & Parent 2008). At the lagging end of the cell, 
retraction of the cell membrane is mediated by the phosphatase and tensin homolog (PTEN). 
Downstream of receptor signaling the MAPK and nuclear factor (NF)-κB signalling 
pathways are also activated. Cellular changes that result from chemoattractant binding 
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include polymerisation of F-actin, the formation of new pseudopods at the leading edge, and 
retraction at the posterior edge of the cell. Calcium ions are also released from the 
endoplasmic reticulum via the ryanodine receptor to elicit cell signalling ( Kurihara et al. 
1993; Berridge et al. 2003; Clapham 2007). Other additional processes are activated as a 
consequence of GPCR-agonist binding, including activation of the respiratory burst, 
degranulation and upregulation of surface molecules ( Sandborg & Smolen 1988; Horuk 
1996).  
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Figure 1.5 Neutrophil recruitment to inﬂamed periodontal tissues   
Plaque bioﬁlm is formed of diverse bacterial species (a). During infection bacterial degradation products (fMLP) are released (b). Following 
bacterial exposure resident macrophages and epithelial cells secrete CXCL8 (c). CXCL8 and fMLP attract circulating neutrophils into the 
affected tissues (d). GPCR binding results in the activation of downstream signalling pathways resulting in directional chemotactic neutrophil 
migration (e). Image devised from several sources ( Nick et al. 1997; Herlaar & Brown 1999; Cicchetti et al. 2002;O ttonello et al. 2005; Futosi 
et al. 2013).  
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Though some chemoattractants share the same receptors and other chemoattractants share the 
same signalling cascade, the resulting chemotaxis isn’t necessarily the same, for example, 
LTB4 is a significantly weaker inducer of chemotaxis compared to CXCL8. Furthermore, 
neutrophils have been shown to prioritise when they encounter multiple signals in favour 
dominant chemoattractants over secondary ones, which aids cell mobilisation in the correct 
orientation (Kim & Haynes 2012).  
The two signaling pathways involved in neutrophil chemotaxis are detailed in Figure 1.5e: 
the PI3-K/PTEN pathway that is activated following exposure to weaker chemoattractants 
such as CXCL8 and LTB4 and the p38 mitogen-activated pathway, which is activated after 
exposure to stronger chemoattractants such as C5a and fMLP (Foxman et al. 1997; Foxman 
et al. 1999). Activation of the respective signaling pathways is dependent on the 
chemoattractant present; inhibition studies of the p38 pathway have been shown to prevent 
the migration of neutrophils towards fMLP and C5a, but not towards CXCL8 or LTB4 (Khan 
et al. 2005). 
The p38 pathway dominates the PTEN pathway and becomes activated, even in the presence 
of weaker chemoattractants, after exposure to stronger chemoattractants which are located at 
the infection/inflammation source (Heit et al. 2002). The switch to prioritise the cell towards 
more potent chemoattractants appears to require PTEN, as Pten-/- neutrophils exposed to 
opposing gradients are unable to preferentially migrate towards the stronger chemoattractants 
(Heit et al. 2008). 
1.4.3. Measuring neutrophil chemotaxis  
Chemotaxis has been a focus of research for more than a century due to its involvement in 
several important physiological and pathological processes including TEM (section 1.2), 
tumour metastasis and angiogenesis. The study of chemotaxis allows the behaviour of cells to 
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be observed in vitro when subjected to a linear gradient of chemoattractant most often via 
microscopy.  
Most chemotaxis assays employ a two-well design whereby cells are seeded between the 
wells, one containing a control or buffer substance and the other with a chemoattractant, and 
cells are able to migrate between them. The first system to measure chemotaxis in vitro was 
the Boyden chamber (Boyden 1962) and derived assays that work with either thick filters or 
thin porous membranes which the cells are placed on. In response to a concentration gradient 
of chemotactic agent, the cells migrate through the membrane and are counted, but the 
information obtained is limited and gradients are steep and undefined. Furthermore, the 
counting of migrated cells can be time consuming, tedious and subject to error. The Boyden 
assays do not assess the cells’ path or locomotion and persistent chemotaxis cannot be 
distinguished from random migration. Advantages of the Boyden chamber include 
employing fluorescence detection of cells and semi-high throughput application using 96 
well plates.  
Another chemotaxis assay type are direct visualisation chambers, these allow cells to be 
observed migrating using time-lapse microscopy and are considered the gold standard for 
investigating true chemotaxis (Wells 2000). Bridge chambers provide a visualisation 
platform for observing the behaviour of cells between the two wells; cells are plated onto 
coverslips which are inverted leaving a gap between the chamber and coverslip for the 
addition of desired chemoattractant. These chambers provide gradients for cells to accelerate 
toward rather than exposure of the cells to absolute concentrations alone. Examples include 
the Zigmond, Dunn and Insall chambers and are described briefly below.  
1. The Zigmond chamber was first described in 1977 for the study of polymorphonuclear 
cells (Zigmond 1977). The chamber permits the generation of shallow gradients at a near 
steady state linear gradient. It has a variable gap between the bridge and coverslip which can 
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result in unpredictable variations in the chemotactic gradient (Zicha et al. 1991). 
Furthermore, the chamber is not designed for inverted microscopes, which modern time-
lapse microscopy commonly employ. 
2. The Dunn chamber is derived from the Zigmond chamber and achieves stability by being a 
sealed, rigid, glass enclosure entirely filled with incompressible medium using thick (0.25-
0.35 mm) coverslips. The circular bridge design can result in variable chemoattractant 
gradient orientation and changing the gradient in Dunn chambers is inefficient (Muinonen-
Martin et al. 2010). 
3. The Insall chamber, derived in turn from the Dunn chamber (Muinonen-Martin et al. 
2010), is designed to ensure better stability between the gap between the bridge and 
coverslip. The bridge structure has a square arrangement with two linear bridges of differing 
widths on opposite sides whilst the other two sides are large coverslip supports. The Insall 
Chamber has been recently referenced in several studies, mainly observing cell movement in 
Dictostelium discoidium (Phillips & Gomer 2012; Choi et al. 2013; Kaul et al. 2013; Herlihy, 
Pilling, et al. 2013; Herlihy, Tang, et al. 2013). The chamber is made from nonpolarising 
polymethyl methacrylate (PMMA) blanks and allows the use of thin cover slips because of 
the supports within the bridges, which is not possible for Dunn and Zigmond chambers 
because the cover slips bend and occlude the chamber. Furthermore, the cover slip can easily 
be sealed in place avoiding the need for cover slip springs, unlike the Zigmond chamber, 
which can potentially deform the chamber and distort the gradient.  
Though other more advanced options exist for the study of chemotaxis, including 
microfluidic devices and transmigrational models (Toetsch et al. 2009), the ease and 
simplicity of a bridge chamber enables chemotaxis measurements under time restrictive 
conditions, such as when working with clinical samples.  
21 
 
1.5. Neutrophil priming 
During the process of TEM, neutrophils are exposed to stimuli such as cytokines, 
chemokines and growth factors, which lead to partial activation of the cell that in turn 
enhances its ability to respond to a secondary stimulus (Hallett & Lloyds 1995). This effect, 
known as priming, allows for maximal neutrophil activation characterised by the killing of 
pathogenic agents via several mechanisms (as outlined in section 1.6) as well as the increased 
potential of the cell to release cytokines which further contribute to the inflammatory process 
(Gustafsson et al. 1997; Dias et al. 2011). Neutrophil priming has been demonstrated both in 
vitro and in vivo (Condliffe et al. 1998) and the signal transduction processes involved in 
priming utilise calcium dependent and independent pathways (Thelen et al. 1993). 
Neutrophil priming in chemotaxis is required for the cell to respond to other chemokines, 
such as MIP1α, allowing for maximal recruitment to the site of inflammation. Release of 
GM-CSF at inflammatory sites, documented in diseases such as rheumatoid arthritis and 
glomerulonephritis (Xu et al. 1989; Matsuda et al. 1996), can prime neutrophils to activate 
receptors present on the cell surface, such as CCR5.  
1.6. Neutrophil killing mechanisms 
Neutrophils action antimicrobial killing via several major mechanisms as outlined below. 
1.6.1. Phagocytosis and Reactive Oxygen Species (ROS) generation 
Phagocytosis is the process of pathogen engulfment by the host cell and its subsequent 
destruction. Internalisation is achieved through the binding of two different receptor classes; 
Fcγ receptors and complement receptors (Witko-Sarsat et al. 2000). Bacteria that have been 
opsonised by antibody or complement molecules bind to FcγRII or complement receptors 
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respectively, which aggregate on the cell surface (Wilson et al. 1995) leading to the 
intracellular activation of Src-tyrosine kinases, which in turn trigger various signalling 
pathways that coordinate to phagocytose the bacterial particle, forming a structure known as 
a phagosome (Greenberg et al. 1996; Nordenfelt & Tapper 2011). The phagocytosed 
bacterium is destroyed by the merging of vesicles with the phagosome that contain 
microbicidal molecules such as proteolytic enzymes and binding proteins such as lactoferrin, 
which are contained within granules formed from the Golgi apparatus. The formation and 
release of Reactive Oxygen Species (ROS) also occurs within the phagosomal space within 
the cell, in what is commonly known as the “respiratory burst”, killing the engulfed microbes 
(El-Benna et al. 2008) and activating granule proteins from their pro-forms.  
ROS are powerful oxidizing agents formed endogenously as bi-products in metabolism in 
addition to being a form of defence against invading pathogens (Dröge 2002). Reduction of 
molecular oxygen to water results in a large free energy release giving rise to ROS. The 
ROS-generating system is composed of cytosolic and membrane subunits to generate ROS at 
the expense of NADPH known as the NADPH oxidase. NADPH components include 
membrane components gp91
phox
, g22
 phox
, and the GTPase Rac1 and cytosolic components 
p47
 phox
, p67
 phox
, and p40
 phox
, which when assembled become the functional oxidase. The 
NADPH-oxidase initiates the electron transfer to oxygen resulting in superoxide (O2
.
), an 
anion that can activate other ROS-generating enzymes as outlined in Figure 1.6. O2
.
 is acted 
on by such enzymes which add more electrons forming other ROS species: O2
.
 is converted 
to hydrogen peroxide (H2O2) either spontaneously or by the enzyme superoxide dismutase 
(SOD-2) and finally H2O2 can be converted to hypochlorous acid (HOCl) by 
myeloperoxidase or to water by the enzyme catalase ( Harrison & Schultz 1976; Chapple 
1996; Battino et al. 1999; Robinson 2008). HOCl is a powerful antimicrobial (Klebanoff 
2005) that elicits bactericidal activity by chlorinating bacteria (Winterbourn 1985). 
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In addition to the NADPH oxidase system creating ROS, nitric oxide synthase present in 
primary granules can produce nitric oxide (NO
.
) when the neutrophil is activated, for 
example, by stimulation by cytokines (Evans et al. 1996) or during bacterial infection 
(Wheeler et al. 1997). 
During attempted neutrophil phagocytosis of large foreign particles, ROS and cytolytic 
content release into the extracellular environment may occur. This process is known as 
“frustrated phagocytosis” and can cause damage to other cells (Sheppard et al. 2005). Yet 
despite the potential to cause damage, ROS formation in immune defence is vital, as evident 
in people with severe impairments in this pathway. For example, sufferers of chronic 
granulomatous disease (CGD) – a hereditary condition occurring in 1 in every 250,000 births 
(van den Berg et al. 2009) in which defects in the NADPH-oxidase enzyme system result in 
the inability to generate ROS – are vulnerable to recurrent bouts of severe infections 
(Curnutte 1993).  
As well as acting as powerful microbicidal weapons, ROS are also generated by 
chemoattractant stimulation and play a role in signal transduction of cell movement 
(Dickinson & Chang 2011). One study demonstrated ROS produced by NADPH oxidase 
activity could regulate pseudopod formation and chemotactic migration in neutrophils via 
actin glutathionylation and polymerisation (Sakai et al. 2012). Furthermore, inhibition of 
NADPH oxidase-dependent ROS formation within healthy neutrophils led to diminished 
chemotaxis efficiency when exposed to a chemoattractive gradient. Hydrogen peroxide, a 
membrane-permeable ROS that can travel across cell membranes via aquaporins (Bienert & 
Chaumont 2014), is able to direct cell movement in a gradient driven manner (Niethammer et 
al. 2009). This finding was further supported by another study in which ROS were found to 
deactivate PTEN resulting in the build-up of PIP3 at the leading edge of the migrating cell 
which is necessary for chemotaxis (Kuiper et al. 2011). 
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Figure 1.6 NADPH-mediated ROS generation 
Neutrophil activation results in NADPH-oxidase assembly. Reduction of oxygen yields 
superoxide (O2
.
) which is converted to hydrogen peroxide (H2O2) by superoxide dismutase 
(SOD-2). H2O2, in combination with chloride ions (Cl
-
), is subsequently converted to 
hypochlorous acid (HOCl) by myeloperoxidase (MPO). The hydroxyl radical (
.
OH) is also 
produced during superoxide and HOCl generation. 
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1.6.2. Degranulation and Neutrophil Serine Proteases (NSPs) 
Neutrophils produce an array of microbicidal proteins including hydrolytic enzymes and 
antimicrobial peptides (AMPs) capable of digesting pathogens and their products via non-
oxidative pathways. These are stored within specialised compartments known as granules 
within the cytosol and there are four types: azurophilic (primary), which contain 
myeloperoxidase (MPO), a haem containing protein which catalyses the formation of 
hypochlorous acid from hydrogen peroxide (Faurschou & Borregaard 2003) and defensins as 
well as neutrophil serine proteases (NSPs); specific (secondary) and gelatinase (tertiary) 
granules include lactoferrin, metalloproteinases and lysozyme; and secretory vesicles which 
can kill bacteria and fungi (Faurschou & Borregaard 2003). The granules are formed during 
promyelocyte maturation (Häger et al. 2010) by aggregation of immature transport vesicles 
that bud off from the trans-Golgi network (Sossin et al. 1990). Granules fuse with the 
phagosome during pathogen uptake and with the plasma membrane for extracellular content 
release, however the latter usually only involves tertiary and secretory vesicles – leakage of 
products of primary and secondary granules occurs due to leakage from the phagosome, 
which is common during frustrated phagocytosis. Extracellular secretory vesicle content 
release results in the presentation of adhesion and chemotactic receptors that promote 
neutrophil transmigration.  
1.6.2.1. Granule-associated proteins: Neutrophil Serine Proteases 
Neutrophil serine proteases (NSPs) include neutrophil elastase (NE), cathepsin G (CG), 
proteinase 3 (PR3) (de Haar et al. 2004) and the recently described neutrophil serine protease 
4 (NSP4) (Perera et al. 2012). NSP synthesis is regulated at the transcriptional level during 
granulocyte development and also at the post-translational level. They are stored in their 
proteolytically active mature form within azurophilic granules until they fuse with the 
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phagololysosome or undergo limited exocytosis upon exposure to specific stimuli (Owen & 
Campbell 1999; Kobayashi et al 2005). The lysosomal signal peptidase cathepsin C (CTSC) 
activates NSPs via N-terminal dipeptide removal ( McGuire et al. 1993; Adkison et al. 2002) 
as they leave the Golgi complex (Pham 2006). In the absence of CTSC the pro-forms of the 
NSPs are either constitutively secreted (Garwicz et al. 2005) or degraded (Pham & Ley 
1999). NSPs have many bacterial and fungal targets which include components of cell walls 
and virulence factors (Belaaouaj et al. 2000; Reeves et al. 2002; Weinrauch et al. 2002). 
NSPs released extracellularly can bind to the external cell surface in active form, acting on a 
variety of host chemokines, cytokines, growth factors and cell surface receptors, contributing 
to both pro- and anti-inflammatory and immune processes. For example, PR3 has been 
shown to cleave the pro-inflammatory cytokines CXCL8 (Padrines et al. 1994), IL-1β 
(Coeshott et al. 1999) and membrane bound tumour necrosis factor alpha (TNFα) ( Robache-
Gallea et al. 1995; Armstrong et al. 2009) resulting in their activation. Other targets of NSPs 
demonstrate anti-inflammatory effects, such as inactivation of MIP1α (Ryu et al. 2005) and 
CXCL8 (Leavell et al. 1997). In addition, NSPs have been shown to inactivate IL-6 at 
inflammatory sites (Bank et al. 2000), thus NSPs appear to play a key role in orchestrating 
immunostimulatory signals. NSPs are known to be associated with neutrophil extracellular 
traps (NETs) (Brinkmann et al. 2004), furthermore, NE has been shown to be fundamental to 
NET release (Papayannopoulos et al. 2010) and cathelicidin (hCAP18/LL-37) is cleaved by 
PR3, forming LL-37, which is also known to facilitate NET formation (Neumann et al. 
2014).  
1.6.2.2. Granule-associated proteins: LL-37 
One well-described NSP target is human cathelicidin antimicrobial protein (hCAP18), a 
member of the α-helical cathelicidin protein family expressed in several cell types including 
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neutrophils (Yang et al. 2009), NK cells (Büchau et al. 2010), mast cells (Di Nardo et al. 
2003) and epithelial cells (Vandamme et al. 2012). Activation of TLRs (Liu et al. 2006) 
and/or alteration in the cytokine milieu, such as increased TNFα (Kim et al. 2009) as a result 
of infection/tissue damage, can cause degranulation and subsequent release of the inactive 
hCAP18 precursor, which is stored in specific granules. Release of hCAP18 precursor into 
the extracellular environment/entry into the phagosome results in exposure to PR3, and 
subsequent cleavage to yield the bactericidal 37-amino-acid peptide LL-37 (Sørensen et al. 
2001). 
LL-37 can interact with negatively charged membrane components of pathogens including 
bacteria, fungi and enveloped viruses, resulting in membrane disruption and cell lysis (Sood 
et al. 2008; Dean et al. 2011; Wong, Ng, et al. 2011; Wong, Legowska, et al. 2011). LL-37 
can also stimulate neutrophil chemotaxis, induce chemokine receptor stimulation, suppress 
neutrophil apoptosis and can also interact and potentiate the actions of other immune cells 
such as DCs (Lande et al. 2007). In addition, LL-37 has been shown to have 
immunomodulatory functions (Nijnik & Hancock 2009). For example, soluble LL-37 can 
enter host cells via endocytosis without damaging the cytoplasmic membrane (Sandgren et 
al. 2004), whereas LL-37 can disrupt the nuclear membrane, thereby facilitating the 
formation of neutrophil extracellular traps (NETs; section 1.6.3) during innate immune 
responses (Neumann et al. 2014).  
The far-ranging effects of LL-37 are thought to be attributed to its ability to activate multiple 
receptors (De Yang et al. 2000) including CXCR2 receptor (Zhang et al. 2009), and TLR 
receptors (Liu et al. 2006). Furthermore, LL-37 can induce macrophages to release CXCL8, 
indirectly attracting more immune cells to the inflammatory site (Montreekachon et al. 
2011). LL-37 has also been found to be implicated in wound and bone healing, as blood 
monocytes are stimulated by LL-37 to migrate to the site of bone fracture and differentiate 
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into bone-forming cells known as mono-osteophils (Zhang et al. 2010). LL-37 can also 
recruit endothelial progenitor cells to the site of wound healing, inducing their proliferation 
and thereby inducing angiogenesis (Pfosser et al. 2010).  
1.6.2.3. Granule-associated proteins: Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases (MMPs) are contained within gelatinase granules and are 
synthesised during the late maturation process in the bone marrow. Neutrophils are the 
dominant sources of particular MMPs, including MMP-8 and MMP-9 within the circulation 
(Jönsson et al. 2011) and are responsible for the rapid release of MMPs that occur in blood 
upon stimulation with endotoxin or pro-inflammatory cytokines (Borregaard & Cowland 
1997; Claesson et al. 2002). The release of MMP-9 is assumed to serve as a sensitive and 
early marker of neutrophil activation (Pugin et al. 1999). MMPs, of which 24 are found in 
mammals, are secreted or anchored to the cell surface to exert their effects in the extracellular 
space; MMP-8, 9 and 12 are all secreted. MMPs are not typically expressed in healthy tissues 
whilst by contrast MMPs can be detected in repair/remodelling processes, in 
diseased/inflamed tissues and in cell cultures. MMPs are responsible for the turnover, 
degradation, catabolism and destruction of the extracellular matrix (Pilcher et al. 1997). Thus 
increased or dysregulated levels of many MMPs are observed in any disease characterised or 
associated with inflammation (Nathan 2002). MMPs can proteolyse many endogenous 
molecules resulting in their deactivation, such as the chemokines CXCL5 (ENA78) and 
CXCL6 (GCP2), as well as their activation, such as CXCL8, leading to a marked increase in 
chemotactic activity (Van den Steen et al. 2000; Van den Steen et al. 2003) and can cleave 
the pro-inflammatory cytokine IL-1β, activating it (Schönbeck et al. 1998). MMP-9 also 
targets the serine protease inhibitor α1-antitrypsin, a potent inhibitor of NE, enabling it to 
carry out its antimicrobial function (Liu et al. 2000). 
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1.6.3. Neutrophil extracellular traps (NETs)  
Neutrophil extracellular traps (NETs) are strand-like extrusions of de-condensed nuclear 
chromatin complexed with histones and granule proteins, released by neutrophils following 
dissolution of the nuclear and granule membranes into the extracellular space. NETs are 
believed to function as an active and terminal defence mechanism to immobilise pathogens 
(Brinkmann et al. 2004; Fuchs et al. 2007). NETs firstly trap pathogens, including fungi 
(McDonald et al. 2012), bacteria (Urban et al. 2006) and viruses (Jenne et al. 2013), 
preventing their dissemination and aiding subsequent phagocytosis by other immune cells. 
Pathogens are also exposed to high concentrations of antimicrobial peptides and enzymes 
trapped within the chromatin which include MPO, NE and LL-37 ( Urban et al. 2009; Scott 
& Krauss 2012). In addition, histones within the chromatin backbone have also been shown 
to have significant antimicrobial activity ( Papayannopoulos & Zychlinsky 2009; 
Papayannopoulos et al. 2010; Phillipson & Kubes 2011;). 
The process of NET formation (NETosis) is not yet fully understood but there appear to be 
two methods of NET release. One involves the release of NETs from dying neutrophils 
known as ‘suicidal NETosis’ that occurs within 2-3 hours of exposure to stimuli including 
phorbol myristate (PMA). The second form, termed ‘vital NETosis', involves NET extrusion 
from intact neutrophils, which can occur within 60 minutes upon exposure to TLR-signaling 
stimuli such as LPS, platelets or pathogenic bacteria ( Clark et al. 2007; Pilsczek et al. 2010; 
Kaplan & Radic 2012; Yipp & Kubes 2013). During vital NETosis, the neutrophil plasma 
membrane remains intact and the process is not dependent upon MPO, elastase or NADPH 
oxidase (Urban et al. 2009) and the NETosis neutrophils have been shown to be capable of 
other cellular functions including chemotaxis (Clark et al. 2007). Suicidal NETosis requires 
ROS production through NADPH oxidase (Keshari et al. 2013), MPO (Metzler et al. 2011) 
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and HOCl (Palmer et al. 2012). During NET formation chromatin is completely de-
condensed, a process regulated by histone citrullination (Wang et al. 2009) catalysed by the 
nuclear enzyme peptidylarginine deiminase 4 (PAD4) (Wang et al. 2004). Knockout mice 
lacking PAD4 have impaired NETosis and reduced host defences to infection (Li et al. 
2011). Stimulation by microbial products requires NADPH oxidase activity (Bianchi et al. 
2011) but stimulation by host immune complexes does not require ROS production (Chen et 
al. 2012). Opsonisation of several oral bacteria with complement has also been shown to 
promote NET formation (Palmer et al. 2015). 
NET formation has been liked to various neutrophil-mediated pathologies including sepsis 
(Clark et al. 2007) and systemic lupus erythematosus (SLE) nephritis (Hakkim et al. 2010). 
Excessive NET formation and endothelial cell activation are also associated with pre-
eclampsia in pregnancy (Gupta et al. 2010). NETs have been seen in an experimental in vivo 
model of dysentery as well as human appendicitis samples (Brinkmann et al. 2004). 
1.6.4. Other contributions of neutrophils/neutrophil proteins  
1.6.4.1. Cytokine production 
Cytokines represent an integral component of the signalling network among various cells and 
many are essential for the development and regulation of innate and adaptive immune 
responses. Cytokines regulate the responsiveness and maturation of particular cell 
populations, modulate the balance between cellular and humoral immune reactions and are 
important determinants of health and disease (O’Shea & Murray 2008). They constitute a 
large family of small proteins produced by both immune and non-immune cells that act 
within their local environment to direct biological processes involving neighbouring cells 
such as inflammation, immunity, repair and angiogenesis (Feldmann 2008). Cytokines are 
released by neutrophils constitutively or upon activation by local stimuli (Cassatella 1999) 
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contributing to both physiological and pro-inflammatory processes. The receptors that induce 
cytokine production in neutrophils include the Fcγ-, complement, GPCR- and PRR receptors 
(Benelli et al. 2002). Transcriptional activation of the corresponding genes in neutrophils is 
dependent on several transcription factor families including NF-κB (McDonald et al. 1997; 
Cloutier et al. 2007; Cloutier et al. 2009). Neutrophils express cytokines belonging to various 
families including pro-inflammatory cytokines (such as IL-1β and IL-6), chemokines (such 
as CXCL8 and MIP1α) and colony stimulating factors (such as G-CSF and GM-CSF) 
(Tecchio et al. 2014). At sites of infection neutrophils can release IL-17, which acts upon 
neutrophils indirectly by increasing their number through G-CSF production (Gaffen 2008), 
thereby increasing their recruitment to the affected area. IL-17 can also attract macrophages 
(Sergejeva & Lindén 2009); in turn these activated macrophages can prolong the lifespan of 
neutrophils via the release of cytokines including IL-1β, TNFα and GM-CSF (Lee et al. 
1993; Hume et al. 2002). 
1.6.4.2. Cell-cell cross-talk 
Neutrophils can communicate with other immune cells including lymphocytes, macrophages 
and DCs through direct cell-cell contact or via production of soluble mediators in response to 
intracellular pathogens and viruses. Cross talk occurs through the ability of neutrophils to 
secrete host cytokines and express cell surface molecules that interact with other immune 
cells (Mantovani et al. 2011). For example, neutrophil products such as the chemokine 
MIP1α can recruit DCs to sites of infection (Charmoy et al. 2010) and the release of LL-37 
can induce maturation of immature DCs (Bandholtz et al. 2006).  Neutrophil/DC binding has 
been shown to promote DC maturation into effective antigen presenting cells (APCs) 
(Boudaly 2009). Neutrophils can traffic to lymph nodes in response to infection (Abadie et 
al. 2005) and have been shown to act as APCs to T-cells within lymph nodes (Beauvillain et 
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al. 2011). Neutrophils are a major source of the cytokine B-cell-activating factor (BAFF) that 
is required for B-cell survival and activation (Scapini et al. 2008). At the site of inflammation 
neutrophils contribute to monocyte influx by secreting chemokines including CCL2, CCL3 
and CCL20.  
Neutrophil membrane microparticles derived from activated neutrophils have also been 
shown to exhibit immunomodulatory properties. Microparticles are small membrane 
fragments (<1µm) released by blebbing during cellular activation and contain cell surface 
proteins. In the case of neutrophils, these include CD11b, CD62 and CD66 and have been 
shown to exhibit immune-activating properties on platelets and endothelial cells as well as 
immunosuppressive functions on macrophages (Pluskota et al. 2008; Dalli et al. 2008).  
1.6.4.3. Calgranulins 
Calgranulins constitute a subgroup of calcium-binding proteins including  S100A8, S100A9 
and S100A12, all of which are highly abundant within neutrophils: S100A8 and 9 comprise 
~45% of cytosolic proteins (Edgeworth et al. 1991) and are constitutively produced (Hessian 
et al. 1993). When stimulated, large amounts of S100A8 and 9 can be excreted by 
neutrophils (>100 µM from 1 x 10
6
 neutrophils) (Test & Weiss 1986). These proteins are 
found in high concentrations in inflamed tissues (Odink et al.1987) and can activate 
neutrophils as demonstrated by their ROS-inducing capabilities (Grimbaldeston et al. 2003). 
Both S100A8 and 9 homodimers and the heterodimer S100A8/9 (which forms in the 
presence of calcium and is subsequently known as calprotectin), are all chemotactic for 
neutrophils (Ryckman, McColl, et al. 2003; Ryckman, Vandal, et al. 2003). S100A8, 
S100A9 and S100A8/9 are examples of DAMPs (Bianchi 2007) that can exhibit both intra- 
and extra-cellular activities; they are regulators of NADPH oxidase and can activate the 
transcription of pro-inflammatory genes (Vogl et al. 2007) inside the cells and can act as 
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proinflammatory factors once secreted (Kessel et al. 2013), such as by promoting phagocyte 
migration (Ryckman, Vandal, et al. 2003; Vandal et al. 2003). 
1.7. Neutrophil-related diseases 
Individuals with defects in neutrophil function have helped define and explain the different 
roles neutrophil proteins have in overall neutrophil function and how this affects individuals 
as a whole. Infections arising as a consequence of disorders of neutrophil function typically 
involve the skin, mucosa, gums, lungs or cause deep tissue abscesses. Table 1.2 details 
diseases in which neutrophil defects cause systemic problems. Papillon-Lefèvre Syndrome 
(PLS) is covered in more detail in section 1.10.2.  
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Table 1.2 Disorders of neutrophil function 
Area 
affected 
Disorder Cause Neutrophil defect Effects References 
Homeostasis 
Severe congenital 
neutropenia (SCN) 
25% of cases caused by 
defects in the ELA2 gene 
No neutrophil elastase (NE). 
Failed neutrophil maturation. 
Endoplasmic reticulum stress 
and neutrophil apoptosis 
Grenda et al. 2007;Zeidler et 
al. 2009 
Recruitment 
Leukocyte adhesion 
deficiency (LAD): 
I, II and III 
Integrin mutations: 
LAD I = mutations in 
CD18 
LAD II = fucose transferase 
LAD III = Kindlin-3 
Failure of neutrophils to 
undergo trans-endothelial 
migration (TEM) 
Recurrent infections and 
severe periodontal disease 
Abram & Lowell 2009; 
Hanna & Etzioni 2012 
Chemotaxis Job's syndrome 
Mutations in the STAT3 
gene 
Defective chemotaxis 
Recurrent infections with 
opportunistic organisms e.g. S. 
aureus 
Hill et al. 1974 
 
Localised 
aggressive 
periodontitis (LAP) 
Associated with IL-17 
polymorphisms 
Defective chemotaxis Severe periodontitis 
Daniel et al. 1993; 
Chaudhari et al. 2016 
Pathogen 
killing 
Chronic 
granulotomous 
disease 
defects in NADPH-oxidase 
assembly 
Inability to form NETs or 
generate ROS 
Chronic intestinal 
inflammation, recurrent 
systemic infections 
Fuchs et al. 2007; Berg et al. 
2009; Casanova & Abel 
2009; Bianchi et al. 2009;  
 
Chédiak-Higashi 
syndrome 
mutations in the lysosomal 
trafficking regulator (LYST) 
gene 
decrease in phagocytosis 
Ulceration of the oral mucosa, 
severe gingivitis and 
periodontal disease 
Introne et al. 2015 
 
Specific granule 
deficiency (SGD) 
Mutations in the 
CCAAT/enhancer binding 
protein (CEBPE) 
transcription factor 
Neutrophils lack secondary 
and tertiary granules 
Ulceration of the oral mucosa 
and severe periodontal disease 
Khanna-Gupta et al. 2007 
 
Papillon-Lefèvre 
Syndrome (PLS) 
Mutation in cathepsin C 
gene 
deficiency in NSPs 
Skin disorder (palmoplantar 
keratoderma) and severe 
periodontitis 
Hart et al. 1999; Toomes et 
al. 1999 Nakano et al. 2001; 
Korkmaz et al. 2010; Perera 
et al. 2012;  
 
Myeloperoxidase 
(MPO) deficiency 
Mutations in MPO gene Deficiency of MPO 
Increased risk of systemic 
candida albicans infections 
Mauch et al. 2007 
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1.8. Characteristics of chronic inflammation 
Inflammation is a feature of the biological response to harmful stimuli/agents. There are two 
major types: acute, which usually features a fast-onset (minutes or hours), a self-limiting 
“classical” response reflecting the body’s response to infection or injury with neutrophils as 
the major cell type involved (Hotamisligil 2006); and chronic, characterised by a slow, 
severe progression (weeks and beyond) involving cells of the adaptive immune system and 
the simultaneous destruction and healing of the tissue from the inflammatory process. A state 
of chronic inflammation can cause inappropriate responses, such as in the absence of 
pathogenic stimuli which can lead to autoimmunity. The inflammatory response, if not 
adequately regulated, can lead to excessive tissue damage and spill-over into normal tissues. 
Underlying causes of chronic inflammation include the persistent presence of an injurious 
agent, prolonged exposure to a toxic agent or autoimmune disease. 
A component of chronic inflammation at the cellular level is the imbalance between the 
production of ROS and physiological antioxidant defences (Hold & El-Omar 2008), a 
condition known as oxidative stress. The release of MPO and the diffusion of ROS 
extracellularly, such as during frustrated phagocytosis, enables extraphagosomal oxidation. If 
cellular antioxidant systems do not inactivate ROS, they can react with cellular 
macromolecules and enhance the process of lipid peroxidation, cause DNA damage and/or 
induce protein carbonylation and nucleic acid modifications (Yu 1994; Dean et al. 1997). 
Carbonyl groups can be generated on proteins through oxidation of arginine, proline and 
lysine residues or by direct reaction of these amino acids with oxidants such as HOCl and 
chloramines ( Vissers & Winterbourn 1991; Requena et al. 2001. Protein carbonyls can also 
result from covalent attachment of electrophilic aldehydes produced during lipid 
peroxidation, such as 4-hydroxynonenal (HNE) to cysteine, lysine and histidine residues 
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(Uchida & Stadtman 1993). These oxidised products generally have decreased biological 
activity, for example, HNE modification of calprotectin inhibits the bacteriostatic properties 
of the protein (Harrison et al. 1999; Lusitani et al. 2003; Wilkie-Grantham et al. 2015), 
leading to metabolic dysregulation and alterations in cell signalling and other cellular 
functions implicated in the pathogenesis of various inflammatory diseases states (Ames et al. 
1993; Wiseman & Halliwell 1996). Oxidative stress occurs frequently in conditions 
characterized by immune activation and inflammation and can occur in diseases including 
Alzheimer's disease, RA, diabetes, sepsis, chronic renal failure, respiratory distress syndrome 
and periodontitis (Basu et al. 2009). 
1.9. Role of neutrophils in chronic inflammatory diseases  
As neutrophils represent a large proportion of the leukocyte population, investigating their 
role in chronic inflammatory diseases is of interest and, furthermore, the contribution 
neutrophils make to the progression of chronic inflammatory pathologies is increasingly 
evident. Below are some examples of chronic inflammatory diseases that demonstrate how 
the presence of neutrophils and their products may contribute to disease progression: 
1.10. Chronic inflammatory disorders  
1.10.1. Gingivitis and periodontitis 
Oral tissues are constantly exposed to bacteria and their products; the exposed surface of soft 
and hard (tooth enamel) tissues in close association create a niche in which bacteria can 
survive, multiply and colonise forming plaque biofilms (Bolstad et al. 1996). More than 400 
bacterial species have been cultured from periodontal pockets and plaque biofilms and 1,200 
phylotypes have been identified by molecular methods (Dewhirst et al. 2010), however few 
are implicated in disease (Signat et al. 2011). Characteristics of pathogenic periodontal 
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bacteria include the ability to colonise and form plaque biofilms, evade the host immune 
system and release virulence factors that induce an inflammatory response. Saliva, gingival 
crevicular fluid (GCF) and epithelial keratinocytes of oral mucosa protect the underlying 
tissues of the periodontium. In addition, immune cells are ever present, infiltrating tissues 
from the blood stream in response to endogenous and exogenous chemoattractants as 
described earlier (section 1.4.1) (Gamonal et al. 2001). Neutrophils are the major primary 
defence cell mobilised during an immune response against bacterial pathogens within the 
periodontal tissues (Scott & Krauss 2012), concentrated in the GCF, a fluid exudate flowing 
from the crevice between the tooth and gingival tissues (Brill 1962; Kinane et al. 1991), of 
the periodontium (Cooper et al. 2013). They comprise 50% of the inflammatory cell infiltrate 
within the junctional epithelium and 90% of the infiltrate within gingival extracellular fluid 
(Kowashi et al. 1980). As stated earlier, upon exposure to pathogenic stimuli neutrophils can 
release AMPs, MMPs and ROS, excessive production of which can cause collateral host 
tissue damage within the periodontal tissues (Shin et al. 2008; Scott & Krauss 2012). 
Gingivitis is an inflammatory disorder characterised by infiltration of the connective tissues 
adjacent to the crevicular and junctional epithelia by inflammatory-immune cells, where 
neutrophils are dominant. The inflammation is caused by the accumulation of plaque at the 
gingival margin (Page & Schroeder 1976). In susceptible patients with gingivitis, the 
inflammatory response can progress to involve the periodontal attachment apparatus, leading 
to destruction of the periodontal ligament and alveolar bone loss, a condition known as 
periodontitis (Listgarten 1986). Periodontitis is initiated by bacteria within the subgingival 
biofilm, but progresses due to abnormal host inflammatory-immune responses to the biofilm 
organisms that fail to re-establish a “health-associated” biofilm, eventually resulting in bone 
resorption and receding gingival epithelium (Graves & Cochran 2003). During the course of 
infection, there is a characteristic shift in the bacteria that exist in the gingival plaque biofilm 
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that causes dysbiosis. Early colonisers are Gram positive bacteria that create favourable 
conditions for some of the more fastidious and virulent species of Gram negative bacteria 
strongly implicated in the development of periodontitis such as Porphymonas gingivalis and 
Fusobacterium species (Haffajee et al. 1998), which eventually replace them (Socransky & 
Haffajee 2005). The tissue destruction evident in periodontal disease results for the most part 
from the actions of the immune system and in particular the pro-inflammatory effects of 
cytokines and the induction of tissue degrading proteinases (Gemmell et al. 1997). 
Of the different types of periodontal disease, chronic periodontitis develops in individuals 
later in life with a slow rate of progression and can serve as a risk factor for other 
inflammatory diseases including type 2 diabetes (Herring & Shah 2006), rheumatoid arthritis 
(Pischon et al. 2008) and cardiovascular diseases (Pihlstrom et al. 2005; Dietrich et al. 2013). 
Risk factors for periodontitis include smoking (Palmer et al. 2005), obesity, age, gender 
(males over females), socioeconomic status, an individual’s oral microflora and underlying 
genetic factors (Michalowicz et al. 1991). The multifaceted nature of these risk factors makes 
assessment of the magnitude of the effect of a particular risk factor being more relevant than 
another difficult.  
Chronic inflammatory conditions such as periodontitis are associated with increased systemic 
oxidative stress ( Morel et al. 1991; Noguera et al. 2001; Chapple & Matthews 2007; 
Chapple et al. 2007; D’Aiuto et al. 2010; Dias et al. 2013a). As explained earlier (section 
1.6.1), neutrophils produce ROS as a method of killing pathogenic organisms, however, 
excessive ROS production can also cause detrimental effects to host cells. Reduced 
glutathione (GSH) is an important intracellular anti-oxidant; it is reversibly converted to its 
oxidised form (GSSG) by donating electrons to ROS. Thus neutralising them. In the absence 
of sufficient GSH, ROS can oxidise a number of structurally important host macromolecules 
including proteins, lipids and carbohydrate resulting in irreversible cellular damage 
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( Gutteridge et al. 1981; Halliwell & Cross 1994; Waddington et al. 2000) and oxidatively 
stressed cells.  
Peripheral blood neutrophils from chronic periodontitis sufferers have been shown to 
generate significantly higher levels of ROS in the absence of any stimulating agent and also 
after in vitro FcγR stimulation compared with gender- and age-matched healthy controls 
( Asman et al. 1986; Gustafsson & Åsman 1996; Matthews et al. 2007a; Matthews et al. 
2007b;). The hyper-responsive neutrophil phenotype in chronic periodontitis could be an 
innate property of the neutrophils (hyperactivity) or involve sensitising or priming (section 
1.5) by cytokines or bacterial components (hyper-reactivity) (Matthews et al. 2007a). A 
study by Matthews et al. (2007b) showed that non-surgical periodontal therapy in patients 
with chronic periodontitis resulted in a reduction but not a complete removal of the hyper-
reactive neutrophil phenotype with elevated extracellular ROS release remaining in patients 
versus controls. This suggests the role of peripheral priming of neutrophils may underlie the 
hyper-reactive neutrophil phenotype exhibited by patients with chronic periodontitis, but the 
neutrophil hyperactivity (ROS release in the absence of a stimulus) may remain independent 
of priming. Effects of both a hyperactive and hyper-reactive neutrophil phenotype with 
regard to enhanced ROS generation results in an altered GSH:GSSG balance with a reduction 
in the antioxidant capacity of blood, saliva, plasma and GCF in chronic periodontitis patients 
compared to healthy controls (Grant et al. 2010; Konuganti et al. 2012; Biju et al. 2014; 
Baser et al. 2015). In addition, increased ROS release correlates with intracellular GSH 
depletion in neutrophils from chronic periodontitis patients (Dias et al. 2013b).  
Periodontal tissue damage may also arise due to premature neutrophil activation during 
migration, extracellular release of microbicidal products (e.g. NE and ROS) during the 
killing of some microbes (such as frustrated phagocytosis), or failure to resolve acute 
inflammatory responses (Smith 1994). There is also evidence of ROS production by 
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phagocytes activating osteoclasts, one of the major subtypes of cells found in bone involved 
in bone resorption (Galli et al. 2011).  
Neutrophil behaviour has been shown to be dysfunctional in specific types of periodontal 
disease. Localised aggressive periodontitis (LAP), previously known as localised juvenile 
periodontitis (LJP) (Kantarci et al. 2003) is a disease of adolescence with a genetic basis 
demonstrated by high incidence rates in individuals from the same family. LAP differs from 
chronic periodontitis, which largely occurs in adults and develops at a slower rate of 
progression. There are distinct differences in LAP sufferers compared to other forms of 
periodontitis including variations in the periodontal microflora and the specific involvement 
of first molar and incisor teeth. LAP patients otherwise appear to be systemically healthy 
individuals (Genco et al. 1986). A significant number (65-75%) of LAP sufferers have been 
shown to exhibit defective neutrophil chemotaxis (Lavine et al. 1979; Genco et al. 1980; Van 
Dyke et al. 1985; Page et al. 1985).  
1.10.2. Papillon-Lefèvre Syndrome  
Papillon-Lefèvre Syndrome (PLS) is a rare inherited autosomal recessive disease 
characterised by diffuse palmoplantar keratosis and severe precocious periodontitis (Papillon 
and Lefèvre 1924), in which tissue damage ensues during the eruption of the primary 
dentition causing severe inflammation of the periodontal tissues, destruction of collagen 
fibres of the periodontal ligament and alveolar bone loss that results in the loss of both the 
primary and secondary dentition (Battino et al. 2001; Dhanrajani 2009). Signs and symptoms 
appear between 1 and 4 years of age, typically resulting in permanent tooth loss during 
adolescence. The prevalence of PLS is estimated to be 1-4 cases per million and whilst there 
is no predominant racial or gender predilection, a third of reported cases involve parental 
consanguinity (Hart & Shapira 1994). Systemic immunodeficiency in PLS is relatively mild, 
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with 15-20% being pre-disposed to recurrent infections (Pham et al. 2004), yet local 
periodontitis is profoundly aggressive.  
PLS is caused by mutations in the gene encoding cathepsin C, (CTSC), also known as 
dipeptidyl peptidase I, (DPPI), resulting in loss of activity. The CTSC gene is located on 
chromosome 11 and spanning 4.7 kb and over 50 mutations in the gene have been reported as 
responsible for PLS with phenotypes ranging from specific loss of function (resulting in a 
deficiency) to complete absence of the enzyme (Hart et al. 1999; Toomes et al. 1999 Nakano 
et al. 2001; Korkmaz et al. 2010; Perera et al. 2012). In neutrophils, CTSC is responsible for 
the activation of granule-derived neutrophil serine proteases (NSPs) and its loss causes the 
subsequent cessation of NSP activity ( Pham & Ley 1999; de Haar et al. 2004). NSP 
deficiency results in a failure to eliminate periodontal bacteria and is thought to be the 
underlying cause of the severe periodontal disease in PLS patients but comprehensive and 
systematic characterisation of neutrophil function in PLS has been hampered by the rarity of 
the disease and case studies limited to individual patients.    
1.10.3. Obesity  
Obesity is a condition characterised by abnormal or excessive fat accumulation that poses a 
risk to general health; an individual with a body mass index (BMI) exceeding 30 kg/m
2
 is 
regarded as obese (WHO 2013). Obesity was classified as a disease by the American Medical 
Association in 2013 (Frellick 2013). Worldwide obesity has nearly doubled since 1980 with 
the highest numbers of obese individuals residing in Western countries including the USA 
and Europe (Pengelly & Morris 2009) and approximately 3.4 million adults a year die from 
obesity-related complications (WHO 2013). Obesity involves a complex pathological process 
arising as a consequence of environmental and genetic interactions, certain medical disorders 
such as Cushing’s and Prader-Willi Syndromes (Farooqi & O’Rahilly 2006; Han et al. 2010) 
42 
 
as well as lifestyle factors including inactivity and poor dietary habits (Kumanyika et al. 
2002). 
Direct adverse effects of obesity include altered blood pressure, insulin resistance and a low 
grade chronic inflammatory state ( Aguirre et al. 2002; Hotamisligil 2006) that contributes to 
obesity-related diseases. Obese individuals have a more than ten-fold risk of developing 
type-2 diabetes compared with normal weight individuals (Kopelman 2007) and 90% of 
diabetes patients are overweight or obese (Bray 2004). Furthermore, obesity is strongly 
associated with stroke incidence, respiratory disorders and osteoarthritis (O’Rourke 2009), 
with disease severity correlating with the extent of obesity (Suvan et al. 2011). The 
inflammatory state induced by metabolic surplus features a subclinical inflammatory 
response with few or no symptoms, characterised by increased circulating levels of pro-
inflammatory proteins and leukocytes (Bastard et al. 2006). Obesity may influence the risk of 
acquiring an infection or the outcome of an infection once it is established. Possible 
mechanisms include immune system dysregulation, reduced cell-mediated immune 
responses, obesity-related co-morbidities and pharmacological issues (Huttunen & Syrjänen 
2013; Falagas et al. 2009). Obesity has been shown to increase mortality rates in influenza 
(Louie et al. 2011; Yu et al. 2011), increase the incidence of urinary tract infections (Semins 
et al. 2012) and nosocomial infections (Choban et al. 1995; Kaye et al. 2011), and has 
positive associations with periodontitis (Suvan et al. 2015).  
1.10.3.1. Adipose tissue biology 
Adipose tissue is the major source of fatty acids in mammals and there are two types; brown 
adipose tissue (BAT) and white adipose tissue (WAT). BAT is a source of energy for non-
oxidative phosphorylation, which generates heat to aid adaptation to cold environments 
(Redinger 2009). WAT is the major source of total body fat and the source of fatty acids that 
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are used to generate adenosine trisphosphate (ATP) via oxidative phosphorylation in order to 
supply the body’s energy requirements. WAT is distributed all over the body with the major 
depots being subcutaneous, intra-abdominal, omental and visceral tissues (Gesta et al. 2007). 
WAT (which will subsequently be referred to as adipose tissue) functions include: 1) the 
storage of triglycerides under conditions of excess calorie consumption and their release 
during fasting periods, 2) thermoregulation, 3) insulin sensitivity and 4) mechanical organ 
protection. The cell types that comprise adipose tissue include adipocytes, macrophages, 
fibroblasts and endothelial cells. Adipocytes have a unique ability to change size in 
accordance with the body’s metabolic needs and without changing their cellular phenotype. 
Immune cells present in adipose tissue have been shown to have both anti-inflammatory and 
pro-inflammatory roles. For example, the macrophage M2 anti-inflammatory subtype is 
involved in immunosuppression and tissue repair, new blood cell formation and removal of 
necrotic adipocytes ( Cursiefen et al. 2004; Cinti et al. 2005), whereas the M1 pro-
inflammatory subtype is characterised by cytokine release that drives immune responses 
(Zeyda & Stulnig 2007; Reilly & Saltiel 2014). In lean individuals’ adipose tissue the M2 
macrophage phenotype dominates, thus maintaining a non-inflammatory adipose tissue state 
(Lumeng et al. 2007). 
1.10.3.2. Effects of obesity on metabolic and immune function  
Many hormones, cytokines, signalling factors, transcription factors and other bioactive 
molecules have roles in both metabolic and immune pathways. Both systems regulate each 
other; the inflammatory response to infectious/injurious agents requires metabolic support 
such as lipid mobilisation and energy redistribution during immune responses (Khovidhunkit 
et al. 2004).  
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In the obese state, the presence of heightened circulating levels free fatty acids (FFA) occurs, 
which act as ligands for TLR-4 and therefore may contribute to systemic inflammation (Shi 
et al. 2006; Kim et al. 2007) by activation of down-stream pro-inflammatory kinases 
including protein kinase C (PKC; Capurso & Capurso 2012). In addition, circulating FFA 
can activate macrophages, triggering a cytokine-driven inflammatory cascade and insulin 
resistance via TNFα, IL-6 and IL-1β (Saberi et al. 2009; Chawla et al. 2011). Oxidative 
stress is another major mechanism by which inflammation in obesity is initiated. This can 
occur as a result of elevated glucose levels within adipose tissues being taken up by resident 
endothelial cells and stimulating ROS generation within the cell, which in turn activates 
inflammatory signalling cascades (Brownlee 2001). Circulating levels of endothelial 
activation markers such as E-selectin, P-selectin and plasminogen activator inhibitor-1 are 
increased in obesity indicating an activation of endothelial cells (Vázquez et al. 2005). 
As body weight increases, adipose tissue changes its mass, distribution, cellular composition 
and function resulting in impaired tissue function. During sustained adipocyte hypertrophy 
the vasculature fails to adequately perfuse the expansion of adipose tissue resulting in tissue, 
hypoxia and apoptotic cell death. The cellular debris left behind causes the recruitment of M1 
macrophages and T cells via chemokines such as monocyte chemotactic protein-1 (MCP-1) 
from the circulation (Kim et al. 2007; Rausch et al. 2008). Recruited macrophages change in 
terms of M1:M2 macrophage ratio; with an increase in the M1 resulting in elevated tissue 
and systemic levels of pro-inflammatory cytokines (Esposito et al. 2003; Lehrke et al. 2004; 
Wellen & Hotamisligil 2005; Skurk et al. 2007) such as TNFα and IL-6 that inhibit adipocyte 
differentiation (Sethi & Vidal-Puig 2007). M1 macrophage cytokine release also recruits 
neutrophils to adipose tissue (Mraz & Haluzik 2014). The adipocyte-derived pro-
inflammatory cytokines, also known as adipokines, spill over into systemic circulation, 
contributing to a low-grade state of chronic inflammation. The adverse production of 
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adipokines is thought to be the key factor in obesity, giving rise to obesity associated diseases 
(Klöting & Blüher 2014) including cardiovascular disease and the metabolic syndrome, a 
disorder associated with abnormal carbohydrate and lipid metabolism (Molica et al. 2015). 
Metabolic syndrome encompasses a range of metabolic disorders including high blood 
pressure, inflammation, oxidative stress, insulin resistance, visceral obesity and impaired 
glucose regulation (Bjorntorp 1991; Lemieux et al. 2001; Eckel et al. 2005; Van Guilder et 
al. 2006). One underlying reason for the development of metabolic syndrome can include 
genetic pre-disposition to insulin resistance, however lifestyle factors such as diet and 
exercise might also lead to insulin resistance (DeFronzo & Ferrannini 1991).   
1.10.3.3. Adipokines  
Adipose tissue has been shown to function as an endocrine organ that can secrete numerous 
factors that, in excessive adiposity, can cause disease through dysregulated immune 
responses (Ouchi et al. 2011) as adipose tissue is a source of more than 600 adipokines (Lehr 
et al. 2012). The overlapping functions of macrophages and adipocytes demonstrate the 
definite link between metabolic and immune pathways. In fact, adipocyte precursors (pre-
adipocytes) have the potential to differentiate into macrophages after exposure to particular 
conditions (Charrière et al. 2003). In addition to macrophages, adipocytes produce a number 
of bioactive molecules that influence and communicate with other organ systems and can 
contribute to systemic inflammation. These adipokines have been found to make a significant 
contribution to chronic low-grade systemic inflammation characteristic of the obese state.  
Adipokines are soluble proteins that include chemokines, complement components, pro-
inflammatory and anti-inflammatory cytokines (Li et al. 2011). Upon receptor-binding they 
initiate intracellular signalling cascades resulting in phenotypic changes to the cell through 
altered gene expression and regulation. They are involved in a number of homeostatic 
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processes including food intake, lipid metabolism, insulin sensitivity, glucose metabolism, 
insulin secretion, immunity and inflammation (Blüher & Mantzoros 2015). They are 
effective at low concentrations and usually act on cellular receptors expressed by tissues 
within the surrounding environment of the cells they are produced by. Table 1.3 details well-
known and recently discovered adipokines. Adipokines, like other cytokines, are able to 
influence the secretion of other adipokines in networks, for example, IL-1β and TNFα can act 
synergistically in stimulating IL-6 secretion by human gingival fibroblasts (Kent et al. 1998). 
Conversely, the secretion of some adipokines can be inhibited by others, for example, IL-6 
and TNFα secreted by adipocytes inhibit the anti-inflammatory adiponectin from being 
released by adipocytes (Fasshauer et al. 2003; Bruun et al. 2003). 
The functions of many adipokines have been elucidated from the study of gene knockout 
animals. For example, knockout mice for the ob gene, which codes for leptin, are 
immunodeficient (Kimura et al. 1998) as characterised by impaired phagocytosis and 
abnormal cytokine gene expression (Loffreda et al. 1998). For some of the adipokines their 
function is only noticeable when the knockout animal is placed under certain conditions. 
Loss of the gene that codes for adiponectin has no dramatic effect on the normal diet of mice 
for example, but when fed on a high sucrose diet they develop insulin resistance and high fat 
accumulation in muscle tissue compared to control animals (Whitehead et al. 2005). TNFα is 
constitutively expressed in adipose tissue and provides a direct link between obesity and 
insulin resistance, demonstrated by the improved responsiveness of obese rats to insulin 
when treated with a TNFα receptor antibody (Hotamisligil et al. 1993).  
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Table 1.3 Characteristics of well-known adipokines  
(Adapted from Ouchi et al. 2011). IR = insulin resistance 
 
Adipokine Primary source 
Binding partner/ 
receptor 
Function References 
Adiponectin Adipocytes 
Adiponectin receptors 1 
and 2 
Anti-inflammatory; Induces M1 to M2 
switching in macrophages and reduces 
TNFα expression in adipose tissue. 
Decreases gluconeogenesis in liver. 
Wulster-Radcliffe et al. 2004; 
Ohashi et al. 2010;  Maeda et al. 
2002; Ouchi et al. 2000; Lago et 
al. 2007 
IL-1β 
Stromal vascular 
fraction cells 
IL-1 receptor Pro-inflammatory Dinarello 2009 
IL-6 
Adipocytes, 
stromal vascular 
fraction cells, 
liver and muscle 
IL-6 receptor 
Pro-inflammatory; stimulates 
angiogenesis and release of acute phase 
proteins 
Blanchard et al. 2009 
Leptin Adipocytes 
Ob-Ra (neutrophils) and 
Ob-Rb (monocytes) leptin 
receptors 
Regulates appetite, energy homeostasis 
and immune and inflammatory 
processes 
Otero et al. 2006; Matarese et 
al. 2005; Mantzoros et al. 2011; 
Eder 2009; Zarkesh-Esfahani et 
al. 2004 
Resistin 
Neutrophils and 
macrophages 
Unknown 
Promotes insulin resistance (IR) and 
inflammation through IL-6 and TNF 
secretion from macrophages 
Patel et al. 2003; Telle-Hansen 
et al. 2013 
TNFα 
Stromal vascular 
fraction cells and 
adipocytes 
TNF Receptors 1 and 2 
Pro-inflammatory, increases 
expression of cell adhesion molecules 
on endothelial cells 
Ware 2008; Locksley et al. 
2001; Bradley 2008 
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1.10.3.4. Neutrophils and obesity 
Neutrophils are the key initial responder to infectious agents and hence the impact of obesity 
on neutrophil function is attracting further study. The presence of neutrophils within adipose 
tissue has been demonstrated early in the course of weight gain in mice fed a high fat diet for 
90 days, peaking at 1.5% of the total stromal vascular fraction cells (Talukdar et al. 2012). 
Neutrophil infiltration via M1 macrophages results in a coordinated inflammatory response 
that includes the recruitment of and crosstalk between B- and T-cells, (Gerhardt et al. 2001) 
via the secretion of cytokines such as CXCL8 (Bruun et al. 2004; Mraz & Haluzik 2014) and 
CXCL2 (Rouault et al. 2013). These cytokines further mobilise neutrophil migration into the 
tissues; both are over-expressed in obese compared to lean individuals (Nijhuis et al. 2009). 
Neutrophils recruited to adipose tissue appear to promote the M2 to M1 macrophage 
phenotype switch (Elgazar-Carmon et al. 2008) that results following their exposure to 
interferon (IFN)-γ and/or TLR ligands (Mosser & Edwards 2008). Furthermore, neutrophils 
have been shown to participate in adipose tissue vascular inflammation (Leik & Walsh 2004; 
Shah et al. 2010). The levels of neutrophil elastase (NE) are raised in the adipose tissue of 
high fat diet-fed mice compared to normally-fed mice, inhibition of which resulted in 
improved glucose tolerance and insulin sensitivity and a reduction in neutrophil recruitment 
into the adipose tissue (Talukdar et al. 2012). In addition, NE has been found to degrade 
insulin receptor substrate 1 (Houghton et al. 2010). Neutrophils are thought to play important 
roles in obesity-related diseases such as during the development and progression of 
atherosclerotic plaques (Naruko et al. 2002; Ionita et al. 2010). In models examining 
thrombus formation, a complication of cardiovascular diseases, neutrophils were found to be 
the first cell type to adhere to endothelial cells at vessel injury sites (von Brühl et al. 2012), 
which was shown to precede platelet activation (Darbousset et al. 2012). Furthermore, NETs 
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have been shown to trigger platelet activation and thrombus formation in vitro (Fuchs et al. 
2007).  
1.10.4. Association between periodontitis and obesity  
Many chronic systemic inflammatory diseases associate with each other. The root cause of 
such associations is thought to be due to the shared presence of inflammatory 
markers/proteins that feature in the respective diseases and include CRP, inflammatory 
cytokines and leukocytes. Examples of inflammatory disease associations include rheumatoid 
arthritis with systematic lupus erythematosus (SLE; Bencze 1970), cardiovascular disease 
and diabetes (Kannel 1979), cancer with diabetes ( Wolf et al. 2005; Richardson & Pollack 
2005; Pannala et al. 2009) and notably, periodontitis with obesity.  
Obesity is associated with systemic inflammation that in turn is associated with increased 
susceptibility to chronic infectious diseases such as periodontitis (Falagas & Kompoti 2006). 
Many epidemiological studies have demonstrated an association between obesity and 
periodontitis in humans (Saito et al. 2001; Saito et al. 2005; Chaffee & Weston 2010; Nibali 
et al. 2013) and also the reverse, i.e. that maintaining a normal weight by regular exercise is 
associated with lower periodontitis prevalence (Wakai et al. 1999; Merchant et al. 2003 
Karjalainen et al. 2009). A meta-analysis study reported that the odds of having periodontitis 
increased by 27% and 81% for overweight and obese patients respectively relative to normal-
weight patients (Suvan et al. 2011). The periodontitis-obesity association can also be 
demonstrated across the life course (Dalla Vecchia et al. 2005; Saito et al. 2005; Ekuni et al. 
2008; Khader et al. 2009).  
The recently established relationship between obesity and periodontitis is consistent with a 
well-established paradigm of the relationship between obesity-associated type 2 diabetes and 
the incidence of periodontitis (Preshaw et al. 2012). This relationship appears to be bi-
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directional, i.e. having type 2 diabetes increases susceptibility to periodontitis and an 
individual suffering from periodontitis has an increased risk of developing obesity-related 
diseases including insulin resistance (Matsuzawa-Nagata et al. 2008). As obesity and type 2 
diabetes are highly interrelated, both are therefore thought to contribute to the development 
and progression of periodontal diseases; thus a three-way relationship has been suggested 
with each condition influencing the other two (Zhu & Nikolajczyk 2014).  
The link between obesity and periodontitis was first shown in 1977 using a ligature-induced 
periodontitis in obese Zucker rats, demonstrating bone resorption and periodontal 
inflammation were more severe in the obese cohort compared with controls (Perlstein & 
Bissada 1977). The underlying mechanisms for the association between obesity and 
periodontal disease are not well known and many studies reporting upon the association are 
cross-sectional in nature making a cause-and-effect relationship difficult to establish. Pro-
inflammatory adipokines and other bioactive substances are thought to be the major link, 
however, which may affect the periodontal tissues directly or indirectly (Ylöstalo et al. 
2008). Obesity could increase an individuals’ susceptibility to periodontitis by altering the 
host immune responses (Falagas & Kompoti 2006) via systemic oxidative stress as a result of 
the dysregulated production of pro-inflammatory cytokines, such as TNFα and IL-6 (Ando & 
Fujita 2009). One example of the hallmarks of periodontitis is the resorption of alveolar 
bone, caused by the increased expression of RANKL (receptor-activator of nuclear factor-κB 
ligand) which binds osteoclast pre-cursors and causes them to differentiate into bone 
resorbing cells (Cochran 2008); RANKL expression can be induced by the adipokines TNFα 
and IL-1β (Nagasawa et al. 2007). GCF and serum levels of some adipokines, notably leptin 
and IL-6, are altered in individuals who are obese and/or have periodontitis compared to 
normal weight, periodontally healthy controls (Zimmermann et al. 2013). Oxidative stress 
might be a major mechanism underlying obesity-related complications; in obese individuals 
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GSH concentrations were lower than those of normal weight individuals (Albuali 2014). In 
addition, GSH levels are reduced in periodontitis patients (Chapple et al. 2002; Grant et al. 
2010; Tsai et al. 2005) and the GSH level is inversely related to the severity of periodontal 
disease (Biju et al. 2014). The mechanism for this may relate to alterations in the redox 
balance and a systemic increase in ROS following obesity that may trigger gingival oxidative 
damage, which may lead to the progression of periodontal inflammation (Tomofuji et al. 
2009; Azuma et al. 2011). Another potential mechanism linking the two diseases is 
homotolerance, in which pre-exposure to TLR2 agonists LPS or FFA in macrophages causes 
a de-sensitisation to LPS re-stimulation, characterised by an inhibition of TNFα stimulation 
(Dobrovolskaia et al. 2003; Zelkha et al. 2010; Amar & Leeman 2013). Obesity has been 
shown to cause attenuated immune responses to P. gingivalis in mice, when, after infection 
with the bacteria, diet-induced obesity mice featured greater alveolar bone loss and higher 
levels of P. gingivalis compared to lean controls (Amar et al. 2007). Furthermore, 
macrophages isolated from diet-induced obesity mice secreted reduced levels of pro-
inflammatory cytokines following infection with P. gingivalis compared to lean mice, 
showing that obesity can interfere with the ability of the immune system to appropriately 
respond to infectious bacteria (Zhou et al. 2009).  
1.11. Project aims 
Understanding the extent to which neutrophils contribute to the pathogenesis of chronic 
inflammatory diseases remains to be fully elucidated. Neutrophils are well-known in host 
defences against acute, infectious episodes and their involvement in more long-term 
conditions is gaining momentum. Recent studies of their activity repertoire reveal greater 
lifespan potential than previsouly thought and the ability to perform a broader range of 
activities outside of direct pathogen-killing. Therefore, the overall aim of this thesis was to 
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contribute to the current understanding of the role of neutrophil functions in different 
diseases associated with chronic inflammation. In order to achieve these aims, the work 
described in this thesis had the following specific objectives: 
1. To optimise a method for the study of neutrophil chemotactic accuracy ex vivo. 
2. To assess neutrophil function in acute and chronic oral disease states.  
3. To assess neutrophil function in obese patients pre- and post-bariatric surgery. 
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2.1. Study volunteer donors 
2.1.1. Selection of healthy volunteers 
With the exception of clinical study work, all volunteers for blood sample donations were 
staff and students recruited from The School of Dentistry. The volunteers’ ages ranged 19-37 
years of age and were selected if they had no remarkable medical histories. All participants 
had BMI’s ranging 18-25, were non-smokers and were not taking any medication. Ethical 
approval was obtained from South Birmingham Research Ethics Committee (LREC 
2004/074) and written consent was gained from all participants. 
2.1.2. Gingivitis study - volunteer selection 
A 21 day model of experimental gingivitis (Löe et al. 1965) was conducted by the 
Periodontology Department of the School of Dentistry, as previously described by Chapple et 
al. (1996). Ethical approval was obtained from South Birmingham Research Ethics 
Committee (LREC 2004/074) and all volunteers gave written informed consent. Fifteen 
volunteers with no current or historic periodontal disease, not undergoing any 
orthodontic/prosthetic dental treatment and with unexceptional medical histories were 
enrolled. 
2.1.3. Chronic periodontitis - volunteer selection 
Two patient cohorts sre described here. The first cohort was used for the study of chemotaxis 
in chronic periodontitis as part of a larger clinical study in which GCF was collected, but was 
to be used for other experimental assays. Therefore GCF was collected from an additional set 
of chronic periodontitis patients to use in the assays described in this thesis. 
2.1.3.1. Periodontitis patient cohort 1 
Periodontitis patients were recruited from the Periodontology Department within the School 
of Dentistry along with gender- and age-matched healthy controls. Ethical approval for the 
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study was obtained from the West Midlands Research Ethics Committee (10/H1208/48) and 
all 20 volunteers provided written informed consent. Exclusion criteria for both patient and 
control subjects included diabetes, pregnancy, smokers and use of vitamin supplements. 
2.1.3.2. Periodontitis patient cohort 2 
GCF samples were collected from a cohort of 10 chronic periodontitis patients and ethical 
approval was obtained from the West Midlands Research Ethics Committee (14/SW/1148) 
and all gave written consent. Patient ages ranged between 30-60 years; gender: 5 female and 
5 male. Exclusion criteria for the patients included diabetes, pregnancy, smokers and use of 
vitamin supplements. GCF collection took approximately 30 seconds using paper strips 
(Lamster et al. 1986). 
2.1.4. Papillon-Lefèvre Syndrome (PLS) - volunteer selection 
Five Papillon-Lefèvre Syndrome (PLS) patients (age range 9-14 years) from different 
families were recruited by Professor Iain Chapple following a specialised clinic run by 
Dermatological and Periodontal specialists at the Birmingham Children’s Hospital (BCH). 
Ethical approval for the study was obtained from the West Midlands Research Ethics 
Committee (14/WM/1175) and all volunteers provided written informed consent. Prior to 
study commencement, all patients had been genotyped and their dermatological and 
periodontal status determined by clinical specialists from within the BCH. Healthy gender-
matched controls (aged 19-21) were recruited from undergraduate students within the School 
of Dentistry as described in section 2.1.1. Exclusion criteria for the healthy volunteers 
included diabetes and those taking medication. Control selection criteria included 
unremarkable medical histories and no evidence of periodontal disease. 
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2.1.5. Obese patient - volunteer selection 
Twenty-three patients (ages ranged 27-65) undergoing gastric band surgery were recruited 
from Heartland’s Hospital Community Weight Management Service by Mr Paul Super. 
Ethical approval for the study was obtained from the North West Research Ethics Committee 
(15/NW/07) and patients provided written informed consent. Patient exclusion criteria 
included pregnancy and smoking. Gender- and age-matched controls were also recruited 
from staff within the School of Dentistry. Exclusion criteria for the controls included a BMI 
over 27, pregnancy, smoking, and evidence of systemic disease and use of 
medications/vitamin supplements. 
2.2. Neutrophil isolation 
The following section details the isolation of neutrophils from whole blood using a 
discontinuous gradient (Pertoft et al. 1978) for use in further assays. Venous blood samples 
were collected in lithium heparin vacutainers (Greiner, Bio-One); the amount of blood 
collected depended on the experiment but did not exceed 30ml. 
2.2.1. Reagents for neutrophil isolation 
2.2.1.1. Percoll gradients 
Percoll (1.13g/ml, 8ml; GE Healthcare 17-0891-01), 1.098g/ml density was layered 
underneath Percoll (8ml) 1.079g/ml density in a 25ml centrifuge tube (Sarstedt). The 
composition of the Percoll gradients, which includes distilled water and sodium chloride 
(NaCl) (S9625 Sigma) dissolved in distilled sterile water, is documented in Table 2.1. The 
layered Percoll densities were stored at 4
o
C prior to use. 
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Table 2.1. Percoll density composition 
                        Density 
Component 1.079g/ml 1.098g/ml 
 
Percoll 
 
19.708ml 
 
24.823ml 
Water 11.792ml 6.677ml 
NaCl 3.5ml 3.5ml 
 
2.2.1.2. Lysis buffer 
Lysis buffer was made by adding NH4Cl (8.3g; Sigma, A9434), KHCO3 (1g; Sigma, P9144), 
Na2 EDTA 2H2O (0.04g; Sigma, E5134) and bovine serum albumin (2.5g; BSA; Sigma, 
A4530) sequentially to 1 litre of distilled water and stored 4
o
C prior to use. 
2.2.1.3. Phosphate buffered saline (PBS) 
PBS was made by adding NaCl (7.75g; Sigma, S9625), KH2PO4 (0.2g; Sigma, P5379) and 
K2HPO4 (1.5g; Sigma, P8281) to distilled water, the solution was adjusted for pH (7.3) and 
made up to 1 litre. The solution was subsequently autoclaved and stored at 4
o
C prior to use. 
2.2.1.4. Glucose supplemented phosphate buffered saline (gPBS) 
gPBS was made weekly using 1 litre of sterile PBS to which glucose (1.8g; Sigma G8270), 
CaCl2 (0.15g; Sigma C1016) and MgCl2 (1.5ml; 1M, Sigma M1028) was added sequentially 
and stored at 4
o
C.  
2.2.2. Neutrophil isolation method  
Whole blood (approximately 8ml) was layered on top of the pre-prepared Percoll gradients 
(Section 2.2.1.1). The tubes were then centrifuged (IEC Centra, CL3R) for 8 minutes (min) at 
150 relative centrifugal force (rcf), followed by 10 min at 1,200 rcf. The different cell layers 
that formed after centrifugation are shown in Figure 2.1.  
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Figure 2.1 Separation of blood by differential Percoll gradients  
After the two initial centrifugation steps the blood layers separate within the Percoll; the 
neutrophil layer sits above the red blood cell layer. 
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Plasma, monocyte and Percoll layers were removed by manual aspiration using a Pasteur 
pipette (Appleton Woods, KC230). The neutrophil layer, located at the top of the red blood 
cell layer, was aspirated and transferred to a 50ml centrifuge tube (Kartell) containing lysis 
buffer (35ml) (section 2.2.1.2). The tube was gently inverted and incubated for ten min at 
room temperature to lyse the red blood cells and subsequently centrifuged (6 min, 500 rcf). 
The supernatant was discarded and the pellet re-suspended in lysis buffer (5ml), incubated 
for 5 min at room temperature prior to re-centrifugation as before. The supernatant was 
removed and the cells were suspended in PBS (3ml) (2.2.1.3) and centrifuged again to 
remove any remaining lysis buffer and re-suspended in PBS (3ml). The cells were counted 
using a haemocytometer (Neubauer, Reichart) as explained in Figure 2.2 and viability 
(typically >97%) was checked using trypan blue dye exclusion (Sigma, T8154). Briefly, cells 
were mixed 1:1 with trypan blue and visualised by light microscope (Leitz Laborluxs). 
Neutrophils were re-suspended at concentrations required and used immediately in the assays 
detailed in subsequent sections. 
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Figure 2.2. Haemocytometer for calculating cell concentration  
Nine squares (shown in red) were the designated regions for counting neutrophils. The entire 
grid has a surface area of 1mm
2
 and a depth of 0.1mm, this represents a total volume of 10
-4 
cm
3
. As 1 cm
3
 = 1ml, the second part of the equation scales the cell count up to per ml.  
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2.3. Collection of plasma 
Plasma was isolated from blood collected into 6ml lithium heparin anticoagulant tubes by 
centrifugation (30 min, 1000rcf, 4°C; IEC Centra, CL3R), aliquoted (500μl) into cryotubes 
and stored at -80°C. 
2.4. Enhanced chemiluminescence assay for ROS 
2.4.1. Reagents prepared for use in the ROS assay 
2.4.1.1. Blocking buffer (PBS 1% BSA) 
BSA (10g; Sigma, A4503) was dissolved in 1 litre PBS to give 1% BSA in PBS. The 
solution was aliquoted into 20ml working volumes and stored at -20°C until use. 
2.4.1.2. Luminol and isoluminol 
A stock solution (30mM) was made by dissolving luminol (0.5g; Sigma, A8511) or 
isoluminol (0.5g; Sigma A8264) in 94.05ml 0.1M NaOH and stored at 4C.  The working 
solution was made by diluting 1ml stock luminol or isoluminol with 9ml PBS and the pH 
adjusted to 7.3 with dilute HCl. The final well concentrations for use in the ROS assays were 
0.45mM for luminol and 0.9mM for isoluminol respectively. 
2.4.1.3. Lucigenin 
A stock solution (1mg/ml) of lucigenin (Sigma. B49203) in PBS was prepared and stored at 
4C.  The working solution (0.33mg/ml) was made by diluting the stock solution 1:3 in PBS. 
The final well concertation was 0.05mg/ml. 
 
 
62 
 
2.4.1.4. Horseradish peroxidase (HRP) 
HRP (Sigma, P8415) was diluted in PBS to give a working concentration of 100 Units 
(U)/ml which was stored at -20°C until use. When used in the ROS assay the final well 
concentration was 1.5U/well. 
2.4.1.5. Plate preparation for ROS assays 
Blocking buffer (2.4.1.1) was defrosted to room temperature and 200µl was added to each 
well of a white 96 well microplate (Costar, 3915) and incubated at 5°C overnight. Before use 
in ROS/NET assays the plates were washed five times with PBS using a microplate washer 
(BioTek, ELx50). 
2.4.2. Enhanced chemiluminescence assay for ROS 
Neutrophils were prepared as previously described (2.2.2) and cells (100µl, 1x10
6 
cells/ml) in 
gPBS (2.2.1.4) were added to white 96-well plates blocked as previously described (2.4.1.5). 
To detect total ROS generation luminol (30µl, final concentration 0.45mM) (2.4.1.2) was 
added. To detect extracellular radical generation, isoluminol (60µl, final concentration 
0.9mM) (2.4.1.2) in addition to HRP (15µl, 1.5 units) (2.4.1.4) were added. To detect 
superoxide generation, lucigenin (30µl, final concentration 0.05mg/ml) (2.4.1.3) was added. 
The total volume of each well was made up to 175µl using PBS and the light output was 
recorded for 1 second per well in relative light units (RLU) using a microplate luminometer 
(LB96v Bethold Technologies U.K. Ltd.) at 37C cycling around the plate over the course of 
the experiment. The plate was read for 30 min before 25µl of stimuli were added to give a 
total volume of 200µl per well and read for a further 120 min. For experiments including a 
priming stage, in which neutrophils were exposed to a priming agent for 30 min prior to 
stimulation, the agent or control (10µl) were added to the relevant wells. 
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2.4.3. Stimuli/priming agents used to induce ROS 
2.4.3.1. Priming 
GM-CSF (Sigma SRP3050) was diluted in PBS to give 200ng/ml working solution in which 
10µl was added to the relevant wells giving a final concentration of 10ng/ml in the well. 
2.4.3.2. Stimuli for induction of ROS 
The range of stimuli used for ex vivo stimulation of peripheral neutrophils for the assay of 
ROS formation is listed in Table 2.2. All bacteria used are known periodontal pathogens 
grown as described later (2.8).  
Table 2.2 Stimuli used to induce neutrophil ROS production 
Bacterial strain (ATCC number)/other 
stimulus 
ATCC number/ 
Supplier and Cat 
No. 
Concentration 
per well 
Fusobacterium nucleatum subsp. 
Polymorphum (F. nucleatum) 
10953 3 x 10
7
 
Aggregatibacter actinomycetemcomitans 
serotype b  (A. actino) 
43728 3 x 10
7
 
Opsonised Staphylococcus aureus (Ops S. 
aureus) 
9144 1.5 x 10
7
 
Phorbol 12-myristate 13-acetate (PMA) Sigma P8139 25μM 
2.5. Assays of NET release 
2.5.1. Micrococcal nuclease (MNase) assay of NET release  
Neutrophils (100µl, 1x10
6 
cells/ml) were suspended in RPMI (Sigma R8758) and added to 
blocked white 96 wells plates previously described as for the ROS assay (2.4.1.5). Additional 
RPMI was added to give a final volume of 175µl after consideration of any additional agents. 
After a 30 min initial incubation (37°C), stimuli or RPMI (25µl/well) were added and the 
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plate was incubated for up to 3 hours (37°C). After stimulation NET-DNA was digested: 
MNase (Worthington, LS004797; 15µl, 1 unit/ml) was added per well and re-suspended by 
pipette aspiration. The plate was incubated at room temperature for 20 min. After 
centrifugation (10 min, 1800 rcf) to pellet the cells, supernatant (150µl) was removed and 
added to a black 96 well plate (Costar 3912) and fluorescent green nucleic acid stain, 
SYTOX
®
 (Invitrogen, S7020; 15µl, 10nM diluted in RPMI) was added. Fluorescence was 
recorded from each well in arbitrary fluorescent units (AFU) using a fluorometer (Twinkle 
LB970, Berthold Technologies) with an excitation wavelength of 485nm and an emission 
wavelength of 525nm. 
2.5.2. Visualisation assay of NET release 
NET visualisation, a qualitative means of assessing NET production, was performed using 
24-well plates (Costar 3524) which were blocked with PBS containing 1% BSA (500μl) and 
incubated at 4ºC previously overnight. The blocking buffer was removed by vacuum 
aspiration and neutrophils (1 x 10
5
/ml, 200μl suspended in RPMI) were added to each well. 
After an initial incubation (30 min, 37°C), stimulus (50µl) and additional RPMI (50µl) were 
added and the plate was incubated for a further 2 hours at 37°C. Post incubation fluorescent 
green nucleic acid stain SYTOX
®
 (Invitrogen, S7020; 100nM, 25µl diluted in RPMI) was 
added to each well. Cells were visualised using a fluorescence microscope (Nikon Eclipse 
TE300, Surrey, UK) using a x20 objective lens and images captured by digital camera 
(Nikon CoolPix 450, Surrey, UK). 
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2.5.3. Stimuli used to induce NETs 
The stimuli listed in Table 2.3 were used for in vitro stimulation of peripheral neutrophils for 
the assay of NET production. All stimuli were diluted in RPMI to their respective 
concentrations.  
Table 2.3. Stimuli used to induce neutrophil NET formation 
Bacteria/other stimulus 
ATCC number/ 
Supplier and Cat N
o
 
Concentration 
per well 
Staphylococcus aureus (S. aureus, 
opsonised) 
9144 3 x 10
7
 
Phorbol 12-myristate 13-acetate (PMA) Sigma P8139 50nM 
Hypochlorous acid (HOCl) Sigma 0.75mM 
2.6. Chemotaxis assay 
2.6.1. Chemotaxis assay protocol 
Neutrophils (1 x 10
6
/ml) were suspended in RPMI supplemented with BSA (Sigma, A8412; 
1.5µl/ml 7.5%). Coverslips (22mm x 22mm; VWR International, VWRI631-0125) were 
washed in HCl (0.2M) followed by sterile water and dried on filter paper. The coverslips 
were coated in BSA (400µl at 7.5%; Sigma A8412) and excess fluid was removed by 
aspiration. Immediately after aspiration, neutrophil suspension (400µl) was added and the 
coverslips were incubated for 30 min at room temperature. The Insall chamber (Muinonen-
Martin et al. 2010) was used to study chemotaxis (Figure 2.3). The chamber was washed 3 
times with RPMI (400µl). A large droplet of RPMI was left on the chamber after washing. 
After the 30 min incubation, the coverslip with the cell suspension was inverted and placed at 
the top of the chamber ensuring that the pipette loading bays were exposed. Excess fluid 
surrounding the coverslip and within the chemoattractant wells was removed using filter 
paper. Finally, desired chemoattractant or RPMI (70µl) were injected into the 
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chemoattractant well and cell movement analysed by microscopy. The chamber was viewed 
using a Zeiss Primovert microscope at x20 magnification and images were captured using a 
Q Imaging Retiga 2000R camera. Images were processed using Q proimaging software 
(Surrey, Canada) and generated every 30 seconds for a total of 40 frames creating a stack of 
40 images.  
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Figure 2.3. Schematic representation of the Insall Chamber  
Aspiration of excess fluid from the inverted coverslip forms a seal allowing for the 
introduction of chemoattractant through the exposed wells. 
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2.6.2. Chemotaxis image analysis 
The image stacks were analysed further using Image J 1.45SR software (Maryland, USA). 
The manual tracking plug-in MtrackJ (Meijering et al. 2012) was used and for each set of 
images and unless otherwise stated, 15 cells were chosen and tracked through the stack. The 
numerical data generated was then exported into excel and used to calculate cell speed, cell 
velocity and chemotactic index (CI) per experiment, which are defined in Figure 2.4. These 
measurements have been calculated using formulas derived by Sapey et al. (2011) and 
Muinonen-Martin et al. (2013) as shown in Figure 2.4. Statistical analysis of each parameter 
was calculated using Prism 5.0 software (GraphPad, USA).  
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Figure 2.4 Chemotaxis parameters 
Speed, velocity and chemotactic index (CI) were all used to provide an accurate profile of cell chemotaxis. 
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2.6.3. Circular statistics 
The XY coordinates of the cell tracks were further analysed using the circular statistics 
(CircStat) toolbox from MATLAB software (Mathworks, USA) to ascertain the significance 
of the directionality of cell movement over the time course on an angular scale. Data was 
processed to yield circular rose plots, angle histograms and the mean resultant vector, which 
is a measure of the distribution of the cells on a quantifiable scale.  
2.6.4. Stimuli used to induce chemotaxis 
Table 2.4 shows all the chemoattractants, both bacteria and host-derived, used for the 
different studies outlined in this thesis. All were diluted in PBS (2.2.1.3) to their respective 
working concentrations. In addition, Cathepsin G (CG 25µg/ml; Sigma C4428) was pre-
incubated (30 min at room temperature) with MIP1α (100ng/ml) in a particular study to 
demonstrate the effect of cleavage of the chemokine to induce chemotaxis. 
Table 2.4. Chemoattractants used to induce neutrophil chemotaxis 
Stimuli Supplier/Cat No. Concentration in chamber 
Interleukin 8 (CXCL8) Sigma SRP3098 200ng/ml 
fMLP Sigma F3506-5MG 10nM 
MIP1α R&D Systems 270-LD-010 100ng/ml 
GM-CSF Sigma SRP3050 20pg/ml 
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2.7. Neutrophil cell culture method for cytokine release 
2.7.1. Supplemented RPMI for cell culture assay 
RPMI (34.5ml; Sigma, R8758) was supplemented with glutamine (0.3g/l), foetal calf serum 
(20ml; Sigma, F4135 diluted to 10% in RPMI), HEPES (2.23g; Sigma, H4034 diluted in 
20ml RPMI and adjusted for pH to 7.3) and streptomycin (100µg/ml; Sigma, P4333). The 
solution was filter sterilised using 0.22µm syringe filters (Millipore SLGVV255F) and the 
solution was stored for up to a week at 4C prior to use. 
2.7.2. Overnight culture of stimulated neutrophils  
Neutrophils (100µl, 2.5 x 10
6
 per well) were suspended in supplemented RPMI (2.7.1). An 
additional 300μl of supplemented RPMI was added to each well. After a 30 min incubation 
step at 37C, stimuli/RPMI control (100μl) was added to the relevant wells and incubated for 
18 hours at 37C (Hatanaka et al. 2006). Post incubation viability was assessed using Trypan 
Blue exclusion (1:1 dilution) and cell counting. Cells were pelleted by centrifugation (10 
min, 2000 rcf; SciSpin micro, Geneflow). The supernatants were collected and stored at -
80C for subsequent future measurements.   
2.7.3. Stimuli used for overnight culture assay 
Table 2.5 describes the various stimuli used to stimulate cytokine release from the 
neutrophils. LPS derived from E. coli (Sigma, L5543) was diluted with supplemented RPMI 
containing AB plasma (10% v/v; Sigma, H4522). All handling of LPS was done so using 
siliconized tips (Sigma, Z719595) and eppendorfs (Sigma, T3281). All other bacterial stimuli 
were diluted in RPMI to desired concentrations.  
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Table 2.5. Stimuli used during overnight cell culture.  
Multiplicity of infection (MOI) respresents the number ratio of bacteria to neutrophils. 
Bacteria/ 
other stimulus 
ATCC 
number/ 
Supplier and 
Cat No. 
Concentration 
per well 
Anaerobic
/ 
aerobic 
Bacteria/
ml if 
OD600=1 
Multiplicity 
of infection 
(MOI) 
  
E. coli LPS Sigma, L5543 5µg/ml - 
1.62 x 10
9
 
-   
F. nucleatum 10953 3 x 10
7
 
Anaerobi
c 
6.80 x 10
9
 
300:1   
A. 
actinomycetemcomi
tans b 
43146 3 x 10
7
 
Anaerobi
c 
1.69 x 10
8
 
300:1   
Opsonised S. 
aureus 
9144 1.5 x 10
7
 Aerobic 1.69 x 10
9
 
150:1   
2.8. Storage and preparation of bacterial stimuli.  
For use as neutrophil stimuli, anaerobic and aerobic periodontal bacteria were originally 
obtained from the Forsyth Institute (Boston, USA) or purchased from the American Type 
Culture Collection (ATCC: F. nucleatum) with the exception of T. forsythia which was 
provided by Mike Milward. All bacteria were stored at -80
o
C in 2ml cryovials containing 
1.5ml tryptone soya broth supplemented with DMSO 10% v/v.  
To grow the bacteria, the frozen aliquots were defrosted at room temperature, inoculated 
(100μl) and spread onto agar plates using a sterile loop. After 3-5 days of growth subsequent 
cultures were grown by inoculating broths by scraping a single colony using a sterile loop. 
Broth cultures were incubated overnight in order to reach stationary growth phase (approx. 
10
9
/ml). Broth concentration was monitored using additional agar plates inoculated from 
broth cultures. The bacterial broth suspensions were pelleted and then washed twice with 
PBS by centrifugation (3,000 rcf, 10 min) and, heat-killed (60 min at 85
o
C) whilst suspended 
in sterile PBS. A portion of the suspension was also re-inoculated onto agar plates to ensure 
the bacteria were dead. Bacterial numbers were estimated from the PBS suspension using a 
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spectrophotometer (Jenway 6300) at optical density 600nm (OD600nm). The OD600nm values 
used to estimate bacterial growth were calculated by the Forsyth Institute, Boston and are 
listed in Table 2.6. All bacteria were stored at -20C. 
Table 2.6. Bacteria used in neutrophil assays 
Bacterial strain 
ATCC 
number 
Anaerobic/ 
aerobic 
Bacteria/ml 
if OD600=1 
Multiplicity 
of infection 
(MOI) 
F. nucleatum subsp. 
polymorphum 
10953 Anaerobic 1.62 x 10
9
 
300:1 
A. actinomycetemcomitans b 29523 Anaerobic 6.80 x 10
9
 
300:1 
Opsonised S. aureus 9144   Aerobic 1.69 x 108 
150:1 
Streptococcus constellatus 27823 
Anaerobic 1.69 x 10
9
 
500:1 
Actinomyces viscosus 43146 
Anaerobic 8.30 x 10
8
 
300:1 
Tanerella  forsythia 43037 
Anaerobic 
8.30 x 10
8
 300:1 
2.8.1. Preparation of anaerobic bacteria 
Agar and broths were used as described in Table 2.7. Bacteria were grown on blood agar 
plates in an anaerobic chamber (Don Whitley Scientific, Modular Atmosphere Controlled 
System, CAL-3200, Shipley, UK) with carbon dioxide (9.97%), hydrogen (9.92%) with 
nitrogen balance at 37
o
C. Colonies were subsequently picked off the plates and grown in 
brain heart infusion (BHI) broth, aliquoted into 10ml batches and autoclaved (121
o
C, 15min). 
Broths not immediately used were stored at 4
o
C for up to three weeks. 
2.8.2. Preparation of Opsonised S. aureus 
S. aureus was grown aerobically in a 5% CO2 chamber (Gallenkamp Plus II Incubator) at 
37
o
C on tryptone soya agar (TSA) plates which were autoclaved at 121
o
C for 15min. After 
cooling to approximately 40
o
C the liquid was poured into petri dishes (Sterilin 101/IRR) and 
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allowed to set. The plates were stored at 4
o
C for up to 3 weeks when not in use. Plate 
colonies of S. aureus were subsequently grown overnight in tryptone soya broth (TSB) which 
was separated into 10ml aliquots and autoclaved. Broths not immediately used were stored at 
4
o
C for up to three weeks. After washing in PBS, bacterial density was determined 
spectophotometrically (section 2.8). For opsonisation the suspension was further diluted in 
sterile PBS to give a suspension of 1x10
9
 bacteria per ml. The bacteria were heat treated by 
incubation at 80C for 20 min prior to the addition of 33µl Vigam liquid (5mg/ml IgG; Bio 
Products Laboratory) per ml of bacteria and incubated overnight at room temperature with 
constant agitation to allow opsonisation. Following incubation the bacteria were again 
washed twice in sterile PBS by centrifugation and re-suspension, and stored at -80C. 
Bacterial numbers were again estimated by spectrophotometry to allow resuspension in PBS 
to give 6x10
8
/ml prior to use. 
Table 2.7. Preparation of agar and broths for bacterial growth 
 
Bacteria Growth media 
Supplier/Cat 
No. 
Preparation 
Anaerobic Blood agar 
Oxoid, 
CM2071 
Ready to use 
 
Brain Heart Infusion (BHI) 
broth 
Oxoid, 
CM1135 
37g in 1 L dH2O 
Aerobic Tryptone Soya Agar (TSA) 
Oxoid, 
CM0131 
20g in 500ml dH2O 
 
Tryptone Soya Broth (TSB) 
Oxoid, 
CM0129 
10g in 1 L dH2O 
 
2.8.3. Identification of bacteria by Gram stain 
Bacterial colonies were picked off agar plates using a sterile loop and emulsified in a droplet 
of distilled water on a microscope slide. The slide was then passed several times through a 
flame to evaporate the liquid and fix the bacteria. Crystal violet (2g in 20ml 95% ethanol; 
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Sigma, C0775), mixed 1:1 with ammonium oxalate (1%, 0.8g in 80ml distilled water; Sigma 
A8545) was added for 30 seconds followed by the addition of Lugol’s iodine (Sigma, L6146) 
for another 30 seconds after which the slide was rinsed with distilled water. Acetone was 
added and immediately rinsed with water. Finally the slide was treated with carbol fuchsin 
(1ml diluted with 9ml distilled water; BDH, 351874U) for 30 seconds and rinsed with 
distilled water. After blotting dry, the slide was viewed under oil immersion microscope 
(Leitz Dialux 22).  Images were captured using a digital camera (Nikon Coolpix 990) and are 
shown in Figure 2.5.    
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Figure 2.5. Photographs of cultured bacteria used as neutrophil stimuli 
 
Gram stains of grown bacteria: a = S. aureus (Gram positive), b = A. actinomycetemcomitans b (Gram positive), c = F. nucleatum (Gram negative, ), 
d = A. viscosus (Gram positive), e = S.constellatus (Gram positive). x20 magnification.    
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2.9. Protein quantification from biological samples  
The protein content of collected GCF and plasma samples were measured using the 
bicinchoninic acid (BCA) protein assay as previously described (Smith et al. 1985). 
2.9.1. Bicinchoninic acid (BCA) assay preparation 
Plasma samples were diluted 1:100 with distilled water. GCF samples were used neat. 
Standards (ranging 0-1mg/ml) were made using BSA (Sigma, P0834) diluted in PBS. 
2.9.2. BCA assay protocol 
BCA reagent (Sigma, B9643) was added to copper (II) sulphate solution (Sigma, B9643) at a 
1:50 dilution and 200μl was added to each well of a 96 well microplate (Corning, 3591). 
Standard/sample (10μl) was added to their corresponding well and incubated (30 min, 37oC). 
Absorbance was measured immediately after in a microplate reader (BioTek ELx800) at a 
wavelength of 570nm. 
2.10. Cytokine/protein quantification from oral health and disease samples  
2.10.1. IL-1β and TNFα detection by ELISA 
2.10.1.1. IL-1β and TNFα ELISA reagent preparation 
TNFα and IL-1β were quantified from GCF samples using commercially available kits 
(Thermo Scientific, EH3TNFA and KHC0011 respectively). All GCF samples were diluted 
1:6 with sterile PBS. Standrards (ranging 0-250pg/ml for IL-1β and 0-1,000 pg/ml for TNFα) 
were diluted 1:2 using provided reagent diluent. 
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2.10.1.2. IL-1β and TNFα ELISA protocol 
Standard/pre-diluted test samples (50μl) were added in duplicate to relevant wells. 
Biotinylated anti-IL-1β/ TNFα solution (100μl) was added per well and the plate was sealed 
and incubated at room temperature for 2 hours. After a manual wash step (400μl per well, 
aspirated and repeated x4) using wash buffer, streptavidin-HRP (100μl) was added and the 
plate was sealed and incubated for 30 min at room temperature. After a repeat wash step 
chromogen substrate (100μl) was added to each well. The plate was incubated in darkness at 
room temperature for 30 min after which Stop Solution (100μl) was added. Absorbance was 
immediately measured using a microplate reader (BioTek ELx800) at 450nm.  
2.10.2. LL-37 detection by ELISA 
2.10.2.1. LL-37 ELISA reagent preparation 
LL-37 was quantified from plasma and cell culture supernatant samples using a commercial 
ELISA kit (Hycult Biotech, HK321). Plasma samples were diluted 1:100 with diluent buffer 
and cell culture supernatants were used neat. Standards, ranging 0-100ng/ml were diluted 
serially (1:2) using diluent buffer. 
 
2.10.2.2. LL-37 ELISA protocol 
Standard/pre-diluted test sample (100μl) was added in duplicate to relevant wells. The plate 
was covered with an adhesive seal and incubated for 1 hour at room temperature with mild 
agitation (Luckham R11/TW, speed 2), after which the plate was washed 4x using wash 
buffer (300μl per well). Tracer solution (100μl) was added and the plate was incubated again 
for 1 hour at room temperature. After a repeat wash step, strepavidin-peroxidase solution 
(100μl) was added to each well and incubated again for 1 hour at room temperature. Post 
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incubation the plate was washed and 3,3’,5,5’-Tetramethylbenzidine (TMB; 100μl) substrate 
was added to each well and the plate was wrapped in aluminium foil to exclude light and 
incubated for 30 min at room temperature. Finally oxalic acid stop solution (100μl) was 
added and absorbance was read immediately using a microplate reader (BioTek ELx800) at 
450nm. 
2.10.3. Neutrophil elastase (NE) detection by ELISA 
2.10.3.1. NE ELISA preparation 
Neutrophil elastase (NE) was quantified from plasma and cell culture supernatants using a 
platinum ELISA kit (eBioscience, BMS269). All plasma samples were diluted 1:100 using 
sample diluent and cell culture supernatants were used neat in the assay. Standards (ranging 
1-10ng/ml) were diluted with reagent diluent. 
2.10.3.2. NE ELISA protocol 
Standard/pre-diluted test sample (100μl) was added to the relevant wells (in duplicate) of the 
provided antibody-coated microwell plate, covered with an adhesive film and incubated on a 
microplate shaker (set to 400rpm) at room temperature for an hour. Post incubation the plate 
was washed 4 times with wash buffer (300μl), after which HRP-Conjugate anti-α1-PI 
polyclonal antibody (150μl) was added per well and the plate was covered and incubated 
again at room temperature for an hour with agitation (Luckham R11/TW, speed 2). After 
another wash step, TMB (200μl) substrate solution was added to all wells, the plate was 
wrapped in aluminium foil to exclude light and incubated at room temperature for up to 20 
min. Stop solution (50μl; 2M HCl) was subsequently added to all well and absorbance was 
read immediately using a microplate reader (BioTek ELx800) at 450nm.    
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2.10.4. Protein carbonyl detection by ELISA  
2.10.4.1. Protein carbonyl ELISA reagent preparation 
Plasma carbonylation, was measured in samples as previously described (Carty et al. 2000) 
and recently reviewed (Augustyniak et al. 2015). Oxidised BSA standards were kindly 
provided by Dr Irundika Dias (Aston University). BSA (Sigma P0834) (40mg/ml) was 
reduced with ascorbic acid (25mM) and ferrous ammonium sulphate (0.1mM) diluted in PBS 
containing EDTA (1mM). Plasma samples were all diluted to give 20μg/ml as measured by 
the BCA assay (2.9.2). The samples were diluted in sodium carbonate buffer (50mM; 1.59g 
Na2CO3 with 2.93g NaHCO3/L distilled water; pH 9.2) and used immediately. 0.05% and 1% 
Tween-20 (Sigma, P2287) were prepared by diluting 1:2000 and 1:100 with PBS 
respectively. Di-nitrophenol hydrazine (DNPH; Sigma, D199303; 10mM) was prepared by 
diluting in 2M HCl.  OPD substrate was prepared by adding a 20mg o-phenylenediamine 
tablet (Sigma, P5412) to 10ml of citrate buffer (0.15M; 49ml of 21g/l citric acid added to 
51ml 35.6g/l Na2HPO4; pH 5) with 10µl 8.8M hydrogen peroxide (Sigma, 516813) 
immediately before use.  
2.10.4.2. Protein carbonyl ELISA protocol 
Oxidised BSA standard or diluted plasma sample (50µl at 20mg protein/ml) was added in 
duplicate to a clear Nunc-Immuno 96 well microplate (Sigma, M5785); the plate was covered 
with aluminium foil and incubated for 1 hour at 37
o
C. The plate was washed 3 x using PBS 
containing 0.05% Tween-20 (200µl/well), after which di-nitrophenol hydrazine (50µl/well) 
was added to derivitise the standards/sample and the plate was incubated covered at room 
temperature for 1 hour. After a repeat wash the plate was blocked with PBS Tween-20 1% 
(200µl/well) and incubated overnight at 4
o
C. Post incubation the plate was washed as before, 
and antiserum mouse IgE antibody (Sigma, D8406; 50µl/well; diluted 1:2000 in PBS Tween-
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20 1%) was added and the plate was incubated covered at 37
o
C for 2 hours. After re-washing 
the plate, peroxidase labelled rat anti-mouse IgE secondary antibody (50µl; diluted 1:500 in 
PBS Tween-20 1%; Sigma, A9044) was added, and the plate was covered and incubated for 
1 hour at 37
o
C. Post incubation the OPD substrate (50µl/well) was added and the plate was 
incubated covered at room temperature for 15 min. H2SO4 (25µl; 2M) stop solution was 
added per well and the plate was immediately read at 490nm on a microplate reader (BioTek 
ELx800).  
2.10.5. S100A-8/9 detection by ELISA 
2.10.5.1. S100A-8/9 ELISA reagent preparation 
S100A-8 and S100A-9 proteins were quantified from plasma and cell culture samples using 
Duoset Sandwich ELISA kits (R&D Systems, DY4570 and DY5578 respectively). All 
additional reagents required were from the DuoSet Ancillary Reagent Kit 2 (R&D Systems, 
DY008). All plasma and culture supernatants were used neat. Standards (ranging 31.3-
2000pg/ml) were diluted 1:2 in PBS 1% BSA (section 2.4.1.1). 
2.10.5.2. S100A-8/9 ELISA protocol 
Capture antibody (100μl; 4μg/ml diluted with PBS 1% BSA) was added to each microplate 
well. The plate was sealed and incubated overnight at room temperature. After incubation the 
fluid was aspirated from each well and washed 3 x with wash buffer (300μl). The plate was 
blocked with ELISA plate-coating buffer (200μl) and incubated at room temperature for 1 
hour. After a repeat wash step the plate was ready to use.  
Sample/standards (100μl/well) were added to the appropriate wells. The plate was sealed and 
incubated for 2 hours at room temperature. After a repeat wash step detection antibody 
(100μl/well; 500ng/ml diluted with PBS 1% BSA) was added and the plate was incubated for 
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2 hours at room temperature. After a repeat wash, streptavidin-HRP (100μl/well; diluted in 
PBS 1% BSA) was added and the plate was incubated for 20 min at room temperature. Post-
washing, substrate solution (100μl/well) was added per well and the plate was incubated foil-
wrapped for up to 20 min. Stop solution (50μl/well; 2M H2SO4) was added and absorbance 
was immediately read using a microplate reader (BioTek ELx800) at 450nm. 
2.10.6. Cytokine detection by Luminex assay  
2.10.6.1. Luminex assay reagent preparation 
Procartaplex
TM
 multiplex immunoassays (Affymetrix eBioscence) were used to quantify the 
cytokines IL-1β (EPX010-10224-901), CXCL8 (EPX010-10204), IL-6 (EPX010-10213-
901), TNFα (EPX010-10223-901), MIP1α (EPX010-12029-901) and the enzyme MMP-9 
(EPX010-12016-901) from patient and control plasma, and cell culture supernatants. For 
cytokine quantification both plasma and cell culture supernatants were used neat. For MMP-
9, plasma was diluted 1:50 with universal assay buffer and cell culture supernatants were 
used neat. Standards were re-constituted in supplemental RPMI (2.7.1) for cell culture 
supernatants and universal assay buffer for plasma samples (50μl). Each separate standard 
type was then vortexed for 30 seconds and after centrifugation (2000 rcf for 10 seconds) the 
standards were incubated on ice for 10 min to ensure complete reconstitution. The entire 
contents of each standard were pooled and after a repeat vortex and centrifugation step was 
diluted 4-fold serially using the appropriate diluents. 
2.10.6.2. Luminex assay protocol 
All antibody magnetic beads for the respective analytes were pooled; the pool was vortexed 
and 50μl was added to each microplate well after which the plate was immediately inserted 
into a hand-held magnetic plate washer and incubated at room temperature for 2 min. The 
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plate was then washed with wash buffer (150μl/well) and removed from the magnetic plate. 
For plasma sample analysis, universal assay buffer (25μl) was added to wells followed by 
plasma (25μl). For cell culture supernatants, only samples (50μl) were added to their 
respective wells. Standard (50μl) were added to relevant wells; plasma standards were pre-
diluted 1:2 with universal assay buffer. The plate was sealed, covered with a black microplate 
lid and incubated at room temperature with agitation (Luckham R11/TW, speed 2) for 2 
hours. After a repeat washing step using the plate within the magnetic plate washer, each 
detection antibody (25μl/well) was added to every well, sealed and covered, and incubated 
with agitation at room temperature for 30 min. After two repeat wash steps, streptavidin-PE 
(50μl/well) was added to each well and the plate was incubated with agitation for 30 min. 
After two repeat washes, reading buffer (120μl/well) was added to each well and the plate 
was sealed and incubated with agitation for 5 min. Mean fluorescence intensity (MFI) was 
then measured on a Luminex 100/200 (USA) in the Clinical Immunology labs at the 
University of Birmingham. Data was recorded and processed using xPONENT® software 
(USA). 
2.11. Neutrophil function in inflammatory states 
2.11.1. Neutrophil function in gingivitis 
Section 2.1.2 details the volunteers recruited for the study of neutrophil function in gingivitis. 
For each volunteer moulds of their upper mandible were taken in order to construct a soft 
vinyl mouth guard (Figure 2.6) to cover the maxillary left 4-6 teeth to be worn during 
brushing to shield the area from mechanical or chemical cleaning. The maxillary right 4-6 
teeth (undergoing normal hygiene practices) were used as control teeth. For the entirety of 
the study volunteers were asked to refrain from chewing gum or using mouthwashes. The 
study period (Figure 2.7) consisted of an initial pre-baseline assessment (day -14) in which 
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impressions were taken for mouth guard construction and the teeth were professionally 
cleaned. Two weeks following (baseline, day 0), the mouth guard was worn during brushing 
for 3 weeks (up to day 21). At day 21 plaque was removed by prophylaxis and normal 
hygiene practices resumed. Participants were assessed again after resolution of inflammation 
(day 35). Gingivae were assessed throughout the study (days 0, 7, 14, 21 and 35).   
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Figure 2.6. Photograph of an example mould and mouth guard  
These were prepared for each volunteer. 
 
 
Figure 2.7 Schematic diagram of gingivitis study time frame 
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2.11.1.1. Clinical gingival inflammation measurements in 21-day gingivitis 
The progression of gingival inflammation over the course of the study was measured by 
gingival index (GI) scores 0-3 (Löe et al. 1967), plaque index (PI) using a modified Quigley-
Hein index, scores 0-5 (Lobene et al. 1982) as outlined in Figure 2.8 and Table 2.8 
respectively. GCF volume was measured using a Periotron 8000
™
 (Oraflow, USA). Gingival 
and plaque scores were recorded by Dr Martin Ling and GCF volume by Professor Iain 
Chapple. 
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Table 2.8 Gingival Index (GI)  
(Löe et al. 1967)  
 
Gingival Index 
Score Bleeding Appearance 
0 None Normal 
1 None Mild edema 
2 Bleeding on probing Redness, edema 
3 Spontaneous bleeding Marked redness, edema, ulceration 
 
 
Figure 2.8. Quigley-Hein Plaque Index and description  
Taken from (Lobene et al. 1982). 
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2.11.1.2. Gingival crevicular fluid (GCF) sampling and processing 
GCF samples were collected from the volunteers using Periopaper strips (OraFlow, USA) 
inserted into the mesio-buccal gingival crevices of both test and control sites for 30 seconds 
as originally reported by Chapple et al. (2007). GCF strips from each control/test site (3 from 
each side) were pooled into Eppendorf tubes containing PBS supplemented with BSA 
(0.05%, 200μl; 50mg/L). The tubes were incubated at room temperature for 30 min to allow 
GCF to elute, after which the strips were trapped within the lid of each tube. After 
centrifugation (10 min, 2000 rcf; SciSpin micro, Geneflow, UK), the lid and strips were 
removed and the GCF diluent was filter sterilised using 0.22μm syringe filters (Gilson 
Scientific, ANV1322) to remove any cell debris/microbes and stored at -80C prior to further 
use. 
2.11.2. Neutrophil chemotaxis in chronic periodontitis 
Section 2.1.3 details the volunteers recruited for the study of neutrophil chemotaxis in 
chronic periodontitis. Chronic periodontitis was defined by the European Federation of 
Periodontology (Tonetti & Claffey 2005) as a minimum of 2 non-adjacent sites per quandrant 
with probing pocket depths exceeding 4mm and radiographic bone loss above 30%. Whole 
blood (48ml) was collected in lithium heparin vacutainers (Greiner, Bio-One) at baseline 
(prior to treatment) and after treatment. Patient treatment involved tailored oral hygiene 
instruction, non-surgical scaling and root surface debridement of periodontal pockets 
exceeding 4mm. 3 months post-treatment, attended a second therapy appointment. At the 
same time (before and after treatment), a blood sample was also taken from age and sex-
matched periodontally healthy controls using the same exclusion criteria. The healthy control 
group showed no interproximal attachment loss, a low mouth bleeding score (less than 10%) 
and no probing pocket depths exceeding 3mm. 
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2.11.2.1. Clinical measures of gingival inflammation in chronic periodontitis 
The severity to which patient cohort 1 (as outlined in section 2.1.3.1) suffered periodontitis 
was measured by Dr Martin Ling using several parameters including gingival index, plaque 
index, clinical attachment loss (CAL) probing pocket depth (PDD) and bleeding on probing 
(BOP). PI and GI were also measured as outlined in section 2.11.1.1. Periodontal health of 
volunteers was also confirmed by Dr Martin Ling. All clinical parameters were measured 
immediately prior to blood collection for neutrophil assays. 
The additional 10 chronic periodontitis patients in cohort 2 (outlined in section 2.1.3.2) were 
all confirmed as having generalised chronic periodontitis by an experienced examiner.  
GCF was collected from all periodontitis patients using periopapers and volume was 
measured using a pre-calibrated Periotron 8000TM (Chapple et al., 1999).  
2.11.3. Neutrophil function in Papillon-Lefèvre Syndrome 
Section 2.1.4 details the volunteers recruited for the study of neutrophil function in Papillon-
Lefèvre Syndrome (PLS). Whole blood (18ml) was collected from each volunteer 
patient/control in lithium heparin vacutainers on the same day. 
2.11.4. Neutrophil function in chronic inflammation: morbid obesity 
Section 2.1.5 details the volunteers recruited for the study of neutrophil function in morbid 
obesity. Initial patient awareness to the study involved the use of a PowerPoint slide (Figure 
2.9) during patient attendance at a seminar run by dieticians at Heartlands Hospital. Patients 
indicated verbally if they would be interested in taking part in the study at the seminar. 
Written consent was taken upon meeting with the surgeon Mr Paul Super, several weeks after 
their attendance at the dietician’s seminar.  
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Blood samples were taken at three different time points (Figure 2.10.) during patient 
attendance at bariatric clinical appointments. The first blood sample was taken prior to 
commencement of a very low calorie diet, involving 500 calories a day intake for up to 8 
weeks before surgery (time point 1). A second blood sample was taken at the patient pre-
operative assessment (time point 2) and a final blood sample was taken 3 months following 
surgery (time point 3). At each time point, whole blood (~30ml) was collected per patient 
and control in lithium heparin vacutainers at the same time as coordinated between the two 
hospitals. Blood samples from Heartlands Hospital were transported, at ambient temperature 
with minimal disturbance, firstly to the Human Biomaterials Resource Centre (HBRC) at the 
University of Birmingham to be anonymised and then immediately on to the School of 
Dentistry where all experimentation took place. In the interim (up to 4 hours) the control 
blood samples were incubated at room temperature without agitation. 
2.11.4.1. Blood chemistry measurements 
Glycated haemoglobin (HbA1c) was measured using a HemoCue® HbA1c 501 blood 
analyser (HemoCue, Sweden) from collected whole blood at all three sample donations. 
Blood lipids high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol and 
triglycerides (TG) were also measured from whole blood using a CardioChek PA Blood 
Analyser (BHR Pharma, UK). 
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Figure 2.9. Information supplied to patients during seminar  
The slide was presented to prospective patient volunteers by dietitians at Heartlands hospital.  
 
Figure 2.10. Flow diagram of bariatric patient study  
VLCD = very low calorie diet, DH = dental hospital. 
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2.12. Statistical analysis 
All data was processed using Microsoft Excel and statistically evaluated using Graphpad 
Prism 5.0 (GraphPad Software Inc, California, USA). The distribution of datasets (parametric 
or non-parametric) was initially assessed using the Kolmogorov-Smirnov test for normality. 
For paired datasets that featured parametric distribution, a paired T test was used; multiple 
datasets used ANOVA with Tukey post-test. Paired datasets with non-parametric distribution 
used Wilcoxon test; multiple datasets used Friedman test with Dunn’s post-test. Unpaired 
datasets with non-parametric distribution used Mann-Whitney test; multiple datasets used 
Kruskal-Wallis test with Dunn’s post-test. P < 0.05 was deemed significant for all data sets. 
2.13.  Summary of experiemtnal assays per study 
Table 2.9 Assays used per clinical study 
Assay 
Experimental 
gingivitis 
Chronic 
Periodontitis 
PLS Obesity 
ROS assay ✔   ✔ ✔ 
NETs assay ✔ 
 
✔ ✔ 
Chemotaxis assay ✔ ✔ ✔ ✔ 
Cell culture 
  
✔ ✔ 
Cytokine ELISA ✔ ✔ 
  LL-37/NE/protein carbonyl/S100A-8/9 
ELISA 
  
✔ 
 Luminex assay     ✔ ✔ 
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3.1. Introduction 
The Insall chamber was chosen for the study of neutrophil chemotaxis. Originally developed 
to study the movement of Dictyostelium discoideum (Phillips & Gomer 2012; Choi et al. 
2013; Kaul et al. 2013; a Herlihy, Tang, et al. 2013; Herlihy, Pilling, et al. 2013; Muinonen-
Martin et al. 2010), this bridge chamber can be adapted to study fast moving cells making it 
appropriate to study neutrophils. The chamber was chosen because of the potential to provide 
detailed information regarding the kinetics of neutrophil movement in an easy, efficient and 
reproducible manner. A particular focus was on clinical samples for which additional assays 
of neutrophil function were employed simultaneously.  The optimisation of this technique for 
use with neutrophils is detailed in this chapter.  
3.2. Determination of cell viability over time 
Neutrophil viability post-isolation from whole blood was determined to ensure cells retained 
relevant functional capacity for analysis in the chemotaxis assay. Initial incubation on the 
coverslip was for 20 minutes and each video was captured for up to 20 minutes in length. As 
one assay preceded another, pilot data demonstrated that cells not utilised immediately could 
be incubated at room temperature for up to four hours (Figure 3.1). Neutrophils isolated 
initially from whole blood were typically >98% trypan blue-free. There was a significant 
difference in viability between immediate, one, and two hours post-isolation compared with 4 
hours post-isolation, showing that beyond 3 hours post isolation, cell viability was 
compromised, however over 90% of the cells remained viable beyond this time as loss of 
viability relative to “immediate” use was <5%. Therefore a limit of four hours was imposed 
on future assays to balance the logistics of running multiple assays within acceptable cell 
viability. 
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Figure 3.1 Neutrophil viability over time post-isolation 
Neutrophils were isolated (section 2.2) and viability (section 2.2.2) over time was assessed 
over 4 hours. Data expressed as mean ± standard deviation (SD). Statistical test: One Way 
ANOVA and Tukey’s multiple comparisons test (n = 3 neutrophil isolations). * = (p < 0.05). 
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3.3. Cell magnification employed in chemotaxis assays 
The fastest average recorded speed for neutrophil movement is approximately 10μm/min 
using the strong chemoattractant N-Formylmethionyl-leucyl-phenylalanine (fMLP) at 10nM 
(Worthen et al. 1994). With a time course of 20 minutes, a cell could therefore potentially 
travel 200μm. The microscope employed to film cell movement featured magnification 
settings of x10, x20 and x40. Figure 3.2 illustrates the extent to which a neutrophil may 
travel if positioned within the centre of the microscope frame using the three different 
magnifications. The images demonstrate that a cell viewed with an objective lens at a x20 
magnification would be unlikely to leave the frame, whereas for a x40 the cell would be 
more likely to leave the frame. The potential length a cell could travel when visualised using 
a x10 objective lens represents only a small area of the whole image. In addition, the small 
size of the cells at this magnification is such that ensuring the centre of each cell is selected 
for movement tracking is more difficult, potentially increasing the likelihood of tracking 
errors when analysing resultant videos. Thus a magnification of x20 was chosen for all future 
assays. 
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Figure 3.2  Cell magnification for chemotaxis assay 
The images detail the extent to which neutrophils could travel (orange arrows) in 20 minutes 
within the frame of different objective lenses after exposure to the strongest chemoattractant 
fMLP (10nM). Bars (white) represent 100μm. 
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3.4. Visualisation and circular statistics to analyse neutrophil chemotaxis 
Figure 3.3a-c illustrates the tracking of selected cells in response to a chemoattractant using 
the Insall chamber. One type of image output, “spider diagrams”, provides a simple visual 
summary of the tracks of selected cells. Circular statistics provide the opportunity to analyse 
datasets on an angular scale, providing information about the average direction of movement 
within a group of cells, in the form of “polar plots” and “angle histograms” (descriptive 
statistics). Figure 3.4 shows example graphs using the Circular Statistics Toolbox of 
MATLAB for RPMI (negative control) and the chemoattractant fMLP (10nM). Polar plots 
(Figure 3.4a and b) detail the mean angle of the data points, known as the mean resultant 
vector (MRV). MRV length (MRVL) denotes the strength of the mean angle (red line): the 
longer the line the more data there is to support the angle reported. The MRVL quantifies the 
measurement of circular spread of the samples on the angular scale; it ranges from 0 to 1, the 
closer to 1 the more concentrated the data points are around the mean direction (Berens 
2009). Dashed lines represent MRV confidence intervals (95%). A mean angle close to 90 
degrees is in the direction of the chemoattractant (which is at the 12 O’clock position on 
these representations). Angle histograms (Figure 3.4c and d) show the distribution of values 
grouped in angle bins (5 angle bins) reflecting their numeric range. For RPMI the cells are 
distributed widely, thus the MRVL is short; clearly showing the distribution of cells is 
random. For fMLP (10nM) the MRVL is in the direction of the chemoattractant and its 
length is very close to 1 indicating the cells are angled in a similar orientation. 
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Figure 3.3  Cell track paths of cells 
The cell track image sequences (a) demonstrate cell movement from image 1 to 4 at 
sequential time points (0, 10, 15 and 20 min) with coloured “tails” for the cells selected for 
tracking; bars (white) represent 50μm. The tracks are then plotted on “spider diagrams” such 
as demonstrated at the 20 min time point for RPMI control (b) and when the cells are 
exposed to a chemoattractant such as fMLP after 20 min (c).  
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Figure 3.4  Example circular statistics graphs 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6) using 
RPMI and fMLP (10nM), after which the cells were analysed (section 2.6.2) and the tracked 
information was used to generate circular statistical diagrams. “Polar plots” (a) and (b); the 
red line represents the mean resultant vector (MRV), MRV length (MRVL) is proportional to 
the number of cells close to the mean (each cell is represented as a blue circle on the edge of 
the diagrams), indicating cell directional uniformity. Blue dotted lines represent 95% C.I. 
“Angle histograms” (c) and (d) present the number of cells at a particular angle range, the 
height of the bins (here ranging 0-15) represent the number of cells present per bin (n = 3 
neutrophil isolations; 45 cells tracked per diagram).   
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3.4.1. Using MRVL to indicate orientational accuracy 
MATLAB software generates the MRVL from XY co-ordinates of cells tracked using the 
MtrackJ plugin supplied by Fiji (ImageJ). The MRVL shows similarities to the chemotactic 
index (CI), which is generated by the excel spreadsheet supplied by the Insall group 
(Muinonen-Marten et al. 2013); MRVL indicates how clustered the cells are in a particular 
orientation (regardless of how far the cells have travelled) and makes use of an arbitrary 
numerical scale (ranging 0-1). Unlike the CI, the MRVL, in the absence of graphical format, 
does not show the orientation in relation to the chemoattractant source. This can create a 
significant misrepresentation of the strength of directionality towards the chemoattractant 
when analysing the numerical value of the MRVL alone and in isolation from the graphs. 
Figure 3.5 highlights the dilemma when using the MRVL as a standalone value; it is clear 
that the cells in the RPMI example (Figure 3.5a) are not orientated in the direction of the 
chemoattractant (towards 90°), and should cell speed be taken into account, the cells would 
be shown to move very little, however the angle of the cells is such that the MRVL is high – 
similar to that of fMLP indicating the orientation of cells to be the same (10nM) (Figure 
3.5b), yet when observing the graph of the cells exposed to fMLP the orientation of the MRV 
is in the direction of the chemoattractant source. The use of the MRVL to determine 
orientational accuracy of a cell is therefore of no value and was not employed here. These 
graphs also illustrate the importance of speed and velocity as parameters for the study of 
chemotaxis as speed of the cells is not taken into account in circular statistics and speed may 
be in a random direction, rather than towards a chemoattractant. 
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Figure 3.5  Polar plots of RPMI versus fMLP 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6) using 
RPMI (a) and fMLP (b; 10nM), after which the cell tracks were analysed (section 2.6.2) and 
tracked information was used to generate polar plots. The red line represents the mean 
resultant vector (MRV), MRV length (MRVL) is proportional to the number of cells close to 
the mean; dotted lines represent 95% C.I. 
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3.4.2. Accounting for the mean angle and measurement 
Circular Statistics provide additional information regarding the polar plot diagrams; the mean 
angle of all the cells provides information regarding the directionality of the cells on the 
circular axis. CI and MRVL produce similar results when analysing the same data sets. 
Figure 3.6 shows the MRVL (a) and CI ( b) for 15 cells plotted over a 20 minute time-course 
as previously described (section 3.5) using control buffer (RPMI) and the chemoattractants 
interleukin-8 (CXCL8; 200ng/ml) and fMLP (10nM). Whilst the pattern of the results is 
similar, the spread of data is greater for MRVL than for CI. CI, as a chemotaxis measurement 
parameter, was published during the course of these studies (Sapey et al. 2011). To assess the 
similarity between both CI and MRVL, the two sets of values were compared by correlation 
and also by Bland-Altman analysis (Figure 3.6c and d). The linear regression result shows 
that while a positive interchangeable relationship exists between the CI and the MRVL, the 
strength, as shown by the coefficient of determination (R
2 
= 0.55), is only moderate, 
moreover according to Bland-Altman, in order for one method to be reliably replaced by 
another method,, 95% of data points should lie within the limits of agreement (Figure 3.6d), 
this is not the case for CI and MRVL indicating that one value could not reliably be 
interpreted as the other. If the MRVL was adjusted to incorporate the mean angle then the 
result would be expected to be closer to the CI than the MRVL alone. In order to achieve 
this, the angle quadrants of generated polar plots were given a number designation ranging -1 
to 1 as shown in  Figure 3.7. The vector length for a given result (i.e. one sample averaging 
15 cells) would then be divided by the angle quadrant value to give the Adjusted MRVL 
(AMRVL). The resulting value would then be plotted in the same manner as the CI value. 
When compared to CI, the AMRVL (Figure 3.8a and b) similarities are stronger than for CI 
and MRVL alone. When the two sets of values were further analysed by Bland-Altman plots 
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(Figure 3.8c and d) the coefficient of determination was higher (R
2
 = 0.85) indicating a more 
positive interchangeable relationship, also >95% of data points lie within the limits of 
agreement on the Bland-Altman plot Figure 3.8d). The degree of similarity between AMRVL 
and CI was such that only the CI result will be utilised in all further chemotaxis assays. The 
circular statistics diagrams will be presented for visual qualitative purposes only. 
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Figure 3.6 Similarities between mean resultant vector length (MRVL) and chemotactic 
index (CI) 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and tracked information was used to calculate 
the MRVL (a) and CI (b) from the same set of chemotaxis experiments using RPMI and the 
chemoattractants CXCL8 (200ng/ml) and fMLP (10nM). Data are expressed as mean ± 
standard error of the mean (SEM). Correlation and Bland-Altman analysis (c and d); 
horizontal red lines indicate the limits of agreement which are defined as the mean difference 
plus and minus 1.96 times the standard deviation of the differences (75 cells, n = 5 neutrophil 
isolations). 
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Figure 3.7 Calculating the adjusted mean resultant vector length (AMRVL) 
Calculated polar plot quadrants (a) were given a number designation; 1 is the quadrant with 
the directionality closest to the supposed chemoattractant source. The further around the 
circle, the lower the given value (0.5 for yellow, -0.5 for orange and -1 for red) as the cells’ 
orientation is further away from the chemoattractant source. The AMRVL (b) was calculated 
from the MRVL and the quadrant angle designation was derived from the mean angle value 
(5 cells shown as an example). 
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Figure 3.8 Comparing the adjusted mean resultant vector length (AMRVL) to 
chemotactic index (CI) 
AMRVL (a) and CI (b) plotted from the data yielded in Figure 3.7. Chemotaxis experiments 
employing RPMI and the chemoattractants CXCL8 (200ng/ml) and fMLP (10nM). Data 
expressed as mean ± standard error of the mean (SEM).  Correlation (c) and Bland-Altman 
analysis (d): horizontal red lines indicate the limits of agreement which are defined as the 
mean difference plus and minus 1.96 times the standard deviation of the differences (75 cells, 
n = 5 neutrophil isolations). 
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3.5. Chemotaxis assay time length 
Whilst the most reliable and representative result for the measurement of chemotaxis is likely 
achieved using the maximum observation and recording time, limitations exist for the study 
of neutrophils using the Insall chamber. The rapid responsivity of chemotaxing neutrophils is 
such that unlike experiments involving Dictostelium in which a time course of 72 hours in 
length is typical and the Insall chamber is sealed to prevent evaporation, there is no need to 
seal the chamber when studying neutrophil movement after 20 minutes. The fast-moving 
immediate responses of neutrophils to the chemoattractants employed in this project 
eliminates the need to seal the chamber, a consequence of which is the potential evaporation 
of chemoattractant/negative control. Beyond 20 minutes under the heat/intensity of the light 
microscope, evaporation occurs making it unsuitable to measure neutrophil chemotaxis. The 
maximal video length for cell tracking was therefore set at 20 minutes. In order to identify 
the optimal filming time, a range of 5-20 minutes was evaluated.  
Figure 3.9 illustrates the speed, velocity and CI for the allotted time points. At 5 minutes the 
cells responded as expected to the chemoattractants fMLP and CXCL8, however as 
observation length increased, speed and velocity increased, reaching an apparent plateau 
between 15 and 20 minutes. Significant differences were seen between 5 minute and 20 
minute time points for optimal concentrations of CXCL8 and fMLP and the negative control 
RPMI, with speed and velocity measurements (p < 0.05). There was no significant difference 
in CI throughout the time course; indicating that this measure of chemotaxis was not 
dependent upon recording length. A time limit of 20 minutes was therefore used in all future 
experiments. 
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Figure 3.9  Chemotaxis at different time points 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and tracked information was used to generate 
speed (a), velocity (b) and CI (c) measurements over a 20 minute time course using RPMI 
(negative control) and the chemoattractants CXCL8 (200ng/ml) and fMLP (10nM). Data is 
expressed as mean ± standard error of the mean (SEM). The blue/red dotted lines for velocity 
and CI mark 0 as a reference point. (n = 10 different blood donors; 15 cells tracked per 
chemoattractant/RPMI). Statistical test: One Way ANOVA and Tukey’s post-test. * = (p < 
0.05). 
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3.6. Chemoattractant concentrations 
The bacteria-derived peptide fMLP and the host derived chemokines CXCL8 and 
macrophage inflammatory protein-1-alpha (MIP1α) are among the most physiologically 
important chemoattractants for neutrophils. A range of chemoattractant concentrations were 
tested to identify the most effective for use in the Insall chamber.  
3.6.1. fMLP and CXCL8 concentrations 
Figure 3.10 shows the effect of different concentrations of CXCL8 and fMLP on neutrophil 
chemotaxis using the Insall Chamber. Chemokinesis with fMLP (utilising the Boyden 
chamber) can be initiated at concentrations as low as 10pM, however preliminary studies 
using the Insall chamber induced no directed neutrophil movement, therefore the lowest 
concentration utilised was 10nM (Iizawa et al. 1995). Speed and velocity were significantly 
lower at increased fMLP concentrations (50nM and 100nM) compared to the lowest 
concentration (10nM). By contrast CXCL8 showed increased speed and velocity with 
increasing concentration, and significance was reached at 200ng/ml for velocity only. CI for 
both chemoattractants was not significantly affected by the concentration used. fMLP at 
10nM and CXCL8 at 200ng/ml were therefore chosen as optimal concentrations for future 
chemotaxis studies as they demonstrated the greatest directional and overall movement. For 
all subsequent analyses of chemotaxis RPMI was anticipated to be significantly different 
from assays using chemoattractants (p < 0.001) and was thus employed as the negative 
control. 
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Figure 3.10 Optimisation of CXCL8 and fMLP concentrations 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), 
following which the cells were analysed (section 2.6.2) and tracked information was used to 
generate speed (a and b), velocity (c and d) and CI (e and f) measurements for concentration 
ranges of fMLP and CXCL8 respectively. Box and whisker plots (the band within the box 
represents the median, surrounded by the 1
st
 and 3
rd
 quartiles, the ends of the whiskers 
represent the minimum and maximum data points). (n = 10 different blood donors; 15 cells 
tracked per chemoattractant/RPMI). Statistical test: One Way ANOVA and Tukey’s multiple 
comparisons test. * = (p < 0.05), *** = (p < 0.001). 
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3.6.2. MIP1α and GM-CSF concentrations 
Neutrophil chemotaxis towards MIP1α requires pre-incubation with GM-CSF to enable the 
constitutively expressed MIP1α cell surface receptor CCR5 to bind to and respond to the 
chemoattractant (Ottonello et al. 2005). Error! Reference source not found.3.11 shows the 
peed, velocity and CI of a range of GM-CSF and MIP1α concentrations (0.2-200pg/ml and 
10-100ng/ml respectively). The effect of GM-CSF priming was also measured following 
subsequent exposure to fMLP (10nM), and at increasing GM-CSF concentrations (20 and 
200pg/ml) the neutrophil responses to MIP1α were heightened compared to fMLP alone. As 
expected, chemotaxis with MIP1α was not as effective as fMLP, but was clearly evident 
when compared with RPMI negative control. There were significant differences between 
0.2pg/ml GM-CSF with all MIP1α concentration ranges and all other GM-CSF 
concentrations (p < 0.001) for all chemotaxis parameters (Figure a-c). In addition, there were 
significant increases in speed, velocity and CI between 2pg and 20pg/ml GM-CSF priming 
concentrations. There were no differences between 20pg/ml and 200pg/ml GM-CSF. With 
regard to MIP1α concentrations, 100ng/ml was the optimal concentration yielding the 
greatest speed, velocity and CI score, significance was only evident between 10ng/ml and 
100ng/ml with MIP1α when 20pg/ml GM-CSF was used (p < 0.001). Thus MIPα at a 
concentration of 100ng/ml and a GM-CSF priming concentration of 20pg/ml were used in all 
relevant future chemotaxis experiments.  
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Figure 3.11 Optimisation of MIP1α neutrophil priming concentration  
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.5), after which the cells were analysed (section 2.5.2) and tracked 
information was used to generate speed (a), velocity (b) CI (c) plots for concentration ranges of MIP1α with different ranges of GM-CSF. 
Measuremnts were also done of MIP1α in the absence of GM-CSF priming (d). Data is expressed as mean ± standard error of the mean (SEM). (n = 10 
different blood donors; 15 cells tracked per chemoattractant/RPMI). Statistical test: One Way ANOVA and Tukey’s multiple comparisons test. * = (p 
< 0.05), ** = (p < 0.01), *** = (p < 0.001). 
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3.7. Number of cells tracked  
The optimal number of neutrophils selected to measure chemotaxis (speed, velocity and CI) 
was identified by comparing 5, 10, 15 and 20 cells. Figure 3.12 shows the calculated speed, 
velocity and CI with increasing numbers of cells tracked. There were no statistical 
differences with increasing numbers of cells for any of the parameters addressed; however 
average velocity and CI demonstrated an increasing trend with more cells present. 15 cells 
per visual field were selected as the standard number to track in future assays to ensure 
reliable results and an achievable cell quantity available for selection within the given time 
frames.  
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Figure 3.12  Impact of cell numbers tracked per assay 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and  tracked information was used to generate 
speed (a), velocity (b) and CI (c) plots with increasing cell numbers using RPMI and the 
chemoattractants CXCL8 (200ng/ml) and fMLP (10nM). Data expressed as mean ± standard 
error of the mean (SEM). (n = 10 different blood donors). Statistical test: One Way ANOVA 
and Tukey’s multiple comparisons test.  
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3.8.  Effects of cell density 
Different cell densities were investigated to assess potential inaccuracies evident with 
increased numbers of cells present within the video frames. To optimise the number of cells 
required for the chemotaxis assay, ten videos utilising fMLP (10nM) as the chemoattractant 
from 10 healthy donor neutrophil isolates at three different densities were analysed. Figure 
3.13a-c shows still photo micrographs of each of the movies recorded at the different 
densities: low; 1 x 10
5
, medium; 1 x 10
6
 and high; 2 x 10
6
 cells/ml respectively. Figure 
3.13d-f shows the effect of increasing cell densities on speed, velocity and CI. The medium 
cell density video (1 x 10
6
 cells/ml) demonstrated greater overall speed, which was 
significantly higher compared with low (p < 0.05) and high (p < 0.001) cell density. This 
may be the result of optimum visuals for the operator – the number of cells does not 
overwhelm the tracking process (which may be the case for the high density video) yet the 
operator is not constrained by the lack of cells (as could be the case for the low density 
video). Velocity and CI demonstrated no significant differences. All further chemotaxis 
assays therefore utilised cells at medium density (1 x 10
6
 cells/ml).  
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Figure 3.13  Differing cell densities for manual tracking 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6) using fMLP (10nM), after which the cells were analysed (section 
2.6.2) using three different cell densities: Low; 5 x 10
6
 cells/ml (a), medium; 1 x 10
6
 cells/ml (b) and high; 2 x 10
6
 cells/ml (c). Tracked information 
was used to generate speed (d), velocity (e) and CI (f). Box and whisker plots (the band within the box represents the median, surrounded by the 1
st
 
and 3
rd
 quartiles, the ends of the whiskers represent the minimum and maximum data points). n = 10 different blood donors; 15 cells tracked per 
analysis. Statistical test: One Way ANOVA and Tukey’s multiple comparisons test. * = (p < 0.05), *** = (p < 0.001). 
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3.9. Intra-individual manual tracking validation 
The manual tracking plugin, MtrackJ, generates information regarding changes in the XY co-
ordinates of selected cells, which when further processed using Microsoft Excel yields the   
speed, velocity and CI, thus quantifying the movement of neutrophils in different states, such 
as in health and disease or after exposure to particular agents. Manual tracking is the gold 
standard technique with regard to monitoring different cells; it requires the observer to click 
on a reference point within a chosen cell for each frame of the stack. In order to ensure the 
use of MtrackJ was not biased by the author of this thesis, who was the sole operator for all 
chemotaxis tracking analyses, ten videos of fMLP (10nM) were repeatedly analysed blindly 
on three separate occasions; a minimum of one week separated each re-analysis. Figure 
3.14a-c shows the average speed, velocity and CI per repeat analysis. The coefficient of 
variation for each parameter was also calculated (Figure 3.14d). There were no statistically 
significant differences between repeat analyses for any chemotaxis parameter. The 
coefficient of variation was greatest between the three analyses for CI (29%), indicating the 
sensitivity of this particular parameter. 
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Figure 3.14 Variation in cell tracking with repeated analyses 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6) using fMLP (10nM), after which the cells were analysed (section 
2.6.2) on three separate occasions using the same videos. The cell density used was 1 x 10
6
 cells/ml. Tracked information was used to generate speed 
(a), velocity (b) and CI (c). Data is expressed as line graphs denoting individual analyses. The coefficient of variation for each respective parameter 
was also calculated (d). n = 10 different blood donors; 15 cells tracked per analysis. Statistical test: One Way ANOVA and Tukey’s multiple 
comparisons test.  
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3.10. Donor variation in chemotactic responses 
To assess the potential impact of day to day variation within donors on the neutrophil 
chemotaxis assay, healthy volunteers (n = 16) were bled on two different days; at least 2 
weeks apart from each other. The entire experiment spanned 2 months. Isolated neutrophils 
were exposed to fMLP (10nM) and speed, velocity and CI (Figure 3.15a, b and c 
respectively) were measured. No statistically significant differences were found between the 
chemotaxis parameters of neutrophils from repeat isolates. The response to fMLP varied 
between donors, however the coefficient of variation was within acceptable limits (Figure 
3.15d). These results indicate that day-to-day variation in neutrophil behaviour creates only 
subtle differences when measuring chemotaxis using the present method and does not appear 
to be a confounding factor when measuring chemotaxis from the same donor at different 
times, e.g. before and after therapeutic intervention.  
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Figure 3.15 Repeat donor chemotaxis assay 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and  tracked information was used to generate 
speed (a), velocity (b) and CI (c) measurements using fMLP (10nM) using the same 
volunteers donating blood on two separate occasions. Averages from each of the cells tracked 
from the 1st and 2nd isolations were used to calculate the coefficient of variation from each 
parameter (d). Data is expressed as line graphs, each dot represents a donor at first (blue) and 
second (red) isolation. (n = 16 different blood donors; 15 cells tracked per isolation). 
Statistical test: paired t test.  
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3.11. Discussion 
Live cell real-time microscopy is a powerful approach to study the characteristics of cell 
movement. The Insall chamber was selected for the study of neutrophil chemotaxis in several 
clinical studies in this thesis because of the ease of use and relatively short application time. 
This enabled the use and re-use of the assay with several different neutrophil preparations 
isolated in tandem, with different chemoattractants or a negative control. As the Insall 
chamber is a recently developed form of bridge chamber, few studies are available reporting 
its use, and of those, only three specifically reference neutrophils (Sapey et al. 2011; Herlihy, 
Tang, et al. 2013; Sapey et al. 2014). Table 3.1 describes the outcome of the different 
parameters measured in this chapter in order to optimise the use of this chamber for the study 
of neutrophil movement in the remainder of this thesis. 
Table 3.1 Optimal parameters for neutrophil chemotaxis with the Insall chamber 
Optimisation experiment Experimental outcome future assays 
Cell incubation prior to assay Up to 4 hours 
Cell Density 1 x 10
6
/ml 
Magnification x20 
Time course 20 minutes 
Chemoattractant concentration 
fMLP (10nM), CXCL8 (200ng/ml), MIP1α 
(100ng/ml) with GM-CSF (20pg/ml) incubation. 
No. of cells tracked/video 15 cells 
Quantitative measures Speed, velocity and CI 
Qualitative measures Spider diagrams, polar plots and angle histograms 
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The ability of neutrophils to undergo chemotaxis was not impeded for several hours post-
isolation, with viability dropping only marginally up to four hours following isolation 
(section 3.2). Neutrophils have recently been shown to survive in the body beyond 5 days 
(Pillay et al. 2010); far longer than previously thought. Thus neutrophils appear to be far 
more than just the ‘kamikaze-like’ cells they were once considered to be and appear capable 
of subtle protein/peptide synthesis and cell signaling activity. In order to optimise conditions 
for their use in the Insall chamber, image magnification and length of video recording 
(section 3.3), were considered for the assay itself and also for subsequent quantification of 
movement using manual tracking software.  
The wealth of information that can be acquired using the Insall chamber is not limited to 
processing by ImageJ or Microsoft Excel. Circular statistics can be employed to generate 
quantitative and qualitative data regarding the orientational accuracy of cell movement. The 
Circular Statistics Toolbox, used by Muinonen-Martin et al. (2013) provides additional 
visual and numerical data to test for uniformity of cell movement in a particular condition. 
When comparing the MRV with the CI the similarities between the two values was apparent 
(section 3.4.1), and when adjusted to include the direction as well as the length of movement 
(the AMRVL), the degree of similarity was such that CI could be substituted for AMRVL 
according to the Bland-Altman analysis (section 3.4.2). The plot diagrams generated from 
MATLAB provide additional visual values to the study of chemotaxis using this chamber.  
It was necessary to optimise the concentrations of chemoattractants used with the Insall 
chamber. Within the literature, fMLP has been shown to have a concentration-dependent 
effect on neutrophils; the results reported in this thesis demonstrated that concentrations 
beyond 10nM impaired chemotaxis. fMLP  has been shown to elicit ROS production at 
concentrations above 10nM, reaching peak ROS production at 1mM, such a peak in ROS 
generation may provide insight into the disruption of chemotaxis at higher concentrations of 
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this chemoattractant (Iizawa et al. 1995). The most effective chemoattractant concentration 
of fMLP using a modified two-chamber chemotaxis assay, such as the Boyden chamber, was 
previously reported to range between 0.1-10nM (Kohidai et al. 2003). Results presented here 
(section 3.6.1) confirm that concentrations above 10nM impaired speed and velocity, 
however no significant differences were evident with regard to CI, demonstrating that at 
different concentrations the chemoattractants have no effect on the orientation of the 
neutrophil movement, but do effect cell speed towards the chemoattractant. fMLP was 
expected to elicit a stronger chemotactic response in neutrophils than host-derived 
chemoattractants as it activates more signalling pathways (Figure 1.5). Differing CXCL8 
concentrations employed in the chemotaxis assay demonstrated that the maximal CXCL8 
concentration yielded the most effective chemotactic response in agreement with Lin et al. 
(2004). Jeon et al. (2002) reported that increases in CXCL8 were accompanied by enhanced 
neutrophil chemotaxis using a microfabricated device. The authors used a maximum 
concentration of 50ng/ml, however their chemotaxis time course was 90 minutes, an 
inappropriate length of time for use with the Insall chamber, which is not sealed to enable its 
re-use. Thus a higher concentration (200ng/ml) was found to be most appropriate for 
chemotaxis with the Insall Chamber.  
The chemoattractant MIP1α used in the absence of any other agent will not induce neutrophil 
migration, as demonstrated by Zhang et al. (1999), even at high concentrations (up to 1µM). 
Ottonello et al. (2005), using the Boyden chamber, showed that acute incubation with GM-
CSF enabled neutrophils to migrate in response to MIP1α. GM-CSF has been shown to 
induce mRNA expression for CCR1, one of the MIP1α receptors, allowing responsiveness to 
the chemoattractant upon exposure to it (Cheng et al. 2001). GM-CSF is a powerful priming 
agent for neutrophils, allowing them to respond effectively to subsequent stimuli (e.g. 
pathogens) (Gasson 1991).  
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Although the MIP1α receptor, CCR5, is constitutively expressed on neutrophils, the absence 
of priming will not allow for stimulation of downstream signalling pathways that lead to an 
alteration in cell movement. Signal transduction by host chemoattractants such as MIP1α is 
MAPK-pathway dependent (Lehman et al. 2001), inducing ERK-2 phosphorylation, however 
host chemoattractants cannot induce ERK-1 phosphorylation in the absence of priming and 
the locomotion of unprimed/naïve neutrophils cannot be triggered due to dependence on 
ERK-1. Pre-treatment with GM-CSF results in ERK-1 activation thereby allowing induction 
of CCR5 competence to MIP1α. The p38 kinase signaling pathway is more important upon 
fMLP-receptor binding (Heit et al. 2002; Heit, Liu, et al. 2008). The combination of both p38 
and ERK-1/2 activation in fMLP is most likely the underlying reason for its greater potency 
(Figure 1.5). 
To ensure the reliability of a particular chemotaxis result it was necessary to track a suitable 
number of cells. Other groups that have used the Insall chamber to study chemotaxis track 
varied numbers ranging from 10-30 cells (Sapey et al. 2011; Herlihy et al. 2013). The data 
presented here (section 3.7, Figure 3.12) did not show a significantly different effect from 
increasing the number of cells tracked, however the cells were taken from healthy donors and 
the chemoattractants used were known to have a potent effect on the cells; thus the number of 
cells tracked may be of greater importance under different conditions using the same 
chemoattractants e.g. health versus disease states. Furthermore, the magnitude of error in data 
quantification would be lower the greater the number of cells analysed. 
Manual tracking is commonly employed for quantifying cell chemotaxis, yet several 
drawbacks to the technique have been identified (Cordelières et al. 2013): firstly defining the 
reference point of the cell (often the centre of the nucleus is used); secondly, precision can be 
a problem as clicking the correct pixel can influence the result of the cells movement; thirdly, 
consistency with clicking (one sample for processing requires 15 cells chosen over a period 
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of 40 frames requires 600 separate clicks), fourthly, there is difficulty in achieving 
consistency between operators. In addition, the process is extremely time-consuming with 
operator fatigue leading to the possibility of inaccurate tracking. To address these potential 
problems, the reference point was designated as the centre of the cell mass, ensuring the 
variance setting was the same for all videos (i.e. to provide a black and white image by which 
clicking would be visually easier). Cell density was assessed in order to achieve the optimal 
number of cells present in any one frame (section 3.8). Tracking 15 cells per video takes 
approximately 6 minutes, therefore a limit of 5 videos for tracking at any one time (total time 
approximately 30 minutes) was set to ensure fatigue did not influence tracking capabilities. 
Finally, the same operator was used for all chemotaxis assays and intra-individual variability 
was assessed (section 3.9) which demonstrated no significant difference with repeat analysis 
of videos. In order to explore the possibility of day-to-day variation affecting neutrophil 
chemotaxis, the same donors were bled at two different times (section 3.10) and although 
variation was evident the differences were not significant, thus data collected from further 
studies, i.e. before and after therapeutic intervention, was not normalised for comparative 
analysis.  
Automated tracking systems are an attractive, alternative method for acquiring quantitative 
data regarding cell movement. As cell detection is based on identifying differences between 
the cell itself and the background, automated tracking using phase-contrast microscopic 
videos is difficult to achieve because of the lower contrast between the background and the 
cells. An alternative method, by which cells can be tracked by automated software analysis, 
uses fluorescently labelled cells. The differential between cell and background is easier to 
achieve with this technique (Debeir et al. 2008), however light excitation/emission 
wavelengths can have a toxic effect on cells due to the generation of free radicals and 
specifically singlet and triplet forms of oxygen, reducing their ability to migrate (Magidson 
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& Khodjakov 2013). Automated tracking provides an opportunity to reduce the subjectivity 
of results to yield high-throughput analysis of time-lapse microscopic images. However, 
several challenges have impeded the development of such software for neutrophils, including 
the rapidly changing cell shape, high cell densities and cells moving in and out of the focal 
plane of the microscope. More recently automated segmentation and tracking algorithms 
have been developed to provide a framework for high-throughput tracking of cells in time-
lapse microscopy videos (Brandes et al. 2015) that do not rely upon fluorescent cell labelling. 
The technique involves taking static images within each frame into account allowing the 
distinction between background and cell, based upon temporal and spatial image variation, 
allowing their detection independent of their morphology and image illumination. Automated 
tracking is therefore being developed as an increasingly attractive alternative to manual 
tracking. 
The Insall chamber, like many of its predecessors, employs simplified environments such as 
static buffer conditions or a single chemoattractant gradient (Nelson et al. 1975; Brown 1982; 
Zigmond 1977; Zicha et al. 1991; Hopkins et al. 1984; Inoue & Meyer 2008; Heit, Robbins, 
et al. 2008) which cannot reflect the complex chemical signalling events in vivo. In an 
attempt to address this challenge, the field of microfluidics has emerged. Microfluidic 
chambers allow the formation of competing gradients of two chemoattractants whilst 
monitoring the behaviour of individual neutrophils. The 2-dimensional (2-D) μ-slide 
chemotaxis chamber (IBIDI, 80302) was tested with isolated neutrophils (section 8.1) as an 
alternative to the Insall chamber for the study of chemotaxis. Despite the obvious advantages 
of the μ-slide (more advanced gradient formation application and the ease of which the 
chamber can be sealed to provide longer-term chemotaxis videos), there were some 
significant drawbacks. These included: gradient formation taking several hours to form 
(Zengel et al. 2011), the chamber is only fit for single use and is technically difficult to use 
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(Irimia 2010). The Insall chamber assay was therefore preferred because of its simplicity, its 
ability to be re-used and its time-effectiveness. 
3.12. Chapter 3 Summary 
This chapter has investigated the optimisation of a neutrophil chemotaxis assay that provides 
ease-of-use and good replicability within a short time frame. The data that can be generated 
using the Insall chamber provides a wealth of novel information regarding the overall 
movement of cells from individuals with different health states and under different 
chemoattractant conditions. Optimisation of this assay provides an opportunity to assess 
chemotaxis in neutrophils from clinical samples alongside other measures of neutrophil 
function. 
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4.1. Introduction 
Chronic periodontitis and chronic gingivitis are among the most common inflammatory 
disorders in humans. Gingivitis does not necessarily always lead to periodontitis, but it is 
regarded as a necessary pre-requisite. As gingivitis is a reversible periodontal disease and 
gingival inflammation is a key driver of periodontitis itself, gingivitis represents a suitable 
model disease to study in order to better understand the pathogenic mechanisms underlying 
periodontitis. Understanding the effects of the chronic inflammation on neutrophils may shed 
light upon how periodontitis can act as a risk factor for other chronic inflammatory diseases. 
This chapter presents results from the assessment of neutrophil ROS, NET formation and 
chemotactic behaviours in a 21-day experimental gingivitis model, to assess the potential 
systemic effects of gingival/periodontal inflammation. In addition, gingival crevicular fluid 
(GCF) was collected to assess the chemoattractive potential of healthy and inflamed sites. 
Neutrophil chemotaxis was also examined in chronic periodontitis patients prior to and 
following non-surgical periodontal therapy. Again, GCF was collected from inflamed and 
non-inflamed sites and measured as for its chemoattractive properties.  
The data collected adds to current understanding of the systemic effects of short-term, 
localised inflammation. 
4.2. Volunteer information 
Section 2.1.2 describes the volunteer selection for the experimental gingivitis study; section 
2.1.3.1 and 2.1.3.2 details the selection process for the periodontitis patient cohorts 1 and 2 
respectively. Table 4.1 describes the age and gender of the experimental gingivitis study 
volunteers and the two periodontitis patient cohorts. For cohort 1, two patients were not 
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included in the chemotaxis assays, one due to withdrawal from the study and the other 
because they were neutropenic. 
Table 4.1 Gingivitis and periodontitis patient demographics  
 Gingivitis 
study 
Periodontitis cohort 1 Periodontitis cohort 2 
 
Control Patient Control Patient 
No. of 
participants 
15        18                  18        10                       10 
Gender 
(% females) 
60 39 50 
Mean age ± SD 
(range) 
22 ±3  
(20-29) 
52 ±11  
(40-75) 
46 ±8  
(37-61) 
46 ±8  
(32-62) 
% >60 yrs. 0 3 1 1 
 
4.3. Clinical measures for 21-day gingivitis study and chronic periodontitis patients 
To determine the extent of experimental gingival inflammation and the severity of 
periodontitis (patient cohort 1), gingival and plaque indices were taken and GCF was 
collected by Dr Martin Ling at both control/healthy and inflamed/diseased sites. In addition, 
for the chronic periodontitis patients (cohort 1), clinical attachment loss (CAL), periodontal 
probing depths (PPD) and bleeding on probing (BOP) were recorded before and after non-
surgical treatment (Appendix II) alongside healthy controls that were assessed 
simultaneously at each time point. CAL, PPD and BOP were measured immediately prior to 
blood collection for neutrophil assays by Dr Martin Ling, who also confirmed periodontal 
health in the healthy controls. Figure 4.1 shows the gingival and plaque indices for the 21-
day gingivitis volunteers and chronic periodontitis patients (cohort 1) with matched healthy 
controls displayed as the percentage of sites above health. The gingival index (GI) ranges 0–
3 (Löe et al. 1967); 0 is deemed as optimal plaque control. The modified Quigley-Hein 
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plaque index ranges 0 to 5; 0 and 1 are deemed to be healthy. The gingival index (GI) scores 
demonstrated the induction of inflammation for the experimental gingivitis study volunteers 
of day 7 with significant increases at test sites by day 21 (**** = p < 0.0001) but not at 
control sites during plaque accumulation; these returned to baseline levels at day 35 
following a professional prophylaxis and resumption of normal brushing at day 21 (Figure 
4.1a). For the chronic periodontitis patients, GI (Figure 4.1c) was significantly higher before 
treatment (p < 0.001) compared with the healthy controls and with post-periodontal treatment 
values; there was no significant difference between control measurements. In the case of 
gingivitis the plaque index (PI) values show that plaque accumulates significantly at the test 
sites following cessation of normal tooth brushing but not the control sites, (p < 0.001), its 
removal  at day 21 triggered a return to baseline levels, as reflected in the scores for both 
control and test sites at day 35 (Figure 4.1b). For the periodontitis patients (cohort 1), 
treatment lowered the PI to a level no longer significantly different to pre-treatment levels or 
to healthy control levels (Figure 4.1d).  
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Figure 4.1 Gingival index (GI) and plaque index (PI) in 21-day experimental gingivitis 
model and in chronic periodontitis (cohort 1) volunteers pre and post periodontal 
treatment 
Percentage of sites above healthy threshold (designated value of 0) for both GI (a and c) and 
PI (b and d) for gingivitis and periodontitis conditions. Data presented as line graphs (a and 
b) and box and whisker graphs (c and d); the band within the box represents the median, 
surrounded by the 1
st
 and 3
rd
 quartiles; the ends of the whiskers represent the minimum and 
maximum data points. n = 15 for gingivitis, n = 18 for periodontitis cohort 1. Statistical test: 
one way ANOVA and Tukey’s test.*** = (p < 0.001).**** = (p < 0.0001). 
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4.4. Gingival crevicular fluid (GCF) volume and protein quantity: 21-day experimental 
gingivitis cohort and chronic periodontitis group 
GCF was collected from the control and test sites of the experimental gingivitis study 
volunteers, the chronic periodontitis patient cohort 1 (diseased and matched-healthy control 
sites), and also from an inflamed area and a non-inflamed area from periodontitis patient 
cohort 2. Figure 4.2 shows the GCF volumes for gingivitis (Figure 4.2a) and chronic 
periodontitis patients cohort 1 and 2 (Figure 4.2b and c respectively). For the gingivitis 
volunteers, the volume of GCF collected was significantly higher at day 21 than at baseline 
(p < 0.05). For periodontitis patient cohort 1, significantly higher volumes of GCF were 
collected pre-treatment compared with post-treatment (p < 0.05) and controls (p < 0.01). 
When compared with healthy controls the volume post-treatment remained significantly 
higher than controls (p < 0.01).  
Although all chronic periodontitis patients were clinically diagnosed, systemic clinical 
measurement data was available for patient cohort 1 only.  Figure 4.3 shows the positive 
correlation between PPD and GCF volumes for pre- and post-treatment for cohort 1 and 
healthy controls. The data indicates that GCF volumes are associated with disease severity, a 
finding reported in other studies involving GCF (Sanikop et al. 2012; Bhadbhade et al. 2012; 
Subrahmanyam & Sangeetha 2003), and may even act as a more reliable marker of disease 
than other clinical markers of gingival inflammation such as BOP and PPD (Oh et al. 2015). 
Although systematically collected clinical measurement data was not available for cohort 2, 
the collected GCF volumes for periodontitis patient cohort 2 healthy sites (0.14μl, SD = 
±0.06) were significantly lower than for diseased sites (0.27 SD = ±0.12) (p < 0.05). 
The protein content of GCF samples from gingivitis study volunteers and chronic 
periodontitis cohort 2 patients was determined for subsequent quantification of the pro-
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inflammatory cytokines TNFα and IL-1β and for the ability of GCF to induce chemotaxis in 
neutrophils collected from periodontally and systemically healthy donors. Figure 4.4 shows 
the protein concentration of the GCF collected after processing (section 2.11.1.2). The trend 
in both gingivitis and periodontitis (cohort 2) shows an increased protein concentration from 
GCF at test/diseased sites with significance (p < 0.01) reached between healthy sites 
(91μg/ml SD = ±14) versus diseased sites only (102μg/ml SD = ±17) in periodontitis 
volunteers. 
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Figure 4.2 GCF volumes collected in experimental gingivitis and chronic periodontitis 
GCF was collected (section 2.11.1.2) at control and test sites and non-inflamed (control) and 
inflamed (test) sites in gingivitis study volunteers (a) and chronic periodontitis patient cohort 
1 (b) and cohort 2 (c). Data is presented as line graphs; each dot represents an individual 
control/healthy (blue) and test/diseased (red) collection site. n = 15 for gingivitis, n = 18 and 
n = 10 for chronic periodontitis patients cohort 1 and 2 respectively. Statistical test: paired t-
test test. * = (p < 0.05) and ** = (p < 0.01). 
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Figure 4.3 GCF concentrations and relation to probing pocket depth (PPD) in chronic 
periodontitis 
Pre-, post-treatment and healthy control site probing pocket depths were correlated with 
collected GCF volumes for chronic periodontitis patient cohort 1, data presented as 
correlation analysis. n = 18. * = (p < 0.05). Statistical test: unpaired t-test test.  
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Figure 4.4 Protein concentration of GCF in gingivitis and periodontitis 
Collected GCF samples were processed (section 2.11.1.2) and the protein concentration was 
determined (section 2.9) in gingivitis (a) and chronic periodontitis cohort 2 samples (b). Data 
is presented as line graphs; each dot represents an individual control/healthy (blue) and 
test/diseased (red) collection site. n = 15 for gingivitis, n = 10 for chronic periodontitis 
(cohort 2).  Statistical test: paired t-test. * = (p < 0.05) and ** = (p < 0.01). 
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4.5. NET formation in gingivitis and chronic periodontitis 
NET formation during experimental gingivitis was also assessed for the first time (Figure 
4.5). Fluorometric quantification revealed few differences in NET production. However, 
significance was identified between day 21 (height of inflammation) and day 35 
(inflammation resolution) with HOCl (p < 0.05) (Figure 4.5c), indicating NET production to 
be higher at day 21; a similar trend  was seen with PMA, despite no significant differences. 
NET production in chronic periodontitis patient cohort 1 has already been reported (White 
2015). In summary, neutrophils isolated from cohort 1 pre- and post-treatment were 
compared with age and gender-matched controls using the stimuli PMA and HOCl. 
Significant increases in NET formation were identified between patient pre-treatment and 
control samples after exposure to PMA (Wilcoxon test;  p=0.021) but not for an HOCl 
stimulus. When  presented as a ratio to the matched healthy controls, NET production by 
patients significantly decreased following treatment in response to PBS, PMA and HOCl 
(Wilcoxon test; p=0.007, p=0.004, p=0.012 respectively) (White et al. 2015; data not shown 
here).   
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Figure 4.5 NET quantification in gingivitis 
Neutrophils were isolated (section 2.2) and NETs were quantified in response to opsonised S. 
aureus (MOI 1 in 150; a), PMA (50nM; b) and  HOCl (0.75 mM; c) (section 2.5). All data is 
shown together (d). Averaged AFU readings were normalised by dividing all values by the 
respective gPBS control for a given time point x 100. n = 15 volunteers. Statistical test: 
ANOVA with Tukey’s post-test. * = (p < 0.05). 
 
 
 
 
 
 
142 
 
4.6. Neutrophil ROS generation in experimental gingivitis and periodontitis 
To assess for potential differences in ROS release from peripheral blood neutrophils with 
induced gingivitis, total ROS production was determined using the chemiluminescent reagent 
luminol (Figure 4.6). The stimuli used activated the three different signalling pathways as 
previosuly described (section 1.3.2). The effect of GM-CSF (10ng/ml) priming (section 1.5) 
was also measured. In the absence of priming, ROS generation revealed minimal differences 
between baseline (day 0), day 21 and inflammation resolution (day 35) following exposure to 
opsonised S. aureus and F. nucelatum (Figure 4.6a and b respectively). However significant 
differences were evident at day 21 with PMA (Figure 4.6c) compared to baseline (day 0; p < 
0.05) and inflammation resolution (day 35; p < 0.001). The effect of priming was only 
significant with PMA stimulation between days 21 and 35 (p < 0.01).  
ROS generation in chronic periodontitis patient cohort 1 has already been reported (Ling et 
al. 2016). In summary, neutrophils isolated pre- and post-treatment were compared with age 
and gender-matched controls using lucigenin (O2
. 
detection). Prior to stimulation O2
. 
release 
was significantly higher in patients pre-treatment than controls (Wilcoxon test;  p=0.011) and 
differences were lost following periodontal treatment when compared with controls. In the 
presence of stimuli, significantly more O2
.
 was released pre-treatment with P. gingivalis 
(Wilcoxon test; p=0.0266) and F. nucleatum (Wilcoxon test; p=0.0064) and again 
significance was lost when comparing patients post-treatment to control values. 
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Figure 4.6 ROS production in gingivitis 
Neutrophils were isolated (section 2.2) and peak values for ROS generation were measured 
in the presence of PBS, opsonised S. aureus (MOI 1 in 150) (a), F. nucleatum (b) (MOI 1 in 
300) and PMA (25 nM) (c) (section 2.4.3). Three different stimulation pathways were 
assayed: Fcγ receptors (using opsonised S. aureus); TLR’s (F. nucleatum); and direct 
receptor-independent stimulation of PKC by PMA. The effect of priming was also measured 
using GM-CSF (10ng/ml) (section 2.4.3.1) Total ROS was detected using luminol (n = 15). 
Peak data was normalised by dividing all values by the respective gPBS for a given time 
point x 100. Statistical test: ANOVA with Tukey’s post-test. * = (p < 0.05), ** = (p < 0.01) 
and *** = (p < 0.001). The colour of the lines denoting significance reflect the respective 
colour of the stimulus used. 
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4.7. Chemotaxis in gingivitis and chronic periodontitis 
Neutrophil speed, velocity and chemotactic index (CI) were measured over time in the 
presence of buffer or chemoattractant (fMLP or CXCL8) in neutrophils from experimental 
gingivitis study volunteers (Figure 4.7) and chronic periodontitis patient cohort 1 before 
(Figure 4.8) and after (Figure 4.9) non-surgical periodontal treatment. Tracked cell paths, 
polar plots and angle histograms were generated illustrating the differences in the course of 
cell movements for gingivitis volunteers (Figure 4.10) and periodontitis patients pre- (Figure 
4.11) and post-treatment (Figure 4.12). Neutrophils isolated from gingivitis volunteers 
showed increased speed at day 21 compared to day 0 for both chemoattractants (p < 0.001) 
and day 35 with fMLP only (p < 0.001). No significant differences were noted with velocity, 
but for CI a small but significant decrease was seen comparing days 21 to the other days for 
fMLP only (p < 0.001).  
For chronic periodontitis patients (cohort 1), pre-treatment neutrophils demonstrated 
significantly lower speed, velocity and CI than neutrophils from healthy volunteers for both 
fMLP (p < 0.01) and CXCL8 (p < 0.05). Following treatment, patient neutrophils still 
exhibited a significantly lower value for all three parameters after exposure to fMLP, 
however with the exception of speed, patient neutrophils were not significantly different in 
their response to CXCL8. Patients’ pre- and post-treatment results were analysed separately 
due to high inter-individual variation that can arise when neutrophils are isolated on different 
days (which was explored in section 3.10).  
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Figure 4.7 Chemotaxis in gingivitis 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cell moments were analysed (section 2.6.2) and tracked information was used to 
generate average speed (a), velocity (b) and CI (c) for neutrophils from gingivitis study 
volunteers in the presence of RPMI (negative control), fMLP (10nM) and CXCL8 
(200ng/ml) chemoattractants. (n = 15; 15 cells tracked per chemoattractant/RPMI). Statistical 
test: ANOVA with Tukey’s post-test. *** = (p < 0.001). 
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Figure 4.8 Chemotaxis in chronic periodontitis (patient cohort 1) pre-treatment 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cell moments were analysed (section 2.6.2) and tracked information was used to 
generate average speed (a), velocity (b) and CI (c) for neutrophils from chronic periodontitis 
patients (cohort 1) pre-treatment compared to healthy controls in the presence of RPMI 
(negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants. (n = 15; 15 cells 
tracked per chemoattractant/RPMI). Statistical test: Wilcoxon test. ** = (p < 0.01). *** = (p 
< 0.001). 
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Figure 4.9 Chemotaxis in chronic periodontitis (patient cohort 1) post-treatment 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cell moments were analysed (section 2.6.2) and tracked information was used to 
generate average speed (a), velocity (b) and CI (c) for neutrophils from chronic periodontitis 
patients (cohort 1) post-treatment compared to healthy controls in the presence of RPMI 
(negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants. (n = 15; 15 cells 
tracked per chemoattractant/RPMI). Statistical test: Wilcoxon test. * = (p < 0.05), *** = (p < 
0.001). 
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Figure 4.10 Gingivitis cell tracks 
Cell tracks, polar plots and angle histograms overlayed for neutrophils isolated at days 0, 21 and 35 neutrophils were generated to give a 
qualitative overview of chemotaxis using RPMI (negative control; a-c), fMLP (d-f) and CXCL8 (g-i) chemoattractants respectively. 
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Figure 4.11 Chronic periodontitis (cohort 1) pre-treatment cell tracks  
Cell tracks, polar plots and angle histograms overlayed for control (a,c,e) and patient (b,d,f) neutrophils were generated to give a qualitative 
overview of chemotaxis using RPMI (negative control), fMLP and CXCL8 chemoattractants respectively. 
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Figure 4.12 Chronic periodontitis (cohort 1) post-treatment cell tracks  
Cell tracks, polar plots and angle histograms overlayed for control (a,c,e) and patient (b,d,f) neutrophils were generated to give a qualitative 
overview of chemotaxis using RPMI (negative control), fMLP and CXCL8 chemoattractants respectively. 
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4.8. Chemotactic capabilities of GCF in gingivitis and chronic periodontitis 
GCF collected from test/diseased and control/healthy sites of experimental gingivitis 
volunteers and chronic periodontitis patients (cohort 2) respectively was analysed for 
chemoattractive properties. Neutrophils were isolated from periodontally and systemically 
healthy blood donors (section 2.1.1) and exposed to GCF after which chemotaxis was 
measured. Figure 4.13 shows the speed, velocity and CI for the 21-day gingivitis study 
volunteer GCF samples at day 0, 21 and 35; GCF protein content was normalised to the same 
levels for all samples. There were no differences at day 0 between the two sites, however at 
day 21 (the height of inflammation) GCF from test sites caused a significant increase in all 
three parameters (p < 0.0001) compared with their corresponding control sites. At day 35 
significance was still evident for velocity (p < 0.05) and CI (p < 0.01) between control and 
test sites. For the chronic periodontitis GCF samples (Figure 4.14), there was a consistently 
significant increase in all three parameters with GCF collected from diseased sites compared 
with healthy sites (p < 0.0001). 
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Figure 4.13 Chemotaxis using GCF from experimental gingivitis volunteers 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cell moments were analysed (section 2.6.2) and tracked information was used to 
generate average speed (a), velocity (b) and CI (c) for neutrophils from healthy blood donors 
in the presence of RPMI (negative control), fMLP (postive control; 10nM), CXCL8 (positive 
control; 200ng/ml) and GCF collected and processed (section 2.11.1.2)  from test and control 
sites of the gingivitis study volunteers. (n = 10; 15 cells tracked per 
chemoattractant/RPMI/GCF sample). Statistical test: Wilcoxon test. * = p < 0.05, ** = p < 
0.01, **** = p < 0.0001. 
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Figure 4.14 Chemotaxis using GCF from chronic periodontitis patients (cohort 2) 
Neutrophils were isolated (section 2.2) and chemotaxis was performed (section 2.6), after 
which the cell moments were analysed (section 2.6.2) and tracked information was used to 
generate average speed (a), velocity (b) and CI (c) for neutrophils from healthy blood donors 
in the presence of RPMI (negative control), fMLP (positive control; 10nM), CXCL8 
(positive control; 200ng/ml) and GCF collected and processed (section 2.11.1.2)  from 
diseased and healthy sites of chronic periodontitis patients (cohort 2). (n = 10; 15 cells 
tracked per chemoattractant/RPMI/GCF sample). Statistical test: Wilcoxon test. * = p < 0.05, 
** = p < 0.01, **** = p < 0.0001.  
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4.8.1. Cytokine quantification in GCF during gingivitis and chronic periodontitis 
The pro-inflammatory cytokines IL-1β and TNFα were quantified by ELISA from the GCF 
collected from control/healthy and test/diseased sites of experimental gingivitis study 
volunteers and chronic periodontitis patients (cohort 2) respectively. Previous experiemental 
work have found both cytokines to be measurable by ELISA in GCF (data unpublished) 
whereas other cytokines, notably CXCL8, are below the detection limit. Furthermore, the 
small collected sample volumes restricted the number of cytokines that could be quantified. 
Figure 4.15 show the results for IL-1β and Figure 4.16 for TNFα, the data is expressed as 
amount (pg) per 30 second sample time as previsouly described (Chapple et al. 1999). For 
GCF from gingivitis sites there was a clear increase in both IL-1β and TNFα at day 21 
compared with baseline (day 0) and inflammation resolution (day 35) (Figure 4.15d and 
Figure 4.16d respectively) which was significant between test and control sites at day 21 (p < 
0.05). For chronic periodontitis (cohort 2), the test sites had significantly greater 
concentrations of both cytokines in diseased sites over healthy (p < 0.01) (Figure 4.15e and 
Figure 4.16e). It is interesting to note that the concentrations of both IL-1β and TNFα are far 
greater than respective gingivitis control and test sites at the height of inflammation (day 21). 
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Figure 4.15 IL-1β ELISA in GCF samples 
GCF was collected and processed (2.11.1.2) after which IL-1β was quantified from control/healthy and test/diseased sites for days 0, 21 and 35 of 
the gingivitis study and in chronic periodontitis patients (cohort 2). n = 10. Statistical test: paired t-test. * = p < 0.05, ** = p < 0.01. 
156 
 
 
Figure 4.16 TNFα ELISA in GCF samples 
GCF was collected and processed (2.11.1.2) before TNFα was quantified from control/healthy and test/diseased sites for days 0, 21 and 35 of the 
gingivitis study and in chronic periodontitis patients (cohort 2). n = 10. Statistical test: paired t-test. * = p < 0.05, ** = p < 0.01. 
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4.9. Discussion 
The chemotaxis results for chronic periodontitis presented here have now been published 
(Roberts et al. 2015) and are detailed in Appendix II. 
Neutrophil ROS and NET production and chemotactic accuracy were assessed in a 21-day 
experimental gingivitis model in which healthy volunteers were prevented from brushing 
specified oral sites in order to induce reversible gingivitis. Neutrophils were isolated and the 
assays were performed at three time points representing baseline, the height of inflammation, 
and resolved inflammation. Neutrophil chemotactic accuracy was also measured in 
neutrophils isolated from a group of chronic periodontitis patients (cohort 1) alongside 
healthy gender- and age-matched controls prior to and following treatment, representing a 
longitudinal study. Finally, GCF was collected from the gingivitis study volunteers and a 
second cohort of chronic periodontitis patients (cohort 2). Two different sites were sampled 
representing health or disease/inflammation in order to measure pro-inflammatory cytokine 
release from GCF and to investigate its potential chemoattractive properties.  
The 21-day experimental gingivitis model provides an opportunity to investigate the 
induction and resolution of inflammation after a short period (35 days in total) of increased 
exposure to accumulating bacteria in a precisely controlled inflammatory process (Löe and 
Theilade 1965; Chapple et al. 1996; Wright et al. 2003). Other reported uses of this model 
include assessing the effects of compounds in drugs (Heasman et al. 1993) and 
environmental toxins such as tobacco smoke (Bergstrom & Preber 1986; Giannopoulou et al. 
2003) on the progression of gingival inflammation. As expected, the cessation of plaque 
removal by brushing resulted in increased gingival and plaque indices for the gingivitis 
volunteers. For the chronic periodontitis patients (cohort 1) both GI and PI were significantly 
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higher pre-treatment compared to both post-treatment and periodontally healthy controls; 
however any significant differences were lost following treatment.  
Gingival crevicular fluid (GCF) is a serum transudate/exudate that can be collected at the 
gingival margin or from the gingival crevice and represents a non-invasive method of 
measuring the inflammatory state of the periodontal tissues. GCF volume is expected to 
increase during inflammation (Löe et al. 1965), thereby demonstrating the induction/presence 
of gingivitis and periodontitis (Wright et al. 2003). In the study of chronic periodontitis, two 
cohorts of patients were studied due to the impossibility of accessing GCF from cohort 1. 
Cohort 2 did not have systematically collected clinical data and thus further details 
describing the extent of their periodontal disease could not be described in detail, but both 
cohorts had GCF volumes measured. Although GCF volume increases with increasing 
inflammation it may not correlate to disease severity but the levels of IL-1β in GCF have 
been postulated to be a marker of disease severity and activity (Baser et al. 2014) and were 
measured in the GCF of cohort 2 as discussed below.   
ROS production over the course of the 21-day gingivitis study showed an increase at the 
height of inflammation (day 21) and in the presence of the priming agent GM-CSF. 
Significance was only reached with a PMA stimulus in both the absence/presence of priming 
at the height of inflammation (day 21) compared to the other two time points (day 0 and 35) 
although increases from day 0 to day 21 were visible with the other stimuli used. These 
results demonstrate the potential for localised acute inflammation to have a systemic impact 
(because neutrophils were collected from peripheral blood), potentially enhancing the 
responsiveness of neutrophils to stimuli such as bacteria or their products or to priming 
agents, but following inflammation resolution the effect on ROS production was reversible. 
ROS generation from chronic periodontitis patient cohort 1 has previously been reported 
(Ling 2015) with results demonstrating a higher level of O2
.
 generation pre-stimulation in 
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neutrophils prior to periodontal treatment (Ling et al. 2016), an indication of hyperactivity 
which has also previously been reported in periodontitis (Matthews et al. 2007a), but which 
was no longer detectable following successful periodontal treatment. In the presence of 
stimulation, neutrophils from pre-treatment patients exhibited enhanced ROS generation, 
indicating a hyper-reactive neutrophil phenotype (Matthews et al. 2007b), which was also 
lost following treatment. The plasma-derived stimulants implicated in neutrophil 
hyperactivity and hyper-reactivity included GM-CSF, CXCL8 and Interferon alpha (IFNα) 
(Dias et al. 2011). Elevated IFNα levels have been identified in periodontitis patients relative 
to healthy controls (Wright et al. 2008); the gene expression profile of periodontitis patient 
neutrophils revealed differential expression of 163 genes, in particular increased expression 
of a number of type-1 IFN-responsive genes (Wright et al. 2008). The constitutively reactive 
nature of the hyperactive neutrophil phenotype may also be due to an altered intracellular 
redox state (GSH:GSSG ratio) reported in chronic periodontitis patient neutrophils leading to 
cellular stress and resultant relocation of NADPH oxidase to the outer cell membrane (Dias 
et al. 2013a) and supporting the contribution of ROS as a significant contributor to the 
systemic oxidative stress reported to characterise periodontitis. 
NET formation was also measured in the gingivitis study volunteers, with all stimuli 
increasing NETs at day 21 which then normalised/decreased by day 35. Significance was 
reached with HOCl at day 21 compared with day 35. Neutrophils and NET-associated 
proteins have been identified within the supragingival plaque of individuals partaking in the 
experimental gingivitis model, demonstrating that biofilms are composed of both microbial 
and host immune cells (Hirschfeld et al. 2015). NET measurements were previously reported 
in periodontitis patient cohort 1 (White 2015), in which no differences in NET production 
were observed patients following treatment when compared with age and gender- matched 
controls. When expressed as a ratio of patient NETs to control NETs pre- and post-treatment 
160 
 
in order to accommodate day-to-day variability of neutrophil assays, the decrease in NET 
production was more pronounced. NET formation has been shown to be upregulated in other 
disorders of chronic inflammation such as in COPD patient sputum when compared with 
healthy controls (Grabcanovic-Musija et al. 2015), pre-eclampsia (Gupta et al. 2005) and 
small-vessel vasculitis (Kessenbrock et al. 2009). However, there is no data to date on 
peripheral blood neutrophil NET production in periodontitis patients in comparison with 
controls other than unpublished data (White et al. 2016 in press), the results of which 
demonstrated no overall NET differences relative to matched controls, though NET 
production was significantly decreased in patients when comparing pre and post-treatment.   
Chemotactic accuracy was measured in both experimental gingivitis and chronic 
periodontitis (cohort 1). Neutrophils from the gingivitis cohort exhibited greater overall 
speed at day 21, but lower CI compared with baseline and resolution. These effects were 
mainly seen with the chemoattractant fMLP. The chronic periodontitis patients (cohort 1) 
demonstrated an overall reduced chemotactic accuracy prior to treatment with both CXCL8 
and fMLP chemoattractants and following treatment only significance with fMLP remained 
compared to healthy controls. Defective neutrophil chemotaxis has been shown in individuals 
with chronic inflammatory conditions including rheumatoid arthritis (Biemond et al. 1986; 
Miesel et al. 1996; Bostan et al.2002; Cedergren et al. 2007)  and COPD (Rahman et al. 
1997; Yoshikawa et al. 2007; Sapey et al. 2011), however few studies have examined 
chemotaxis in chronic periodontitis (Kumar & Prakash 2012). Numerous studies have 
reported  chemotaxis in localised aggressive periodontitis (LAP), a condition associated with 
a strong genetic pre-disposition occurring in otherwise systemically healthy individuals 
(Nibali et al. 2008). Despite the differences between LAP and chronic periodontitis, which 
includes differences in the oral microflora of these patients (Fu et al. 2002), reports of 
defective chemotaxis in LAP help to characterise the defects in the ability of neutrophils to 
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chemotax towards stimuli in a gradient-driven manner. Several studies have reported a 
diminished capacity of fMLP to bind to neutrophils from LAP patients, indicating a reduction 
in receptor numbers on the cell surface, the receptors themselves appearing fully-functional 
(Van Dyke et al. 1981; Van Dyke et al. 1986). Such a finding could explain the diminished 
responsiveness of these cells to a chemoattractive gradient. Furthermore, LAP neutrophils 
have been shown to express reduced levels of the glycoprotein gp110 (ADRM1 or hRpn13) 
(Van Dyke et al. 1987; Van Dyke et al. 1990), and studies in which gp110 function is 
attenuated resulted in diminished neutrophilic responses from healthy individuals in response 
to fMLP (Cotter et al. 1981). LAP neutrophils are also reported to have reduced expression 
of CD38, another receptor required for chemotaxis via fMLP (Fujita et al. 2005). 
Downstream signalling upon chemoattractant-receptor binding results in the activation of 
numerous signalling pathways; the PI3-K mediated activation of phosphoinositide dependent 
kinase-1 (PDK-1) is an essential regulator of chemotaxis and has reduced expression and 
activity in LAP neutrophils (Yagi et al. 2009). The PKC activator diacylglycerol (DAG) 
functions as a second messenger in a variety of neutrophil cellular processes including O2
.
 
production and chemotaxis (Nishizuka 1986; Harvath et al. 1987; Lambeth 1988), and has 
been shown to be elevated in LAP neutrophils. This offers an attractive option for the 
identification of such an abnormality in chronic periodontitis neutrophils, to support the 
potential that neutrophils are kept in a primed state for subsequent enhanced activity 
following exposure to an appropriate stimulus. However, cross-correlation between the 
defects witnessed in LAP and those reported here remains to be elucidated. The in-depth 
identification of deficiencies in LAP neutrophils provides an attractive avenue for further 
work to identify any commonalities between the different clinical definitions of periodontitis.  
GCF represents a convenient, non-invasive, and efficient means to sample biomarkers of 
inflammation in the oral cavity. GCF collected from gingivitis volunteers and chronic 
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periodontitis patients (cohort 2) was used in two assays as detailed in this chapter: first as a 
chemoattractant to measure the ability to induce chemotaxis in neutrophils isolated from 
healthy individuals; and second to quantify the pro-inflammatory cytokines IL-1β and TNFα. 
This chemotaxis data demonstrated the inability of GCF from control/healthy sites to have a 
potent chemotactic effect, conversely, at the height of inflammation (day 21 in experimental 
gingivitis) and in periodontitis samples, all chemotaxis parameters were greater than their 
respective controls, showing a similar effect to CXCL8 and fMLP. GCF carries proteins from 
the gingival tissues and fluid via the crevice, which may provide insights into the 
immunological processes occurring within the gingival tissues ( Adonogianaki et al. 1994; 
Gonzáles et al. 2001; Wright et al. 2003). Proteomic analysis of GCF detected temporal 
changes in numerous proteins during the course of experimental gingivitis, such as neutrophil 
defensins, which were elevated at day 35 in test sites (Grant et al. 2010) and which may 
reflect the role of neutrophils in maintaining a healthy state upon resolution of inflammation 
(Bostanci et al. 2010); cytokines were not detected due to low sub-attomole concentrations. 
The IL-1β and TNFα ELISA results showed a significant increase in both cytokines at the 
height of inflammation in the gingivitis volunteer test sites and in the diseased sites of 
chronic periodontitis patients (cohort 2). Interestingly the concentrations of both cytokines 
were greater in chronic periodontitis healthy sites in comparison to control sites of the 
experimental gingivitis GCF samples, indicating a different level of overall immune 
activation in chronic periodontitis compared to gingivitis. For gingivitis significance was lost 
by day 35. Cytokines can potentially serve as biomarkers of disease; dysregulation of the 
relative balance of cytokines can often be the earliest marker of a pathologic response (Bozza 
et al. 2007; Chun et al. 2007). Numerous studies have reported raised levels of cytokines in 
experimental gingivitis which include LTB4 (Heasman et al. 1993), transforming growth 
factor beta (TGFβ) (Wright et al. 2003) and IL-1α (Offenbacher et al. 2010). The potent pro-
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inflammatory cytokines IL-1β and TNFα both exhibit bone-resorbing activty (Tani-Ishii et 
al. 1999). Enhanced levels during gingivitis alongside expectedly high levels in chronic 
periodontitis provides a more detailed understanding of the conditions to which neutrophils 
within the oral cavity are exposed, which may underly any hyper-reactive responses, 
particularly with regard to ROS generation, a factor known to result in host-collateral tissue 
damage. Increases in IL-1β concentrations have previosuly been reported in experimental 
gingivitis (Gonzales et al. 2001; Offenbacher et a. 2010; Scott & Krauss 2012) and are 
associated with increasing gingival inflammation (Buduneli & Kinane 2011; Boronat-Catalá 
et al. 2014).   
4.10. Chapter 4 summary 
The mechanisms underlying the progression of gingivitis to periodontitis in susceptible 
individuals are poorly understood. Neutrophils are key immune cells involved in protecting 
the host from bacterial challenge. Disruption to neutrophil functions such as ROS, NETs and 
chemotaxis may pre-dispose an individual to further infection and inflammation, 
exacerbating disease pathogenesis. Reduced neutrophil chemotactic accuracy may affect the 
ability of neutrophils to efficiently exit the circulation in order to reach the site of infection, 
potentially allowing periodontal pathogens to colonise in the periodontal tissues with a 
reduced host-immune threat. Moreover increased tissue transit times coupled with enhanced 
ROS generation (Matthews et al. 2007a) and NET production (White et al. 2016), as a result 
of underlying increases in pro-inflammatory cytokines (Ling et al. 2015), may result in 
enhanced collateral host tissue damage contributing to the inflammatory burden. These 
findings add to the current understanding of the effects of acute and chronic inflammatory 
states on the functional abilities of neutrophils and how they in turn may contribute to disease 
progression via host-mediated tissue damage (Grossi et al. 1994). 
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5.1. Introduction 
Papillon-Lefévre Syndrome (PLS) is a rare inherited autosomal recessive disease affecting 1 
in 250,000-1 million people and is characterised by palmoplantar keratosis and severe pre-
pubertal periodontitis leading to premature loss of all teeth. The underlying mutation(s) in 
PLS is in the cathepsin C (CTSC) gene, resulting in loss of activity and subsequent failure to 
activate neutrophil serine proteases (NSPs) and therefore immune response proteins. The 
NSP deficiency has been postulated by many to be the underlying cause for the severe pre-
pubertal periodontitis in PLS as a result of NSP deficiencies failing to eliminate pathogenic 
bacteria. However, the severe inflammation and bone destruction evident in these patients 
indicates a far more complex picture and a more comprehensive assessment of neutrophil 
function in PLS seems likely to reveal a greater depth of understanding of the mechanisms 
that culminate in the destructive localised chronic periodontal inflammation that characterises 
PLS.    
This chapter presents results from a cross-sectional assessment of neutrophil ROS and NET 
production as well as chemotaxis and cytokine release from individuals with PLS compared 
with healthy gender-matched controls. The data collected will add to current understanding 
of aetiology of PLS, in particular the influence of NSPs on neutrophil functionality. 
5.2. Patient background information 
As described in 2.1.4, adolescent patients and young adult control volunteers were recruited 
specifically for this study. Table 5.1 provides summary patient demographics and CTSC 
mutation analyses. Controls were gender-matched, ages ranged from 19-21 and BMI ranged 
~18-23. All volunteers had severe pre-pubertal periodontitis and mutation analysis was by 
direct sequencing by Professor Nalin Thakker and Dr Ratna Veeramachaneni. Patient 1 was a 
compound heterozygote and had the mildest clinical phenotype, but also had a very low 
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neutrophil count at the time of venepuncture and was thus only involved in the study of NET 
quantification. Volunteer 2 had a Y294C mutation (maternal allele) and is thus heterozygous 
for this mutation. The paternal allele was not detected and is probably within the intronic 
region that was not subject to analyses. Figure 5.1 illustrates the palmoplantar keratosis and 
periodontal destruction in one of the patients recruited. 
Table 5.1 Characteristics of patients recruited in PLS study  
 
Patient 
no. 
Age Gender Ethnicity BMI PLS type Mutation 
1 12 Male Caucasian 18.93 Heterozygous 
1/2 G139R; 
1/2 N427T 
2 14 Female Indian 19.90 Heterozygous 
1/2 Y294C; 
1/2 not detected 
3 14 Female Pakistani 20.04 Homozygous 2/2 R272P 
4 9 Male Pakistani 22.83 Homozygous 2/2 R272P 
5 15 Male Pakistani 18.15 Homozygous 2/2 R272P 
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Figure 5.1 PLS patient clinical characteristics  
Hyperkeratosis of the plantar surfaces of the feet (a) and palmar surfaces of the hands (b) in 
one of the patients (left) and the patient’s father (right) who also has PLS (a). Intraoral 
radiograph and photograph showing generalized recession and severe periodontal destruction 
of the patient at aged 5-years (c). Images courtesy of Professor I. Chapple. 
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5.3. Analysis of NETs and NET-related proteins ion PLS 
5.3.1. Quantification of neutrophil elastase (NE) and  cathelicidin (LL-37)  
NE and LL-37 (the active form of cathelicidin) were quantified in plasma (Figure 5.12a-b) 
and cultured neutrophil supernatants both unstimulated and following TLR- (A. actino) and 
FcγR- (opsonised S. aureus) stimulation (Figure 5.12c-d). Both proteins are activated by 
CTSC; NE is activated by CTSC directly and LL-37 is activated via PR3 (Sørensen et al., 
2001), following PR3 activation by CTSC. NE was almost completely absent in both plasma 
and neutrophil supernatants from PLS patients, and when compared to controls (figure a and 
c). LL-37 was absent in plasma from PLS patients but was present at low concentrations in 
cultured neutrophil supernatants following stimulation (figure 5.2b and d), suggesting 
minimal CTSC activity or an alternative processing pathway. These results indicate a local 
and systemic NSP deficiency in the patients.  
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Figure 5.2 NE and LL-37 sample quantification 
Neutrophils were isolated (section 2.2.2) and NE and LL-37 were quantified in plasma 
(section 2.3; a and b respectively) and neutorphil supernatants following an overnight culture 
(section 2.7.2; c and d respectively). Stimuli for cell culture included RPMI, A. actino or 
opsonised S. aureus (MOI 1 in 300 and 150 respectively). Due to undetectable concentrations 
in the patient samples no statistical analyses were performed. Blue hollow circles and filled 
red circles represent control and patient samples (n = 4) respectively.  
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5.3.2. Quantification of NETs and NET bound components 
The ability of PLS patients to produces NETs was measured using a nucleic acid stain 
(SYTOX
®
) in addition to NET-associated antimicrobial peptidss (AMPs) in order to confirm 
the DNA measured was derived from NETs: NE, myeloperoxidase (MPO) and cathepsin G 
(CG). Fluorometric quantification revealed NETs were substantially decreased in patients 
(Figure 5.3a; p < 0.001), a finding confirmed by NET visualisation using fluroescence 
microscopy (Figure 5.3e). NET bound proteases were also substantially decreased or 
deficient in patients and significantly lower (where calculated) compared to controls for 
nearly all stimuli used (Figure 5.3b-d; p < 0.001). The reduced presence of NET-bound MPO 
further supports the lack of NET structures in these patients, who do not otherwise suffer a 
MPO deficiency (p < 0.05). NE and CG, which are both activated by CTSC, were also 
extremely low in PLS patients (p < 0.05). 
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Figure 5.3 NET-DNA and NET-bound protein quantification in PLS 
Neutrophils were isolated (section 2.2.2) and NETs and NET bound proteins were quantified 
in response to PBS (negative control), PMA (50nM), HOCl (0.75 mM) or bacteria (MOI 1 in 
300) (section 632.5). Bacteria were selected for each assay on the basis of clinical relevance, 
in that they are implicated in PLS periodontitis (A. actino) and PLS-related skin abscesses (S. 
aureus). NET quantification (a) in stimulated/un-stimulated conditions (n = 5 patient n = 4 
control); NET-bound elastase detection (b) after stimulation (n = 4); NET-bound MPO (c) 
levels (n = 3); NET-bound CG (d) (n = 3). Blue hollow circles and filled red circles represent 
control and patient samples respectively. Statistical test: Mann-Whitney. * = (p < 0.05), ** = 
(p < 0.01).Where levels could not be detected in patient samples, no statistical tests were 
performed. Representative NET images (e) in the absence of stimuli (PBS) and following the 
addition of PMA highlighting the lack of NET structures in PLS patients.    
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5.4. Neutrophil ROS generation and plasma protein oxidation in PLS patients 
To assess the potential for differences in ROS release from PLS neutrophils relative to  
controls, superoxide and total and intracellular ROS were detected using the 
chemiluminescent reagents lucigenin, luminol and isoluminol, respectively (Figure 5.4a-c). 
the stimuli used activated the three different signaling pathways as previosuly described 
(section 1.3.1). In all conditions ROS generation was the same or higher in PLS patients 
compared to controls. Significance was evident in patients over controls with luminol for 
opsonised S. aureus (p < 0.001) and PMA (p < 0.05). For isoluminol and lucigenin 
significance was evident with PMA only (p < 0.05). Protein carbonylation, a ROS-induced 
marker of oxidative stress, was also measured by ELISA (Figure 5.4d). There was no 
significant difference for protein carbonylation in the plasma between patients and controls. 
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Figure 5.4 ROS and protein carbonylation in PLS  
Neutrophils were isolated (section 2.2.2) and peak values for ROS generation were measured 
in the presence of PBS, PMA (25nM), opsonised S. aureus and heat killed A. actino (MOI 1 
in 300 and 150 respectively) (section 2.4). Three different stimulation pathways were 
assayed: Fcγ receptor (using opsonised S. aureus); TLR (F. nucleatum); and direct receptor-
independent stimulation of PKC by PMA.  ROS production was meaured as total ROS (a) 
detected using luminol (n = 4);  extracellular ROS (b) using isoluminol (n = 4); and 
superoxide (c) using lucigenin (n = 4). ROS release for patients was higher than controls with 
significance for PMA for all three chemiluminescent substrates. Plasma protein 
carbonylation (d), a measure of oxidative stress, was measured by anti-DNP ELISA (n = 5). 
Blue hollow circles and filled red circles represent control and patient samples respectively. 
Statistical test: ANOVA with Tukey’s post-test. * = (p < 0.05), ** = (p < 0.01 
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5.5. Cytokine, MMP-9 and S100A8/9 quantification in PLS patients 
The pro-inflammatory cytokines IL-1β, IL-6, CXCL8, MIP1α and TNFα were quantified 
from culture supernatants and plasma samples by Luminex assay. In addition, MMP-9 
(gelatinase), the major enzyme released by neutrophils involved in the breakdown of the 
extracellular matrix to facilitate movement through the tissues, and the calgranulins S100A8 
and A9 were quantified by ELISA.  
Table 5.2 shows plasma concentrations and cell culture supernatant concentrations; Figure 
5.5a-h shows neutrophil culture supernatant levels in graphical form. Where levels of the 
measured agents were undetectable statistical testing could not be performed, nonetheless in 
plasma the levels of all cytokines/MMP-9/S100A8/9 was higher in patients than controls, 
with significance reached for CXCL8 and MMP-9 (p=0.029). Within cultured neutrophil 
supernatants there was a significant increase in IL-6, CXCL8 and MIP1α (p=0.029) in the 
absence of stimulation indicating a hyperactive neutrophil phenotype. Following A. actino 
challenge (TLR stimulation), cytokines IL-6, CXCL8, MIP1α and TNFα were all higher in 
PLS patients than controls (p=0.029). In addition, S100A9 was also found to be elevated. 
The same results were achieved with opsonised S. aureus (FCγR stimulation) with the 
exception of IL-6.  
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Figure 5.5 Cytokine and calgranulin quantification in PLS 
Neutrophils were isolated (section 2.2.2) and cytokines IL-1β (a), IL-6 (b). CXCL8 (c), 
MIP1α (d), TNFα (e), MMP-9 (f), and calgranulins S100A8 (g) and S100A9 (h) release from 
patient and control neutrophils (n = 4 respectively) isolated and cultured for 16 hours (section 
2.7) and incubated with RPMI (control), A. actino (TLR stimulation pathway) or opsonised 
S. aureus (FcγR stimulation pathway) (MOI of 1 in 150 and 1 in 300 respectively). Blue 
hollow circles and filled red circles represent control and patient samples respectively. 
Statistical test: Mann-Whitney. * = (p < 0.05). 
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Table 5.2 Cytokine and calgranulin quantification from cultured neutrophils in PLS 
Cytokine, MMP-9 and S100A8 and -9 concentrations from isolated neutrophils cultured for 
16 hours from PLS patients and controls (n = 4 respectively). Stimuli included RPMI 
(control), A. actinomycetemcomitans or opsonised S. aureus (MOI of 1 in 150 and 1 in 300 
respectively). Green italicised text highlights results deemed significantly different at p < 
0.05. Where levels could not be detected in patient samples, no statistical tests were 
performed. Statistical test: Mann-Whitney. 
 
RPMI (Unstimulated neutrophil activity) 
Analyte Control (pg/ml) Patient (pg/ml) 
P 
value 
 
1             2                3            4 2                3               4            5 
 
IL-1β 4.38 1.34 0.65 7.58 4.8 49.37 18.15 33.9 0.057 
IL-6 91.94 49.51 65.52 109.55 113.16 860.97 598.24 423.8 0.029 
CXCL8 1838.8 990.2 1310.4 2191 2263.2 17219.4 11964.8 8476 0.029 
MIP1α 20.72 17.99 16.82 24.12 27.64 244.58 293.55 257.74 0.029 
TNFα 0 0 0 0 0 17.06 13.25 19.43 - 
MMP-9 786.31 1210.11 2906.7 6947.75 3,311.35 2,947.85 2,192.06 1,026.27 0.886 
S100A8 367.16 227.32 248.69 384.09 331.53 171.21 695.85 233.55 0.886 
S100A9 150.73 30.67 50.68 632.09 671.37 271.72 944.79 185.31 0.114 
A. actinomycetemcomitans (neutrophil reactivity) 
Analyte Control (pg/ml) Patient (pg/ml) 
P 
value 
 
1             2             3              4 2            3               4             5 
 
IL-1β 60.98 57.45 52.77 122.47 59.03 271.97 233.73 160.1 0.114 
IL-6 502.87 338.42 307.13 401.41 843.56 3847.74 4669.62 2007.99 0.029 
CXCL8 10057.4 6768.4 6142.6 8028.2 16871.2 76954.8 93392.4 40159.8 0.029 
MIP1α 252.06 301.12 228.88 252.31 855.99 1408.84 721.34 849.17 0.029 
TNFα 16.71 31.35 17.39 56.85 81.78 189.43 173.33 135.79 0.029 
MMP-9 1,224.29 1,939.96 2899.5 5,661.66 5,398.59 3,450.59 3,034.44 1,566.67 0.686 
S100A8 481.18 260.27 224.64 466.93 466.93 278.09 320.84 264.73 1 
S100A9 172.20 10.35 81.59 224.67 823.27 359.72 811.75 237.68 0.029 
Opsonised S. aureus (neutrophil reactivity) 
Analyte Control (pg/ml) Patient (pg/ml) 
P 
value 
 
1             2              3             4 2              3              4              5 
 
IL-1β 81.99 85.88 102.26 87.63 81.05 358.62 389.46 131.65 0.343 
IL-6 357.02 191.77 209.19 358.87 290.15 2033.56 2898.57 848.68 0.114 
CXCL8 7140.4 3835.4 4183.8 7177.4 5803 40671.2 57971.4 16973.6 0.029 
MIP1α 194.92 181.81 164.4 270.99 478.93 475.06 613.38 435.67 0.029 
TNFα 39.2 42.2 40.99 25.86 73.85 209.16 213.93 140.61 0.029 
MMP-9 1265.44 3743 6016 4979 2491 1954 2554 4328 0.496 
S100A8 392.99 712.78 955.95 702.08 956.84 524.83 470.49 524.83 0.885 
S100A9 20.83 37.065 95.73 350.81 956.31 428.86 831.13 336.15 0.029 
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Table 5.3 Plasma cytokine and calgranulin quantification in PLS 
Cytokine, MMP-9 and S100A8 and -9 concentrations in plasma from PLS patients and 
controls (n = 4 respectively). Green italicised text highlights results deemed significantly 
different at p < 0.05. Where levels could not be detected in patient samples, no statistical 
tests were performed. Statistical test: Mann-Whitney. 
Plasma 
Analyte Control (pg/ml) Patient (pg/ml) 
P 
value 
 
1             2              3             4 2              3              4             5 
 
IL-1β 0 0 0.41 0 7.06 0 1.78 0 - 
IL-6 16.94 22.91 25.82 19.32 36.62 9.56 20.54 24 0.886 
CXCL8 0.92 1.09 0.76 0.79 3.41 1.11 3.32 1.16 0.029 
MIP1α 0 27.28 4.3 0.65 36.02 11.18 32.44 5.35 0.114 
TNFα 0 0 0 0 47.53 0 0.57 0 - 
MMP-9 24.96 11.44 37.43 6.03 449.59 135.8 554.27 282.5 0.029 
S100A8 0 0 0 0 2674.66 494.55 1436.54 2941.09 - 
S100A9 0 0 0 0 1538.19 412.51 470.74 2001.63 - 
 
 
5.6. Neutrophil chemotaxis in PLS patients 
Neutrophil speed, velocity and chemotactic index (CI) were measured over time in the 
presence of buffer (RPMI) or chemoattractant (fMLP or MIP1α). MIP1α is a target for NSPs 
which deactivate the chemokine. This was confirmed by preliminary chemotaxis work 
involving pre-incubation of CG with MIP1α prior to its use as a chemoattractant, which 
demonstrated that chemotaxis could not be induced (Appendix III). As NSP function is lost 
in PLS individuals, MIP1α was employed in the chemotaxis assays to ascertain whether 
neutrophils from PLS patients chemotax differently to those from healthy controls, in 
particular whether MIP1α chemotaxis is at all enhanced in PLS patients over controls.  Speed 
was significantly lower in patients when exposed to MIP1α (Figure 5.6a), a trend that was 
consistent for both MIP1α & fMLP when velocity (Figure 5.6b) and chemotactic index 
(Figure 5.6c) were measured. Figure 5.7 shows the cell paths of all tracked cells per 
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condition, including polar plots and angle histograms, illustrating the differences in the 
course of the cell movements. PLS patient neutrophils showed significantly reduced speed, 
velocity and chemotactic accuracy compared with controls in response to MIP1α, and also a 
lower CI in response to fMLP.  
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Figure 5.6 Neutrophil chemotaxis in PLS 
Neutrophils were isolated (section 2.2.2) from PLS patients and controls and chemotaxis was 
performed (section 2.6), after which the cells were analysed (section 2.6.2) and tracked 
information was used to generate average speed (a), velocity (b) and CI (c) in the presence of 
RPMI (negative control), fMLP (10nM) and MIP1α (100ng/ml) chemoattractants. Blue 
hollow circles and filled red circles represent control and patient samples respectively (n = 4; 
15 cells tracked per chemoattractant/RPMI). Statistical test: Mann-Whitney. * = (p < 0.05), 
*** = (p < 0.001), **** = (p < 0.0001). 
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Figure 5.7 PLS neutrophil cell tracks 
Cell tracks, polar plots and angle histograms overlayed for control (a, c and e) and patient (b,d and f) neutrophils were generated to give a qualitative 
overview of chemotaxis using RPMI (negative control), fMLP (10nM) and MIP1α (100ng/ml) chemoattractants respectively. 
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5.7. Discussion 
The results and discussion presented here have been published from this thesis (Roberts et al. 
2016); in addition, work demonstrating the chemotactic capabilities of LL-37 has also been 
published (Koro et al. 2016) and is detailed in section 8.6. 
This chapter reports the comprehensive analysis of neutrophil function in PLS patients 
compared with unaffected controls and is the first to explore directional chemotaxis and 
cytokine release in PLS as part of the neutrophils’ functional repertoire.  
PLS neutrophils demonstrated negligible NET formation, as analysed by assays of NET-
DNA, and an almost total absence of the NET-associated AMPs - CG, NE and MPO, despite 
the fact that PLS neutrophils are not MPO deficient as previously reported (Eick et al. 2014). 
Eick et al. seemingly demonstrated that the absence of the MPO protein, which would 
normally be present in PLS neutrophils, was because of a lack of NET presence rather than 
the lack of MPO itself. The absence of, or marked reduction in, NETs provides additional 
data to that recently reported in a single PLS patient (Sørensen et al., 2014). NE and CG are 
both enzymes that are activated by CTSC, and in vitro studies of NSPs have demonstrated 
CG and NE are able to kill A. actinomycetemcomitans in addition to other periodotal bacteria 
(Bangalore, et al. 1990). The NSP deficiency likely compromises neutrophil antimicrobial 
efficacy allowing for the persistance of some pathogenic species over others in PLS. NE is 
known to be necessary for NETosis as demonstrated by the study of neutrophil elastase 
disorders such as ELA2-related neutropenia, where neutrophil elastase activity is deficient 
(Dale et al. 2000) and so NET formation is diminished (Papayannopoulos, et al. 2010). 
Conversely, in HAX1-related neutropenia elastase is functional and HAX1-neutropenia 
patients produce NETs (Happle, et al. 2011).  
The ROS data reported here indicate an enhanced response to opsonised S. aureus (luminol 
detection only) and PMA in the PLS patients, which is consistent with a hyper-reactive 
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neutrophil phenotype (Matthews et al., 2007a) which may contribute significantly to the 
oxidative stress (characterised by elevated lipid hydroperoxide levels) and compromised 
antioxidant levels previously reported in PLS (Battino et al. 2001). The increased ROS 
detected in PLS patient neutrophils ex vivo could be a major contributing factor to the host-
mediated tissue damage at sites where neutrophils are the dominant immune cell, such as the 
periodontium. These results contribute further to previous work demonstrating decreased 
antioxidant defences and increased oxidative stress characterised by greater lipid 
hydroperoxide levels in unstimulated neutrophils from PLS patients (Battino et al. 2001).  
Cytokine measurements demonstrated increased release of pro-inflammatory cytokines (IL-6, 
CXCL8 and MIP1α) from PLS neutrophils in the absence of stimulation, indicating a 
hyperactive phenotype. Furthermore, hyper-reactivity (to a stimulus) in terms of pro-
inflammatory cytokine release and also S100A9 concentration was also evident from the 
supernatants of stimulated cultured neutrophils. Higher S100A8/9 concentrations have been 
reported in inflamed tissues and are known to be markers of neutrophil activation (Foell et al. 
2007). S100A9 is a known target for CG (Ryckman, et al. 2003) to generate neutrophil 
immobilising factor (NIF) which has been reported to inhibit neutrophil migration and 
chemotaxis (Goetzi and Austen 1972). NIF acts as a negative feedback loop, limiting 
neutrophil influx into inflammatory regions. The absence of NIF may be another contributing 
factor to the lack of resolution of inflammation in PLS and the seemingly relentless 
periodontal tissue destruction characteristic of PLS. S100A9 can form a heterodimer with 
S100A8 which has been shown to be involved in the assembly of the NADPH oxidase 
(Kerkhoff et al. 2005), and thus could be one mechanism underlying higher ROS levels 
released by the PLS patients neutrophils in this study. 
Cytokine measurement in plasma was performed to examine their presence in vivo; the 
presence of elevated cytokine/MMP-9 levels in patient plasma over controls further supports 
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the hypereactive PLS neutrophil phenotype, as circulating neutrophils exposed to increased 
concentrations of a combination of pro-inflammatory agents are likely to prime the cells 
within the circulation for enhanced killing activities when they reach periodontal tissues, as 
demonstrated with ROS release (Yao et al. 2015).  
Neutrophil chemotaxis measurements demonstrated defects in PLS patients; a consequence 
of which may be to potentially increase neutrophil tissue transit times and further potentiate 
neutrophil-mediated tissue damage. As NSPs can de-activate MIP1α and CXCL8, the loss of 
NSP function in PLS may result in relentless neutrophil recruitment to periodontal tissues by 
such chemokines. Neutrophil speed and velocity were reduced in response to MIP1α, relative 
to controls, and there was a significant difference in directional chemotactic accuracy of PLS 
neutrophils for both MIP1α and fMLP. Previous studies have identified reduced chemotaxis 
in PLS, however these reports used alternative assays such as the Boyden chamber (Djawari 
1978) and the Zymosan activated serum assay (Firatli et al. 1996), neither of which measure 
directional chemotaxis.  
The underlying explanation for the periodontitis in PLS, in combination with the data 
generated in this chapter, points to two key scenarios: Firstly, continual recruitment to the 
periodontal tissues of neutrophils that exhibit hyper-activity/reactivity. NSPs are a very 
important component of antimicrobial functionality of neutrophils, and the implications of 
NSP deficiency has been linked to the development of periodontitis previously (Pham et al. 
2004; de Haar et al. 2006). Neutrophils lacking both NE and CG are unable to undergo 
cytoskeletal reorganisation despite adhering to immune-complex-coated surfaces in vitro 
(Djawari et al. 1978), the underlying cause being a decrease in the phosphorylation of the 
GTPase RAC1 which is performed indirectly by CG, thus the lack of NSPs in PLS may be an 
underlying cause of the chemotactic defect identified in this study. Moreover, MIP1α 
isoforms are inactivated by NSPs (Ryu et al. 2005), and MIP1α has been shown to act as an 
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osteoclast activation factor, inducing bone resorption (Choi et al. 2000). The constant 
presence of active MIP1α and failure to generate NIF in PLS may drive a relentless 
recruitment and accumulation of activated neutrophils to the inflamed periodontal tissues and 
lead to the subsequent destruction of periodontal connective tissue and alveolar bone. 
Confinement of this recruitment to the periodontal tissues could be a result of the constant 
microbial challenge ever present in this area of the body. In addition, the deficiency of LL-
37, itself a result of PR3 deficiency in PLS patients, increases the incidence of microbial 
infection, notably with the periodontal pathogen A. actinomycetemcomitans as previously 
reported (Eick et al. 2014). Furthermore, LL-37 and its carbamylated variants, which arise 
due to cyanate formation during the neutrophil oxidative burst, has been demonstrated to 
have chemoattractive properties in assays employing the Insall chamber (Koro et al. 2016), 
thus a lack of LL-37, which was not shown to be as potent as fMLP in inducing neutrophil 
chemotaxis, may impact on the hierarchical recruitment of neutrophils from the circulation to 
the site of end-point chemoattractants. 
NSP dysfunction is associated with periodontal disease in other syndromes, including 
Chédiak Higashi Syndrome (Holt et al. 2006) and the allelic variant to PLS, Haim Munk 
Syndrome (Hart et al. 2000). Furthermore, neutrophils from sufferers of Specific Granule 
Deficiency, characterised by defects in the packaging of azurophil and specific granules 
(which contain NSPs and NADPH oxidase components respectively), have been shown to 
exhibit decreased phagocytosis, diminished ROS formation and reduced chemotaxis (Gallin 
et al. 1982). 
 
The second scenario potentially underlying the causation of periodontal disease in PLS is 
compromised antimicrobial killing. PLS patients are known to suffer modest systemic 
infections (mostly skin abscesses), with 15-20% of patients reporting recurrent infections, 
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unlike patients with chronic granulomatous disease (CGD), which is characterised by the 
lack of a functional NADPH oxidase and the subsequent inability to produce ROS or form 
NETs. Interestingly CGD patients are not overtly susceptible to periodontitis (Nussbaum & 
Shapira 2011), suggesting that the periodontal tissue destruction seen in PLS cannot be fully 
explained by compromised neutrophil anti-microbial defences. PLS individuals are not 
systemically immunocompromised and as the results of this study show, PLS neutrophils 
have the capacity to respond to pathogenic stimuli, thus NSPs do not constitute the primary 
antimicrobial defence mechanism, and the underlying cause of periodontitis in PLS cannot be 
explained simply by reduced neutrophil bacterial killing. A far more likely scenario is that 
the periodontal tissue damage in PLS patient’s results from a complex series of events arising 
downstream of the CTSC deficiency which depend upon the diverse range of NSP functions 
normally active at sites of microbial challenge.  
 
Deficient bacterial killing as a result of impaired killing mechanisms results in persistence of 
pathogenic species and triggers the relentless recruitment of hyper-active/reactive neutrophils 
characterised by increased ROS and pro-inflammatory cytokine presence in the 
periodontium. Extended tissue transit times and a failure to de-activate chemokines such as 
MIP1α and CXCL8, likely drives the connective tissue damage and bone loss in PLS. 
Defects in neutrophil function have been shown in several studies of chronic periodontitis 
patients; peripheral neutrophils from chronic periodontitis patients exhibit hyper-reactivity 
with respect to ROS release (Matthews et al. 2007a; Ling et al. 2016) and pro-inflammatory 
cytokine production (Ling et al. 2015) in response to a microbial challenge, and also 
hyperactivity in the absence of an exogenous stimulant (Matthews et al., 2007b).  
Chemotaxis in chronic periodontitis patients has also been found to be defective with only 
partial improvement after non-surgical therapy (Roberts et al. 2015), and oxidative stress is 
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also a strong feature of periodontitis. In PLS, failure to activate and release NSPs has greater 
far-reaching consequences than a superficial observation based purely on defective anti-
microbial defences, and may thus underlie the aggressive periodontal tissue damage seen in 
PLS.  
5.8. Chapter 5 summary 
This study has characterised a range of neutrophil behaviours in PLS patients from 5 
different families, representing a relatively large cohort of patients and providing new 
insights into the functional consequences of CTSC deficiency upon periodontal tissue 
destruction and tooth loss. PLS neutrophils have a substantially reduced capacity for NET 
production, as confirmed by the almost total absence of NET-related proteins. ROS 
generation was higher in PLS and directional chemotactic accuracy was compromised. NSP 
deficiency has previously been purported to be the cause of periodontal tissue destruction in 
PLS. This study adds to this association through the identification of failed key neutrophil 
antimicrobial activities, which likely contributes to the misdirected recruitment of hyper-
responsive neutrophils into periodontal tissues, provides a plausible explanation for the 
severe localised periodontal inflammation and bone loss characteristic of PLS. The locality 
of the inflammation fits with the proposed underlying mechanisms of periodontal 
destruction; an area susceptible to direct and chronic bacterial challenge in which neutrophils 
are the dominant immune cell presence. 
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6.1. Introduction 
Obesity is the greatest global health challenge of our time with over 500 million adults 
categorised as clinically obese worldwide (Swinburn et al. 2011). Obesity was recently 
characterised as a chronic inflammatory disease implicating adipocyte dysfunction and 
endocrine activation of adipose tissue (Capurso & Capurso 2012). The beneficial effects of 
weight loss are well established (Sam 2015) with a reduction in adiposity resulting in 
improved blood lipid levels and an increase in diet-induced thermogenesis (Werling et al. 
2013; Faria et al. 2014). Bariatric surgery is an option for individuals who are morbidly 
obese (BMI >40kg
2
) (Pataro et al. 2012) and have not been able to lose weight by other 
methods, and who suffer a medical problem related to obesity such as severe joint pain, sleep 
apnoea or type 2 diabetes (Balsiger et al. 2000).  
This chapter presents results from a longitudinal assessment of neutrophil ROS and NET 
production, chemotaxis and cytokine release from individuals with morbid obesity prior to 
and following gastric band surgery, which included an initial weight loss period involving a 
very low calorie diet (VLCD), alongside lean gender- and age-matched healthy controls. The 
data generated here will add to understanding of the effects of obesity on neutrophil function 
and the potential improvements that may result from decreasing adiposity. 
6.2. Patient background information 
Section 2.1.5. describes the recruitment process for patient volunteers and healthy controls. 
Twenty-three patients were recruited initially however five patients (2, 3, 9, 17 and 20) chose 
to withdraw from the study at various stages due to personal reasons and changes to their 
surgery choice (patients 3 and 17 switched to gastric bypass surgery). Figure 6.1 details the 
temporal differences between  blood collection, which occurred at three separate time points; 
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time point 1 (T1) in which patients were consented and embarked on a VLCD, time point 2 
(T2) in which patients attended their pre-operative assessment and time point 3 (T3) which 
represented an approximate 3 month post-surgical appointment. At each time point patients 
were weighed and blood was collected. Table 6.1 describes a summary of patient 
demographics; a more detailed table is described in section 8.4. As expected, the majority of 
patients had co-morbidities – all of which are associated with obesity including sleep apnoea, 
hypertension, depression, hypercholesterolaemia and type 2 diabetes (NHLBI Obesity 
Education Initiative Expert Panel on the Identification, Evaluation 1988) and are described in 
table 8.4.  
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Figure 6.1 Patient and control study flow chart  
Data represented as a stacked bar chart (a) and in tabulated form (b) characterising the length 
of time between each blood donation (day 0 represents patient enrolment). Time point 1 
represents a point before VCLD commencement, time point represents a point post-VLCD 
(immediately prior to surgery) and time point 3 represents a point 3 months post-surgery. 
 
Table 6.1 Bariatric patient and control background information 
 
Control Patient 
Female-to-male ratio 17:1 
Mean age ±SD (range) 47 ±9.8 (27-65) 48 ±10.5 (24-67) 
No. with a single co-morbidity n/a 4 
No. with >2 co-morbidities n/a 12 
No. with diabetes (type 2) n/a 7 
Mean % weight loss (T1-3) ±SD (range) n/a 14.6 ±7.1 (0.17-30.2) 
No. taking lipid-lowering drugs n/a 7 
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6.3. Assessment of body mass index (BMI)  
Figure 6.2 details the changes in BMI, calculated by dividing weight (kg) by height (m) 
squared. More detailed information on patient weight loss is detailed in Appendix IV. Patient 
BMI reduced between the three time points, with an initial decline between T1 and T2 
(representing before and after VLCD commencement) followed by a more pronounced 
decrease between T2 and T3 representing before and after surgery. The VLCD relied solely 
on patient compliance with guidance from dieticians as part of the weight loss pathway and 
included options such as the commercially available Cambridge Weight Plan® and 
Weightwatchers® as well as diets planned by the patients themselves. This ensured a 
calorific intake of 1,000 calories per day consuming a varied diet or by restriction to limited 
foods, such as milk and yoghurt only to ensure calorific deficit (Bueno et al. 2013). The 
purpose of the VLCD is to decrease the adipose tissue surrounding the liver in order to 
facilitate a safer surgical procedure (Lewis et al. 2006). 
Due to challenges in recruiting lean, healthy and age-matched controls from staff within the 
Dental Hospital, some of the controls were within the overweight category, however it is 
important to note that weight gain is associated with ageing; the mean age of recruited 
volunteers was 47. In addition, BMI as a clinical measure of overweight/obese status has 
limitations when used as a sole measure of health status. 
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Figure 6.2 BMI changes from time points 1-3 
Changes in BMI between controls (a) and patients (b) during time points 1-3. Data 
represented as line graphs. n = 18. Statistical test: Friedman and Dunn’s post-test. * = (p < 
0.05), ** = (p < 0.01), *** = (p < 0.001). 
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6.4. Whole blood analyses 
Table 6.2 presents the statistical comparison between patients and controls for each analyte per 
time point. The analytes were chosen as their levels are reportedly dysregulated in obesity, and 
weight loss is associated with their normalisation and a reduction in associated health risks as 
explained in more detail in subsequent sections when comparing patients and controls 
separately within T1-3. When comparing patients versus controls separately, statistically 
significant differences were evident between patients and controls at T1 for HbA1c, high 
density lipoprotein (HDL) and LDL (low density liporprotein)/HDL ratio. Significance was 
lost for all outcomes except HDL levels by T3, which remained lower in patients versus 
controls. 
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Table 6.2 Inter-individual analysis of blood analytes 
Green italicised text highlights results deemed significantly different at p < 0.05. Where levels could not be detected in patient samples, no statistical 
tests were performed. Statistical test: Wilcoxon matched-pairs. 
  T1 T2 T3 
  Control Patient Control Patient Control Patient 
HbAc1 
Average ±SD (range) 5.4 ±1 (4.2-6.4) 7.1 ±1.4 (5.1-9.7) 5.1 ±0.45 (4.5-5.8) 6.7 ±1.1 (5.1-8.6) 5.6 ±0.77 (4.5-6.8) 5.5 ±0.9 (4.5-8.3) 
p value 0.0008 0.0002 0.59 
Cholesterol 
Average ±SD (range) 195 ±43 (136-264) 166 ±50 (114-336) 183 ±43 (110-257) 148 ±-47 (100-305) 183 ±36 (132-279) 162 ±43 (113-256) 
p value 0.055 0.045 0.1 
HDL 
Average ±SD (range) 75 ±15 (48-100) 54 ±13 (37-84) 68 ±18 (35-100) 48 ±14 (33-84) 72 ±16 (41-100) 58 ±17 (36-84) 
p value 0.0046 0.0071 0.035 
LDL 
Average ±SD (range) 83 ±37 (45-152) 84 ±43 (42-219) 77 ±37 (40-155) 80 ±45 (32-226) 88 ±36 (39-189) 82 ±38 (17-154) 
p value 0.54 0.88 0.73 
LDL/HDL 
Average ±SD (range) 1.2 ±0.6 (0.5-2.3) 1.6 ±0.8 (0.5-3.8) 1.3 ±0.8 (0.5-3.3) 1.8 ±1.2 (0.4-5.3) 1.3 ±0.7 (0.5-2.8) 1.5 ±0.7 (0.2-2.7) 
p value 0.012 0.026 0.51 
TG 
Average ±SD (range) 95 ±38 (50-187) 143 ±62 (63-292) 89 ±49 (50-244) 121 ±-55 (51-262) 91 ±31 (50-170) 117 ±56 (50-250) 
p value 0.023 0.025 0.098  
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6.4.1. Measurement of glycated haemoglobin (HbA1c)  
Glycated haemoglobin (HbA1c) represents the irreversible binding of glucose to the 
haemoglobin molecule was measured for patients and controls at the three time points 
(Figure 6.3). HbA1c levels reflect the level of glucose in the blood over a 3-month period 
(the approximate lifespan of a red blood cell) – a higher percentage reflects glycaemic status 
and indicates the effectiveness of diabetes management is for those already diagnosed 
(Kilpatrick 2008; Little et al. 2011). The results of this study show a decrease in patient 
HbA1c levels from T1 to T3 (Figure 6.3b and d) reflecting the positive effects of weight loss 
as previously reported (Stanford et al. 2012). The effect was also evident in the 7 diagnosed 
diabetes patients (Figure 6.3c). Control HbA1c levels showed some variation, though no 
significance was reached, reflecting the temporal differences in blood collection over the 
three time points as described in Figure 6.1; at least 6 patient/control pairs had a T1 versus 
T2 gap of more than 90 days and studies have shown the lifespan of red blood cells to be 
approximately 90 days (Cohen et al. 2008).  
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Figure 6.3 Glycated haemoglobin (HbA1c) measurements in patients and controls 
Controls (a) patients (b) and diabetes patients (c) HbA1c levels at each time point and in 
tabulated form (d). The change in HbA1c from T1 to T3 for patients also described (d). Data 
represented as line graphs. n = 18 for total controls and patients, n = 7 diabetes patients. 
Statistical test: Friedman and Dunn’s test.* = (p <  0.05).  
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6.4.2. Assessment of blood lipids 
6.4.2.1. Total cholesterol 
Cholesterol is a lipid-based molecule with numerous physiological functions including cell 
membrane structural integrity, and acting as a precursor for steroid hormones and bile acids 
(Hanukoglu 1992). Increased cholesterol levels are associated with an increased incidence of 
cardiovascular disease (Clarke et al. 2009). Figure 6.4a-b describes the total cholesterol 
levels in controls and patients respectively from T1-3. Seven patients known to be taking 
lipid-lowering drugs (LLD) are also shown separately (Figure 6.4c). The results show an 
overall reduction in lipids in patients from T1-3 (Figure 6.4d) though the magnitude was not 
sufficient to reach statistical significance. The dramatic reduction in cholesterol at T2 may be 
the effect of the VLCD which is known to modify blood lipid levels (Volek et al. 2005). The 
apparent increase in cholesterol by T3 in the majority of patients may reflect the cessation of 
dramatically lowered calorific intake. The administration of LLD for some of the patients 
may account for an independent reduction in total cholesterol. Changes in cholesterol can 
occur over acute time periods and are usually attributable of changes in diet and increased 
exercise (Lennon et al. 1983). 
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Figure 6.4 Total cholesterol measurement in patients and controls 
Controls (a), patients (b) and patients known to be taking lipid lowering drugs (LLD) (c) 
Data represented as line graphs and in tabulated form (d). n = 18 for total patient and 
controls, n = 7 patients on LLD. Statistical test: Friedman and Dunn’s test.  
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6.4.2.2. Assessment of high-density lipoproteins (HDL) 
HDL is one of the major groups of lipoproteins that serve to transport lipids including 
cholesterol and triglycerides systemically and high levels are associated with a decreased risk 
in mortality (Rahilly-Tierney et al. 2011).  HDL levels are known to be altered in obesity and 
sustained weight loss is associated with an increase in HDL levels (Rashid & Genest 2007). 
Figure 6.5a-b describes high-density lipoprotein (HDL) levels in controls and patients 
respectively. Patients taking LLD, which are known to increase HDL levels (Pahan 2006), 
are also shown separately (Figure 6.5c). The general trend is an increase in HDL across the 
study period (Figure 6.5d), though statistical significance was not reached.  
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Figure 6.5 High-density lipoprotein (HDL) measurement in patients and controls 
Controls (a), patients (b) and patients known to be taking lipid lowering drugs (LLD) (c) 
Data represented as line graphs and in tabulated form (d). n = 18 for total patient and 
controls, n = 7 patients on LLD. Statistical test: Friedman and Dunn’s test.  
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6.4.2.3. Assessment of low-density lipoproteins (LDL) 
LDL, another major lipoprotein is also responsible for the transportation of lipids and is 
regarded as “bad cholesterol” due to its capacity to deposit lipid content within arterial walls 
(unlike HDL which can perform the reverse process) (Gordon et al. 1977). Figure 6.6a-b 
describes low-density lipoprotein (LDL) levels in control and patients respectively. Patients 
taking LLD, which are known to decrease LDL levels (Pahan 2006), are also shown (Figure 
6.6c). The differences in LDL between T1 and T3 are mixed with nearly half increasing and 
decreasing respectively (Figure 6.6d). The variation in LDL levels between the time points 
may again reflect the dramatic changes in diet (Krauss et al. 2006).  
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Figure 6.6 Low-density lipoprotein (LDL) measurement in patients and controls 
Controls (a), patients (b) and patients known to be taking lipid lowering drugs (LLD) (c) 
Data represented as line graphs and in tabulated form (d). n = 18 for total patient and 
controls, n = 7 patients on LLD. Statistical test: Friedman and Dunn’s test.  
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6.4.2.4. Assessment of LDL/HDL ratio 
The LDL/HDL ratio is regarded as an indicator of coronary heart disease risk and serves as a 
marker for potential improvements in lipid profiles (Manninen et al. 1992). Figure 6.7a-b 
describes the LDL/HDL ratio in controls and patients respectively, and patients taking LLD 
are also shown separately (Figure 6.7c). The patient ratios show an overall reduction but with 
an absence of statistical significance (Figure 6.7d), reflecting an increase in the proportion of 
HDL levels with weight loss (Leenen et al. 1993).   
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Figure 6.7 LDL/HDL ratio measurement in patients and controls 
Controls (a), patients (b) and patients known to be taking lipid lowering drugs (LLD) (c) 
Data represented as line graphs and in tabulated form (d). n = 18 for total patient and 
controls, n = 7 patients on LLD. Statistical test: Friedman and Dunn’s test.  
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6.4.2.5. Triglycerides (TG) 
Triglycerides (TG) are a type of lipid sourced from food and also produced by the liver from 
sugars. Typically stored within adipose tissue, TG is also a major component of LDL and 
high free circulating levels of TG are associated with cardiovascular disease (Austin et al. 
1998; Sarwar et al. 2007). Figure 6.8a-b describes the TG levels in controls and patients 
respectively, and patients taking LLD are also shown separately (Figure 6.8c). Although the 
overall trend is a reduction in TG from T1-3 (Figure 6.8d), many of the patients show a 
decrease at T2 which can occur with low calorie diets (Mensink et al. 2016) with an increase 
at T3 potentially reflecting an increase in calorific intake. 
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Figure 6.8 Triglyceride (TG) measurements in patients and controls 
Controls (a), patients (b) and patients known to be taking lipid lowering drugs (LLD) (c) 
Data represented as line graphs and in tabulated form (d). n = 18 for total patient and 
controls, n = 7 patients on LLD. Statistical test: Friedman and Dunn’s test.  
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6.5. Neutrophil counts 
Figure 6.9 illustrates the differences in neutrophil numbers, when adjusted for collected 
blood volumes, between patients and controls at each time point. Neutrophil numbers in 
patients were higher at each time point and significantly so at T2; the lack of significance at 
T1 may be a result of increased variability in control numbers.  
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Figure 6.9 Patient and control neutrophil counts at different time points  
Neutrophils were isolated (section 2.2.2) and cell counts per ml were calculated by adjusting 
for volume of blood collected per sample between T1-3. Data represented as a bar graph. n = 
18 for total patient and controls respectively. Statistical test: Wilcoxon matched-pairs, ** = 
(p < 0.01).  
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6.6. Quantification of NETs in obese patients pre- and post- weight loss surgery 
Figure 6.10 shows NET production by control and patient neutrophils at each time point. These 
results are also shown in tabulated form (Table 6.3) due to the number of stimuli and their 
numerical range. At T1 NET formation (Figure 6.10a) was significantly lower in patient 
neutrophils relative to controls for all stimuli employed (p < 0.05 and p < 0.01 for HOCl). 
Significance remained (although lower) at T2 (Figure 6.10b) for HOCl (p < 0.05) and was lost 
completely by T3 (Figure 6.10c). Visual representation of NET formation is shown in Figure 
6.10d. 
Figure 6.11 shows NET production compared within the different time points. Due to the wide 
day-to-day variability that has been previously reported in neutrophil assays (Udén et al. 1983; 
Roth 1993; Winkel et al. 1981; K. Bergström and B. Åsman 1993), it was necessary to present 
the data as a ratio by dividing patient values by controls per result per time point. There were 
significant differences in NET production by patients between T1 and T3 for PMA, HOCl and 
A. viscosus indicating that weight loss is associated with an increase in NET production (Figure 
6.11a). The overall trend was an increase in NET production in all conditions (Figure 6.11b).   
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Figure 6.10 Patient and control NET release at different time points  
Neutrophils were isolated (section 2.2.2) and NETs and NET bound proteins were quantified 
in response to PMA (50nM), S. constellatus (MOI 1 in 500), HOCl (0.75 mM) and A. 
viscosus (MOI 1 in 300) (section 2.5.3). Data presented as box and whisker plots (a-c); the 
band within the box represents the median, surrounded by the 1st and 3rd quartiles, the ends 
of the whiskers represent the minimum and maximum data points. n = 18 for total patient and 
controls respectively. Statistical test: Wilcoxon matched-pairs, * = (p < 0.05), ** = (p < 
0.01). 
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Table 6.3 Inter-individual analysis of NET results  
Green italicised text highlights results deemed significantly different at p < 0.05. Where levels could not be detected in patient samples, no statistical 
tests were performed. n = 18 for total patient and controls respectively. Statistical test: Wilcoxon matched-pairs. 
 
T1 T2 T3 
 
Control Patient Control Patient Control Patient 
RPMI 
Average ±SD 
(range) 
1560 ±1203 (378-
4882) 
1201 ±844 (404-
3274) 
1608 ±1152 (396-
3984) 
1374 ±3254 (999-
14189) 
916 ±480 (352-
2060) 
701 ±326 (263-
1454) 
p value 0.34 0.23 0.14 
PMA 
Average ±SD 
(range) 
4681 ±3426 (725-
634) 
3906 ±4037 (634-
17064) 
4680 ±3254 (999-
14189) 
4779 ±4608 (545-
17434) 
4680 ±3254 (999-
14189) 
4779 ±4608 (545-
17435) 
p value 0.032 0.32 0.19 
S. constellatus 
Average ±SD 
(range) 
7387 ±4726 (1233-
20673) 
6077 ±3451 (923-
12386) 
6770 ±2900 (1105-
12009) 
6017 ±3086 (1164-
1101) 
6769 ±2901 (1105-
12009) 
6017 ±3086 (1164-
11101) 
p value 0.026 0.051 0.89 
HOCl 
Average ±SD 
(range) 
12047 ±5249 (3009-
22216) 
9364 ±4420 (3519-
20302) 
12980 ±7115 (921-
29829) 
10362 ±6919 (576-
24045) 
9844 ±3702 (2475-
16016) 
9194 
±23453(4462-
15406) 
p value 0.008 0.026 0.38 
A. viscosus 
Average ±SD 
(range) 
3132 ±1278 (1405-
5430) 
2600 ±1278 (930-
5133) 
3460 ±1340 (1958-
7258) 
3698 ±1809 (1733-
7869) 
2983 ±1790 (1215-
9173) 
3183 ±2148 (1013-
10390) 
p value 0.032 0.34 0.52 
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Figure 6.11 Patient NET release time point comparison  
Neutrophils were isolated (section 2.2.2) and NETs were quantified in response to PMA 
(50nM), S. constellatus (MOI 1 in 500), HOCl (0.75 mM) and A. viscosus (MOI 1 in 300) 
(section 2.5.3). Data presented as bar graphs of patient/control ratios (a) and in tabulated 
form (b) denoting the overall change in NETs between T1 and T3. n = 18 for total patient and 
controls respectively. Statistical test: Friedman and Dunn’s post-test.   
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6.7. Neutrophil ROS generation in obese patients pre- and post- weight loss surgery 
Figure 6.12, 6.13 and 6.14 and Tables 6.4, 6.5 and 6.6 show ROS production using the three 
chemiluminescent reagents luminol (total ROS), isoluminol (extracellular ROS) and 
lucigenin (extracellular superoxide) respectively. In addition to each stimulus alone, a 
priming step was also included using GM-CSF (10ng/ml). The results show patient 
neutrophils release significantly higher ROS in the presence of a stimulus and priming with 
stimulus at T1 with all three chemiluminescent reagents (Figure 6.12a, Figure 6.13a and 
Figure 6.14a). Over the course of the different study time points, significant differences 
remain for luminol and were partially lost for isoluminol and lucigenin (Figure 6.12b-c, 
Figure 6.13b-c, and Figure 6.14b-c). These results indicate that weight loss in the patients is 
accompanied by a reduction in the levels of ROS release when compared with healthy 
controls. 
Figure 6.15a-f shows ROS production compared within the different time points for luminol, 
isoluminol and lucigenin respectively. The data is presented as patient/control ratios to 
account for day-to-day variability as was done for the NETs analysis. There were no 
significant differences in ROS production by patients between T1 and T3 for any of the 
stimuli used (Figure 6.15a,c and e), despite the overall trend indicating decreases in ROS 
production following stimulation and following priming with stimulation (Figure 6.15b,d and 
f). These results indicate that within-patient variations in ROS do not change in these patients 
despite weight loss.   
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Figure 6.12 Patient and control ROS production with luminol at different time points  
Neutrophils were isolated (section 2.2.2) and ROS generation was detected following 
priming with/without GM-CSF (10ng/ml) and stimulation using opsonised S. aureus (MOI 1 
in 150), T. forsythia (MOI 1 in 300), and F. nucleatum (MOI 1 in 300) (section 2.4.3.2). Data 
presented as box and whisker plots. n = 18 for total patient and controls respectively. 
Statistical test: Wilcoxon matched-pairs, * = (p < 0.05), ** = (p < 0.01). 
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Table 6.4 Patient and control ROS inter-individual analysis with luminol  
Green italicised text highlights results deemed significantly different at p < 0.05. Where 
levels could not be detected in patient samples, no statistical tests were performed. n = 18 for 
total patient and controls respectively. n = 18 for total patient and controls respectively. 
Statistical test: Wilcoxon matched-pairs. 
Luminol 
T1 T2 T3 
Control Patient Control Patient Control Patient 
gPBS 
Average 
±SD 
(range) 
731 ±837 
(66-3243) 
696 ±780 
(83-2803) 
488 ±453 
(91-1348) 
1131 ±1432 
(70-4435) 
1613 ±2798 
(99-10408) 
1882 ±4210 
(103-17167) 
p value 0.03 0.04 0.57 
gPBS + GM-CSF 
Average 
±SD 
(range) 
3240 ±3324 
(91-11308) 
3840 ±5460 
(119-19771) 
4762 ±6475 
(107-20100) 
5065 ±8286 
(82-32288) 
2587 ±4535 
(90-16246) 
2640 ±4984 
(86-18850) 
p value 0.42 0.67 0.56 
Opsonised S. aureus 
Average 
±SD 
(range) 
5790 ±5376 
(514-23189) 
7620 ±8423 
(863-37366) 
3933 ±3206 
(604-11045) 
5048 ±4331 
(925-15575) 
3185 ±3479 
(555-10906) 
3694 ±4535 
(695-19878) 
p value 0.0009 0.29 0.03 
Opsonised S. aureus + GM-CSF 
Average 
±SD 
(range) 
8483 ±7485 
(687-33625) 
10788 ±11420 
(1081-47943) 
9416 ±10320 
(152-31050) 
10090 ±10167 
(863-36048) 
4501 ±5579 
(473-19709) 
4220 ±4885 
(666-20141) 
p value 0.03 0.46 0.26 
T. forsythia 
Average 
±SD 
(range) 
6248 ±7757 
(86-32596) 
9588 ±11335 
(160-44300) 
5121 ±5994 
(181-20766) 
6320 ±6031 
(152-18253) 
3857 ±4728 
(128-16851) 
4980 ±5371 
(214-18615) 
p value 0.03 0.41 0.06 
T. forsythia + GM-CSF 
Average 
±SD 
(range) 
11009 ±8095 
(111-31013) 
17039 ±14845 
(329-55745) 
8961 ±8318 
(251-25390) 
12603 ±11981 
(255-35390) 
5891 ±7999 
(194-30877) 
5684 ±5674 
(255-19894) 
p value 0.01 0.14 0.91 
F. nucleatum 
Average 
±SD 
(range) 
2994 ±3828 
(107-14437) 
3471 ±3669 
(189-12858) 
1945 ±2537 
(103-8245) 
5299 ±9571 
(168-34100) 
1763 ±2872 
(90-11345) 
2329 ±4963 
(107-20388) 
p value 0.007 0.02 0.78 
F. nucleatum + GM-CSF 
Average  
±SD 
(range) 
5408 ±5883 
(165-20458) 
6671 ±7077 
(284-22905) 
2902 ±3303 
(152-12348) 
7664 ±14203 
(292-48950) 
4311 ±10072 
(107-42794) 
2919 ±5148 
(103-21025) 
p value 0.34 0.02 0.32 
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Figure 6.13 Patient and control ROS production with isoluminol at different time points  
Neutrophils were isolated (section 2.2.2) and ROS generation was detected following 
priming with/without GM-CSF (10ng/ml) and stimulation using opsonised S. aureus (MOI 1 
in 150), T. forsythia (MOI 1 in 300), and F. nucleatum (MOI 1 in 300) (section 2.4.3.2). Data 
presented as box and whisker plots. n = 18 for total patient and controls respectively. 
Statistical test: Wilcoxon matched-pairs, * = (p < 0.05), ** = (p < 0.01). 
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Table 6.5 Patient and control ROS inter-individual analysis with isoluminol 
Green italicised text highlights results deemed significantly different at p < 0.05. Where 
levels could not be detected in patient samples, no statistical tests were performed. n = 18 for 
total patient and controls respectively. Statistical test: Wilcoxon matched-pairs. 
Isoluminol 
T1 T2 T3 
Control Patient Control Patient Control Patient 
gPBS 
Average 
±SD 
(range) 
8896 ±2220 
(107-7664) 
2411 ±3333 
(115-11924) 
2206 ±3060 
(140-1066) 
2855 ±3274 
(148-9500) 
2345 ±3422 
(134-12401) 
3949 ±6293 
(144-20358) 
p value 0.44 0.15 0.31 
gPBS + GM-CSF 
Average 
±SD 
(range) 
1743 ±8543 
(173-28453) 
11646 ±14746 
(164-46753) 
9933 ±15176 
(222-58500) 
12342 ±18005 
(243-65402) 
5018 ±9226 
(169-33296) 
4619 ±9802 
(188-41995) 
p value 0.92 0.79 0.35 
Opsonised S. aureus 
Average 
±SD 
(range) 
21045 ±12498 
(3686-42279) 
22095 ±11696 
(3633-37900) 
45281 
±123358 
(5635-538500) 
53006 ±132676 
(7456-577500) 
14023 ±6513 
(5512-29264) 
14660 ±7963 
(1045-33987) 
p value 0.03 0.43 0.37 
Opsonised S. aureus + GM-CSF 
Average 
±SD 
(range) 
28987 ±14712 
(5812-61288) 
33097 ±17324 
(11119-57804) 
64034 
±188350 
(488-817000) 
77534 ±231081 
(5812-
1001500) 
15935 ±8726 
(5615-35686) 
16333 ±9640 
(1169-35423) 
p value 0.002 0.19 0.26 
T. forsythia 
Average 
±SD 
(range) 
13780 ±11267 
(723-35032) 
17326 ±14495 
(872-44707) 
47461 
±138136 
(839-597500) 
41097 ±96418 
(1139-422500) 
26190 ±36335 
(850-123297) 
36426 ±52366 
(834-183587) 
p value 0.02 0.29 0.03 
T. forsythia + GM-CSF 
Average 
±SD 
(range) 
22539 ±13976 
(1254-38596) 
30153 ±21551 
(2166-64205) 
56396 
±157678 
(1471-682500) 
42122 ±72221 
(1048-315000) 
23743 ±26562 
(186-89138) 
35160 ±47673 
(1965-148947) 
p value 0.009 0.37 0.02 
F. nucleatum 
Average 
±SD 
(range) 
11602 ±11560 
(341-38152) 
11736 ±12370 
(440-40921) 
12282 ±24402 
(613-107000) 
14956 ±25218 
(584-99000) 
3915 ±3651 
(723-12546) 
4518 ±4267 
(506-17336) 
p value 0.02 0.67 0.46 
F. nucleatum + GM-CSF 
Average 
±SD 
(range) 
12282 ±24403 
(613-107000) 
14956 ±25218 
(584-99000) 
15945 ±26130 
(941-112150) 
14956 ±25218 
(584-99000) 
6759 ±8872 
(625-33909) 
6038 ±6877 
(736-29634) 
p value 0.02 0.79 0.89 
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Figure 6.14 Patient and control ROS production with lucigenin at different time points  
Neutrophils were isolated (section 2.2.2) and ROS generation was detected following 
priming with/without GM-CSF (10ng/ml) and stimulation using opsonised S. aureus (MOI 1 
in 150), T. forsythia (MOI 1 in 300), and F. nucleatum (MOI 1 in 300) (section 2.4.3.2). Data 
presented as box and whisker plots. n = 18 for total patient and controls respectively. 
Statistical test: Wilcoxon matched-pairs, * = (p < 0.05), ** = (p < 0.01). 
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Table 6.6 Patient and control ROS inter-individual analysis with lucigenin 
Green italicised text highlights results deemed significantly different at p < 0.05. Where 
levels could not be detected in patient samples, no statistical tests were performed. n = 18 for 
total patient and controls respectively. Statistical test: Wilcoxon matched-pairs. 
Lucigenin 
T1 T2 T3 
Control Patient Control Patient Control Patient 
gPBS 
Average 
±SD 
(range) 
731 ±837 
(66-3243) 
696 ±780 
(83-2803) 
488 ±453 
(91-1348) 
1131 ±1432 
(70-4435) 
1613 ±2798 
(99-10408) 
1882 ±4210 
(103-17167) 
p value 0.03 0.04 0.57 
gPBS + GM-CSF 
Average 
±SD 
(range) 
3240 ±3324 
(91-11308) 
3840 ±5460 
(119-19771) 
4762 ±6475 
(107-20100) 
5065 ±8286 
(82-32288) 
2587 ±4535 
(90-16246) 
2640 ±4984 ( 
86-18850) 
p value 0.42 0.67 0.56 
Opsonised S. aureus 
Average 
±SD 
(range) 
5790 ±5376 
(514-23189) 
7620 ±8423 
(863-37366) 
3933 ±3206 
(604-11045) 
5048 ±4331 
(925-15575) 
3185 ±3479 
(555-10906) 
3694 ±4535 
(695-19878) 
p value 0.0009 0.29 0.03 
Opsonised S. aureus + GM-CSF 
Average 
±SD 
(range) 
8483 ±7485 
(687-33625) 
10788 ±11420 ( 
1081-47943) 
9416 ±10320 
(152-31050) 
10090 ±10167 
(863-36048) 
4501 ±5579 
(473-19709) 
4220 ±4885 
(666-20141) 
p value 0.03 0.46 0.26 
T. forsythia 
Average 
±SD 
(range) 
6248 ±7757 
(86-32596) 
9588 ±11335 
(160-44300) 
5121 ±5994 
(181-20766) 
6320 ±6031 
(152-18253) 
3857 ±4728 
(128-16851) 
4980 ±5371 
(214-18615) 
p value 0.03 0.41 0.06 
T. forsythia + GM-CSF 
Average 
±SD 
(range) 
11009 
±8095 
(111-31013) 
17039 ±14845 
(329-55745) 
8961 ±8318 
(251-25390) 
12603 ±11981 
(255-35390) 
5891 ±7999 
(194-30877) 
5684 ±5674 
(255-19894) 
p value 0.01 0.14 0.91 
F. nucleatum 
Average 
±SD 
(range) 
2994 ±3828 
(107-14437) 
3471 ±3669 
(189-12858) 
1945 ±2537 
(103-8245) 
5299 ±9571 
(168-34100) 
1763 ±2872 
(90-11345) 
2329 ±4963 
(107-20388) 
p value 0.007 0.02 0.78 
F. nucleatum + GM-CSF 
Average 
±SD 
(range) 
5408 ±5883 
(165-20458) 
6671 ±7077 
(284-22905) 
2902 ±3303 
(152-12348) 
7664 ±14203 
(292-48950) 
4311 ±10072 
(107-42794) 
2919 ±5148 
(103-21025) 
p value 0.34 0.02 0.32 
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Figure 6.15 Patient and control ROS production time point comparison  
Neutrophils were isolated (section 2.2.2) and ROS generation was detected after with/without 
GM-CSF (10ng/ml) priming using opsonised S. aureus (MOI 1 in 150), T. forsythia (MOI 1 
in 300), and F. nucleatum (MOI 1 in 300) (section 2.4.3.2). Data presented as bar graphs of 
patient/control ratios (a/c/e) and in tabulated form (b/d/f) denoting the overall change in ROS 
between T1 and T3 for luminol, isoluminol and lucigenin respectively. n = 18 for total 
patient and controls respectively. Statistical test: Friedman and Dunn’s post-test.   
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6.8. Chemotaxis in obese patients pre- and post- weight loss surgery 
Figure 6.16 shows the chemotaxis results from all three time points. The results are not 
tabulated as it was deemed unnecessary due to the lack of numerical range and because of the 
limited number of chemoattractants used.  Figure 6.17, Figure 6.18 and Figure 6.19 show the 
cell paths, polar plots and angle histograms of all tracked cells per condition per time point 
respectively, illustrating the differences in the course of the cell movements. There were 
significant differences at all three time points for speed, velocity and CI, with patient 
neutrophil movement lower compared to controls. These results indicate that the weight loss 
in these patients did result in improved neutrophil chemotactic accuracy when compared with 
controls alone. 
 Figure 6.20 shows the chemotaxis results compared between the time points. The data is 
presented as raw values because of low numerical variability enabling statistical analyses 
without the need for data normalisation (as was done for the ROS and NETs analysis). There 
were significant differences between T1-3 with speed for both fMLP and CXCL8 
chemoattractants as well as for RPMI with a trend indicating an overall increase in speed 
from T1-3 (Figure 6.20a). Similar findings were shown with velocity (Figure 6.20c) for 
fMLP and CXCL8 and only with fMLP for CI (Figure 6.20e). There were no significant 
differences for control values across any of the time points. These results indicate there is an 
increase in chemotactic accuracy between time points with weight loss when comparing 
patient results only (Figure 6.20b, d,and f). 
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Figure 6.16 Neutrophil chemotaxis in patients and controls at different time points 
Neutrophils were isolated (section 2.2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and tracked information was used to generate 
average speed (a), velocity (b) and CI (c) for patient and control neutrophils in the presence 
of RPMI (negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants. Data 
shown as box and whisker plots (n = 18; 15 cells tracked per chemoattractant/RPMI). 
Statistical test: Wilcoxon matched-pairs, * = (p < 0.05), *** = (p < 0.001), **** = (p < 
0.0001). 
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Figure 6.17 Neutrophil cell tracks Time point 1 
Cell tracks, polar plots and angle histograms overlayed for control (a, b and c) and patient (d, e and f)  neutrophils were generated to give a 
qualitative overview of chemotaxis using RPMI (negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants respectively. 
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Figure 6.18  Neutrophil cell tracks Time point 2 
Cell tracks, polar plots and angle histograms overlayed for control (a, b and c) and patient (d, e and f) neutrophils were generated to give a 
qualitative overview of chemotaxis using RPMI (negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants respectively. 
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Figure 6.19 Neutrophil cell tracks Time point 3 
Cell tracks, polar plots and angle histograms overlayed for control control (a, b and c) and patient (d, e and f) neutrophils were generated to give a 
qualitative overview of chemotaxis using RPMI (negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants respectively. 
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Figure 6.20 Patient and control chemotaxis time point comparisons  
Neutrophils were isolated (section 2.2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and tracked information was used to generate 
average speed (a), velocity (c) and CI (e) for patient and control neutrophils in the presence 
of RPMI (negative control), fMLP (10nM) and CXCL8 (200ng/ml) chemoattractants. Data 
presented as line graphs of patient (solid lines) and control (dotted lines) raw data (a/c/e) and 
in tabulated form (b/d/f) denoting the overall change in chemotaxis between T1 and T3. n = 
18 for total patient and controls respectively. Statistical test: Friedman and Dunn’s post-test, 
* = (p < 0.05), ** = (p < 0.01), *** = (p < 0.001).  
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6.9. Cytokine release in obese patients pre- and post-bariatric surgery 
Figure 6.21, Table 6.7 and Table 6.8 demonstrate the cell culture supernatant cytokine 
concentrations for IL-1β, IL-6, CXCL8 and TNFα in the absence/presence of relevant 
stimuli. The results show patient neutrophils release significantly higher cytokines in the 
absence/presence of stimuli at T1 compared with controls (p < 0.05) with some significant 
differences remain at T2, that are lost by T3. These results indicate that weight loss in the 
patients is accompanied by a reduction in the levels of pro-inflammatory cytokines released 
when compared to healthy controls. Figure 6.23 shows the concentrations of cytokines 
detected in plasma; there were no significant differences. 
Figure 6.24a, b, e and f show cytokine production compared within the time points 
respectively. The data is presented as patient/control ratios to account for day-to-day 
variability as was performed for the NETs/ROS analysis. There were significant differences 
in IL-1β, IL-6, and TNFα release between T1-3 after exposure to LPS ( p < 0.05). There were 
also significant reductions in the concentration of TNFα between T1-3 in the absence of a 
stimulus and after exposure to opsonised S. aureus. The overall trend is a decrease in 
cytokine production between T1 and T3 (Figure 6.24c, d, g and h) indicating that neutrophil 
pro-inflammatory cytokine release decreases with weight loss.   
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Figure 6.21 IL-1β and IL-6 quantification at different time points 
Neutrophils were isolated (section 2.2.2) and cytokines IL-1β (a/c/e) and IL-6 (b/d/f) released from patient and control neutrophils per time point 
respectively (n = 10) following isolation and culture for 16 hours (section 2.7) and incubation with RPMI (negative control), opsonised S. aureus 
(FcγR stimulation pathway; MOI 1:150), F. nucleatum (TLR stimulation pathway; MOI 1 in 300) or LPS (TLR stimulation pathway). Blue hollow 
circles and filled red circles represent control and patient samples respectively. Statistical test: Statistical test: Wilcoxon matched-pairs, * = (p < 
0.05), ** = (p < 0.01). 
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Figure 6.22 CXCL8 and TNFα quantification at different time points 
Neutrophils were isolated (section 2.2.2) and cytokines CXCL8 (a/c/e) and TNFα (b/d/f) released from patient and control neutrophils per time 
point respectively (n = 10) following isolation and culture for 16 hours (section 2.7) and incubation with RPMI (negative control), opsonised S. 
aureus (FcγR stimulation pathway; MOI 1:150), F. nucleatum (TLR stimulation pathway; MOI 1 in 300) or LPS (TLR stimulation pathway). Blue 
hollow circles and filled red circles represent control and patient samples respectively. Statistical test: Statistical test: Wilcoxon matched-pairs, * = 
(p < 0.05), ** = (p < 0.01). 
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Table 6.7 Patient and control IL-1β (a) and IL-6 (b) release inter-individual analysis 
Green italicised text highlights results deemed significantly different at p < 0.05. n = 10 for total patient and controls respectively.  Statistical test: 
Wilcoxon matched-pairs. 
IL-1β 
T1 T2 T3 
Control Patient Control Patient Control Patient 
RPMI 
Average ±SD (range) 3.76 ±7.8 (0-25) 6.9 ±12 (0-37) 4.6 ±6.7 (0-19) 3.8 ±5.6 (0-17) 3.2 ±6.4 (0.01-16) 3.2 ±6.2 (0-19.2) 
p value 1 1 0.24 
 Ops S. aureus 
Average ±SD (range) 65 ±43 (12-159) 67 ±49 (15-176) 74 ±74 (6.5-212) 69 ±84 (5.3-286) 92 ±64 (39-246) 96 ±131 (15-456) 
p value 0.37 0.56 0.38 
F. nucleatum 
Average ±SD (range) 149 ±117 (8-315) 184 ±152 (16-390) 135 ±137 (6.6-396) 156 ±203 (11-630) 84 ±28 (59-133) 69 ±58 (31-222) 
p value 0.037 1 0.23 
LPS 
Average ±SD (range) 20 ±12 (7-39) 22 ±19 (7-71) 32 ±49 (0.92-157) 35 ±36 (0.82-98) 40 ±34 (11-115) 33 ±50(9.8-173) 
p value 0.84 0.49 0.1 
 
IL-6 
T1 T2 T3 
Control Patient Control Patient Control Patient 
RPMI 
Average ±SD (range) 288 ±293 (80-721) 477 ±607 (15-1475) 438 ±580 (26-2016) 662 ±564 (160-2016) 402 ±613 (32-2016) 453 ±594 (55-2016) 
p value 1 0.004 0.25 
 Ops S. aureus 
Average ±SD (range) 280 ±199 (114-689) 264 ±123 (72-421) 6581 ±986 (4773-7720) 6631 ±1500 (2791-8025) 4904 ±1077 (2628-5829) 4295 ±1034 (2052-5887) 
p value 0.77 0.49 0.23 
F. nucleatum 
Average ±SD (range) 1084 ±572 (129-2044) 1447 ±1106 (88-3401) 7350 ±1213 (4094-8254) 7501 ±998 (4870-8346) 5554 ±647 (3897-6246) 5118 ±1485 (1126-6290) 
p value 0.16 0.92 0.77 
LPS 
Average ±SD (range) 299 ±216 (106-841) 468 ±265 (197-930) 4690 ±2185 (821-7198) 10362 ±6919 (576-24045) 
5930 ±3815 (2544-
14112) 
7655 ±6517 (2729-20466) 
p value 0.028 0.006 0.85 
a 
b 
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Table 6.8 Patient and control CXCL8 (a) and TNFα (b) inter-individual analysis 
Green italicised text highlights results deemed significantly different at p < 0.05. n = 10 for total patient and controls respectively.  Statistical test: 
Wilcoxon matched-pairs. 
CXCL8 
T1 T2 T3 
Control Patient Control Patient Control Patient 
RPMI 
Average ±SD (range) 634 ±573 (145-2016) 845 ±825 (102-2016) 230 ±171(0-455) 476 ±535 (0-1359) 265 ±231 (0-421) 84 ±97 (0-192) 
p value 0.65 0.75 0.5 
 Ops S. aureus 
Average ±SD (range) 6945 ±542 (5603-7383) 
6943 ±396 (6300-
7582) 
348 ±327 (35-1012) 447 ±503 (4-1255) 400 ±257 (121-818) 294 ±222 (87-756) 
p value 0.77 0.49 0.43 
F. nucleatum 
Average ±SD (range) 7216 ±716 (6004-8019) 
7339 ±715 (6216-
8185) 
774 ±628 (97-1908) 937 ±1091 (52-3252) 484 ±293 (188-996) 390 ±253 (120-955) 
p value 0.56 0.84 0.63 
LPS 
Average ±SD (range) 3815 ±1318 (2281-
5989) 
4774 ±1283 (2019-
7477) 
243 ±283 (28-758) 505 ±483 (32-1227) 588 ±166 (379-862) 575 ±340 (259-1323) 
p value 0.04 0.049 0.56 
TNFα 
T1 T2 T3 
Control Patient Control Patient Control Patient 
RPMI 
Average ±SD (range) 2.5 ±1.4 (1-5) 23 ±35 (1.5-109) 12 ±13 (1.5-46) 14 ±18 (1.5-52) 14 ±5.2 (12-28) 15 ±5.7 (11-29) 
p value 0.034 1 0.76 
 Ops S. aureus 
Average ±SD (range) 39 ±23 (15-85) 41 ±27 (12-96) 48 ±26 (8-88) 57 ±58 (4.7-169) 127 ±48 (69-244) 122 ±151 (32-535) 
p value 0.77 0.85 0.32 
F. nucleatum 
Average ±SD (range) 204 ±97 (70-355) 194 ±109 (29-380) 64 ±39 (5.3-142) 133 ±42 (70-187) 71 ±32 (30-110) 60 ±55 (4.4-195) 
p value 1 0.01 0.37 
LPS 
Average ±SD (range) 16 ±5.7 (6.6-26) 15.2 ±13 (4-46) 11 ±7.6 (2.9-27) 33 ±29 (3-84) 31 ±26 (3.3-72) 78 ±58 (23-214) 
p value 0.49 0.04 0.03 
a 
b 
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Figure 6.23 Plasma cytokine quantification in obesity all time points 
Plasma was collected (section 2.3) and cytokines IL-1β, IL-6, CXCL8 and TNFα 
concentrations were measured in patients and controls (n = 10) per time point respectively. 
Levels that could not be detected were designated as 0. 
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Figure 6.24 Patient and control cytokine release in obesity: time point comparisons  
Neutrophils were isolated (section 2.2.2) and cytokines IL-1β (a), IL-6 (b). CXCL8 (e), 
TNFα (f), released from patient and control neutrophils (n = 10) following isolation and 
culture for 16 hours (2.7) and incubation with RPMI (negative control), opsonised S. aureus 
(FcγR stimulation pathway), F. nucleatum ) (MOI of 1 in 150 and 1 in 300 respectively) or 
LPS (TLR stimulation pathway). Data presented as bar graphs of patient/control ratios 
(a/b/e/f) and in tabulated form (c/d/g/h) denoting the overall change in cytokine release 
between T1 and T3. Statistical test: Friedman and Dunn’s post-test, * = (p < 0.05). 
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6.10. Discussion 
The results presented in this chapter detail blood analyses and neutrophil assays at three 
different time points during the course of a VLCD and pre- and post-bariatric surgery. Of the 
patients recruited for the study, more than half had at least two obesity-related disorders. As 
expected, BMI was reduced following a VLCD and 3 months post-surgery, however despite 
the weight loss, which represented a significantly high percentage for some patients, many 
patients remained within the very severely obese category. BMI is typically the most 
common index used for studies involving overweight and obese individuals because of its 
easy calculation, however it has limitations which include an erroneous categorisation of 
body mass without making the distinction between adipose tissue and muscle mass per 
individual (Rimm et al. 1995). Another method of weight measurement commonly used in 
obesity studies is waist-to-hip ratio, which is considered a more accurate reflection of the 
health risks associated with excess adipose tissue in the individual (Noble 2001; Cheng et al. 
2010), however such measurements were not taken at the time points reported here. It is also 
worth noting that changes in BMI as a result of calorie restriction by a VLCD do not 
necessarily result in a reduction in adipose tissue alone, for example, muscle mass is reported 
to be lost even in studies where the level of exercise is known (Dengel et al. 1994; 
Heymsfield et al. 2014).  
HbA1c levels were significantly reduced in all patients and significance was still evident in 
the diabetes patients when analysed separately. The disease is associated with high HbA1c 
levels which can decrease with medical management in agreement with previous reports 
(Redmon et al. 2003; Redmon et al. 2005).  
The lipids measured in this study are consistent with those used in a previous report on 
obesity and lipid levels (Bhatti et al. 2001). Blood lipid profiles infer the extent to which an 
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individual is at risk of suffering other obesity-related disorders, for example, coronary heart 
disease is positively related to LDL concentrations and inversely related to HDL 
concentrations (Kannel 1988). All blood lipid levels were measured with the additional 
analyses of patients taking LLD prior to and throughout the course of their treatment to 
highlight any dramatic differences in these patients which may bias overall results. Although 
the trend of all lipids measured showed an expected decrease (total cholesterol, LDL, 
LDL/HDL and triglycerides) or increase (HDL), as is expected with weight loss (Burton et 
al. 1985; Dattilo & Kris-Etherton 1992), there was a lack of significance between the time 
points for patients. Comparison with healthy gender-matched controls (which showed no 
difference intra-individually) demonstrate that positive differences had occurred with weight 
loss over time. Increased cholesterol synthesis is determined by body weight and is 
significantly associated with adiposity (Nestel et al. 1969). Total cholesterol results reported 
here showed a decrease in most patients, the underlying reason for this is thought to be a 
result of adipose tissue mobilisation inhibiting further cholesterol synthesis by the liver, the 
predominant organ involved in cholesterol synthesis (Vaswani 1983), in addition to increased 
cholesterol excretion in bile with weight loss (Bennion & Grundy 1975). The type of VLCD 
the patients self-administered throughout their treatment may have affected blood lipid 
levels, because even in the absence of weight loss a change in dietary habits, for example, via 
reduced fat intake, can change blood lipid profiles (Leenen et al. 1993). Conversely, some 
studies have reported that weight loss by diet alone is not associated with advantageous 
changes in blood lipid profiles (Thompson et al. 1979; Sörbris et al. 1981; Rabkin et al. 
1981;). Overall the blood chemistry results indicate an improvement in levels with weight 
loss and the extent of the improvement is reflected in the fact that many patients are still very 
severely obese and lipid levels would therefore be expected to further improve with 
continued weight loss. 
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Several studies have focused on the effects of blood lipids on neutrophils. Neutrophils have 
been shown to express LDL receptors (Lara et al. 1997; Haverkamp et al. 2011) and LDL (or 
its oxidised form) has been reported to induce neutrophil calcium flux, oxidant release, 
integrin expression and chemotaxis ( Lehr et al. 1995; van Tits et al. 2000; Kopprasch et al. 
2004;). Neutrophils derived from individuals with dyslipidaemia exhibit elevated resting 
levels of intracellular calcium and raised levels of membrane-bound PKC, but calcium 
signalling in response to fMLP is decreased (which may be a possible reason for the reduced 
chemotaxis also reported in this chapter) (Paragh et al. 1999). Studies using neutrophils 
derived from murine models of hypercholesterolemia reported neutrophils to exhibit 
abnormal function in response to inflammatory stimuli including increased pro-inflammatory 
cytokine gene transcription (Palvinskaya et al. 2013) and reduced chemotaxis into the air 
pouch following an infection with Klebsiella pneumoniae; this finding was associated with 
decreased neutrophil chemotaxis to the CXC chemokines (Madenspacher et al. 2010) and 
fMLP (Palvinskaya et al. 2013).     
Patient neutrophil counts were higher in patients compared with controls, a finding that has 
been reported in numerous studies (Fisch 1975; Nanji & Freeman 1985; Schwartz & Weiss 
1991; Pratley et al. 1995; Nieman et al. 1999; Kullo et al. 2002; Dixon & O’Brien 2006; 
Herishanu et al. 2006; Zaldivar et al. 2006; Womack et al. 2007; Kim & Park 2008; Rensen 
et al. 2009; Al-Sufyani & Mahassni 2011; Ilavská et al. 2012 ). Weight loss is associated 
with a decrease in leukocyte and lymphocyte counts (Walford et al. 1992; Nieman et al. 
1993); one study involving gastric band surgery reported a significant decrease in blood 
leukocyte counts, and in particular neutrophil counts, that correlated with BMI over a three 
year follow-up (Veronelli et al. 2004): the underlying cause was attributed to leptin, which is 
known to stimulate myeloid differentiation (Laharrague et al. 2000) and decreases after 
weight loss (Molina et al. 2003). 
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White blood cell counts are reported to be higher in other inflammatory disorders, such as in 
chronic periodontitis, in which patient numbers have been shown to be higher than in healthy 
gender- and age-matched controls (Al-Rasheed 2012) a characteristic that is thought to drive 
the inflammatory process. Furthermore, raised neutrophil counts and subsequently raised 
levels of MPO represent important markers of the inflammatory response and are considered 
predictors of cardiovascular events (Vincent & Taylor 2005). Recently it was shown in an 
obese mouse model that hyperlipidaemia induces neutrophilia and that neutrophils infiltrate 
arteries primarily during the early stages of atherosclerosis (Drechsler et al. 2010). 
Patient NET release was significantly lower prior to weight loss compared with controls. 
Furthermore, during the course of the weight loss NET production increased in patients. 
These results are in contradiction with the literature, in which NET release is exaggerated in 
states of chronic inflammation, such as chronic airway disease (Wright et al. 2016) and 
vascular disorders (Kaplan & Radic 2012). A possible reason for the results reported here 
could be due to incubation time of the NETs assay, which was limited to two hours due to 
experimental time constraints. NETosis can occur via two mechanisms as previously 
described (section 1.6.3); suicidal NETosis occurs between 2-4 hours following stimulation 
and the majority of NETosis is thought to occur via this pathway rather than the shorter 
pathway of vital NETosis which can occur within 60 minutes (Branzk & Papayannopoulos 
2013). However if this were the case a similar finding would be expected in control 
neutrophils. Greater patient numbers and further experimentation, such as the quantification 
of NET-bound proteins, needs to be performed to yield a more accurate interpretation of the 
effect of weight loss on NET release. 
The ROS results detailed in this chapter demonstrate enhanced ROS release in patient 
neutrophils compared to controls pre-weight loss for all three chemiluminescent reagents 
used. This significance remained at both subsequent time points with total ROS release 
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(luminol), indicating that despite weight loss the neutrophils were still in a hyper-reactive 
state. Extracellular ROS release (isoluminol) and superoxide (lucigenin) were reduced 
compared to controls by T3, indicating a partial reduction in the hyper-active nature of 
neutrophils for ROS release. These results are in agreement with previous studies of 
neutrophil ROS production from obese individuals compared to lean controls (Brotfain et al. 
2015) and the oxidative burst activity during phagocytosis (Nieman et al. 1999). 
Furthermore, ROS release has been reported to decrease in obese individuals after weight 
loss (Yaegaki et al. 2007). Neutrophil hyperactivity has also been demonstrated previously 
(Brotfain et al. 2015), however no statistical significance could be demonstrated in the results 
presented here which could be a result of small patient numbers and the effect of the time 
delay from blood collection to sample processing. Increased ROS production has been 
reported to occur within adipose tissue, leading to an elevation of systemic oxidative stress 
affecting other organs including the liver and aorta (Furukawa et al. 2004) via the effects of 
lipid peroxidation and direct oxidative injury (Higdon & Frei 2003; Fan & Watanabe 2003). 
Furthermore, high lipid and glucose levels can stimulate superoxide production via PKC-
dependent activation of vascular NADPH oxidase in cultured endothelial cells (Sonta et al. 
2004).  
The redox state (GSH:GSSG ratio) of the neutrophil is known to be altered in chronic 
periodontitis, a chronic inflammatory condition in which systemic oxidative stress is a 
characteristic feature, resulting in the relocation of NADPH oxidase to the outer cell 
membrane (Dias et al. 2013a) and consequent increased extracellular superoxide release in 
order to ensure cell survival. The increased weight loss, which is associated with a reduction 
in oxidative stress, may partially restore the GSH balance, resulting in reduced superoxide 
release from the cell which may explain the change in extracellular superoxide release but 
not the overall change in total ROS release by the patient neutrophils. Patient-only 
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comparison of ROS release revealed no significant changes between the time points. This 
result may reflect the fact that many patients are still very obese and thus a systemic 
oxidative stress environment would be expected to remain. 
Neutrophil chemotaxis revealed significant differences per time point and with patient-only 
analysis between the time points. There are limited studies focusing on the effects of obesity 
on neutrophil chemotaxis and the effects of weight loss. One study involving diet-induced 
obesity in mice identified defective chemotaxis following LPS-induced lung injury, a 
possible reason was suggested to be due to decreased surface receptor expression of the 
CXCR2 receptor which binds CXCL8 (Kordonowy et al. 2012), despite the fact that CXCL8 
levels are known to be elevated in obese individuals (Trellakis et al. 2012). Despite this, a 
negative feedback loop exists between CXCL8 and CXCR1/2 receptors which could link the 
two independent observations (Hu et al. 2011). Studies of chemotactic activity from type 2 
diabetes patients reported defective neutrophil functions including defective chemotaxis 
(Mowat & Baum 1971; Tan et al. 1975). Glucose can react with lipids and proteins non-
enzymatically to produce advanced glycation end products (AGEs), if present at high enough 
levels as is expected in poorly controlled diabetes patients. The level of AGEs will increase 
and they have been reported to interfere with leukocyte function (Goldin et al. 2006). AGE 
presence within human neutrophils is linked to a rise in intracellular calcium and to actin 
polymerisation and subsequent impaired chemotaxis (Collison et al. 2002), suggesting that 
exposure to AGEs may be a possible reason for the reduced neutrophil chemotactic accuracy. 
Pro-inflammatory cytokine detection from supernatants of cultured patient neutrophils 
revealed significantly higher levels compared to controls with several stimuli used. 
Significance was evident with IL-1β, IL-6, CXCL8 and TNFα at T1 in the presence of 
stimuli and (for TNFα only) in the absence of a stimulus. These results indicate a hyperactive 
and hyper-reactive neutrophil phenotype. The significance was diminished by T3 indicating a 
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reduction in pro-inflammatory cytokine release in patients compared to controls. No 
significance was measured in plasma, and only CXCL8 and TNFα could be detected. Due to 
time constraints and sample availability, only ten patient neutrophil supernatants were 
measured for cytokine levels. The pro-inflammatory cytokine results demonstrate a decrease 
with weight loss, however the effect is more subtle than expected which is thought to be due 
to the small sample size and the continued obese state of the patients. 
Patient-only analysis revealed a reduction in IL-1β, IL-6 and TNFα over time with some of 
the stimuli, demonstrating that weight loss decreased pro-inflammatory cytokine release by 
patient neutrophils. These results are in agreement with reports within the literature regarding 
increased serum cytokine levels in obesity ( Kopp et al. 2003; van Dielen et al. 2004; 
Tziomalos et al. 2010) reflecting a level of immune system activation. Systemic TNFα levels 
have been shown to correlate with increasing BMI (Kern et al. 1995). TNFα has been shown 
to act directly upon adipocytes and dysregulated levels have been suggested to interfere with 
glycaemic homeostasis and promote greater insulin resistance ( Hotamisligil et al. 1993; 
Fantuzzi 2005; Cawthorn & Sethi 2008) as well as promoting endothelial dysfunction by 
inducing NF-κB signalling, NADPH activation and ROS production (Darvall et al. 2007; 
Gao et al. 2007). Circulating pro-inflammatory cytokines have been shown to prime 
neutrophils (Harkin et al. 2001; Koenderman et al. 2000) which would in turn account for 
their enhanced production when neutrophils are stimulated. Other disorders of inflammation 
have also reported enhanced neutrophil ROS release (Mittal et al.2014)  in addition to 
enhanced pro-inflammatory cytokine production (Chollet-Martin et al. 1992; Nikolaus et al. 
1998; Bordon et al. 2013). 
It is important to note that some of the actions of pro-inflammatory cytokines on metabolism 
and immune responses can be paradoxical, for example, IL-6 has been shown to be abundant 
in obesity (Perreault et al. 2014) and may correlate with insulin resistance (Pradhan et al. 
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2001; Ueki et al. 2004) , yet studies on mice with IL-6 deficiencies have revealed that mice 
exhibit enhanced sensitivity to the metabolic effects of a high fat diet (Mauer et al. 2014). As 
IL-6 is generated as part of the inflammatory process involved in stimulating angiogenesis 
and the release of acute phase proteins (Blanchard et al. 2009), which generally opposes the 
action of insulin, IL-6 may act as a feedback regulator, attenuating catabolic and 
inflammatory signalling to preserve the actions of insulin. Thus IL-6 might provide an 
overall beneficial effect.  
There are a number of limitations and confounding factors that may have contributed to the 
data reported in this chapter. Firstly, the small overall sample size and the need for more 
pronounced weight loss for greater significance in reported data. A study by Zamarron et al. 
(2015) reported continued inflammatory activation of leukocytes within adipose tissue of 
obese mice despite weight loss, supporting the variation in health in response to weight loss 
interventions. In addition, other factors such as medications, dietary and exercise habits, 
which may reduce weight, may not contribute to improved health and therefore immune 
function. 
Secondly, the presence of other obesity-linked disorders, for example, several of the patients 
suffered from obstructive sleep apnoea (OSA), a disorder characterised by repetitive pauses 
of breathing caused by partial or complete collapses of upper airways during sleep 
(Rubinstein 1995; Salerno et al. 2004). OSA is associated with hypertension, strokes and 
coronary artery disease in addition to obesity (Shahar et al. 2001; Shah et al. 2010; Redline et 
al. 2010; Loke et al. 2012). The pauses in breathing are followed by a decrease in oxygen 
saturation leading to hypoxia which can serve as a stimulus for various peripheral blood 
cells, including monocytes and neutrophils (Dyugovskaya et al. 2002; Dyugovskaya et al. 
2003), leading to increased burst of ROS (McCord 1985; Pilkauskaite et al. 2013) and 
endothelial dysfunction (Naruko et al. 2002). Furthermore, levels of TNFα and IL-6 have 
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been reported to be elevated in OSA (Entzian et al. 1996; Vgontzas et al. 1997) and 
neutrophils have been demonstrated to be a source of pro-inflammatory cytokines in OSA 
(Dyugovskaya et al. 2008). Due to limited patient background information, it was not 
possible to know of improvements in the OSA status of the patients or if the extent of weight 
loss had impacted on their condition. 
Thirdly, the presence of additional inflammatory-linked disorders in the patients may 
confound results; a notable example is the periodontal status of the patients, which was not 
known in this study. Despite the strong association between obesity and periodontal disease 
( Dalla Vecchia et al. 2005; Boesing et al. 2009; Nilsson et al. 2012; Dahiya et al. 2012; 
Huttunen & Syrjänen 2013; Taylor et al. 2013; Suvan et al. 2014;) with obese females (who 
made up the majority of patients in this study) are reported more likely to suffer periodontal 
disease than obese males (Haffajee & Socransky 2009), knowledge of the periodontal status 
among obese individuals is limited due to patient non-compliance and the need for specialist 
equipment (Reilly et al. 2009). It would be expected that weight loss would result in 
improved periodontal status due to improvements in systemic inflammatory status, i.e. a 
reduction in the prevalence of diseases such as diabetes, a decrease in the release of pro-
inflammatory cytokines as a result in a decrease in adipose tissue and a change in 
behavioural patterns in turn generating a healthier lifestyle (Wadden et al. 2001; Khader et 
al. 2009). Despite the lack of information for this chapter, periodontal status during the 
course of gastric band surgery in obese patients has been recently reported by Sales-Peres et 
al. (2015). Twelve months post-gastric band surgery they found no improvements in 
periodontal conditions despite weight reduction. One reason for this may have been related to 
the feeding habit changes of patients; eating more times per day in reduced quantities, thus 
the oral condition remained favourable to microbial biofilm support (Hague & Baechle 
2008). Interestingly a recent study reported the beneficial effect of non-surgical periodontal 
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treatment in obese individuals; the results demonstrated GSH levels were significantly lower 
in obese individuals with periodontal disease than in normal weight individuals and the levels 
significantly increased after therapy for both periodontitis groups (Öngöz Dede et al. 2016). 
Thus improvements in disorders related to obesity but not due to weight loss may also act as 
potential confounders. 
Interest has grown in recent years in the far-reaching effects of obesity on immune function. 
Recently categorised as a low-grade chronic inflammatory disorder, the effects of obesity on 
human health have generated new avenues to measure the effects of excess adiposity on 
neutrophil function. The opportunity to measure other neutrophil proteins, such as MPO and 
calprotectin, which are primarily secreted by neutrophils ( Stríz & Trebichavský 2004; 
Nicholls & Hazen 2005) could provide more robust evidence for the contribution of 
neutrophils to the chronic inflammatory state. This, alongside more detailed background 
information, in particular periodontal status, for conditions in which neutrophils are the 
dominant cell could help develop our understanding of the underlying relationship between 
the two disorders. Other adipokines/cytokines could also be measured, such as IL-17α, which 
is increased in obesity and is released by neutrophils and adipose tissue, implicating innate 
immunity and adipocytes in a network which during the chronic low-grade inflammatory 
state of obesity may also affect acute inflammation (Pini & Fantuzzi 2010). Furthermore, IL-
17α can induce other immune cells to secrete chemokines (such as CXCL8 and CXCL6) and 
other cytokines (IL-6 and GM-CSF) leading to an accumulation of neutrophils at 
inflammatory sites (Kolls & Lindén 2004). 
6.11. Chapter 6 summary 
This study has measured a range of neutrophil behaviours in obesity prior to and following 
weight loss. This data reported in this chapter supports the idea that circulating neutrophils 
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are involved in obesity-related inflammation. Neutrophils from obese patients exhibit 
excessive neutrophil activity characterised by higher ROS generation and release of 
cytokines, which appear to enhance the extent of local and systemic inflammation. This 
would be expected to affect the surrounding tissues including the blood vessels that may 
increase the risks of contracting associated cardiovascular disorders. Weight loss reduction 
was associated with improved outcomes characterised by lower ROS production and 
cytokine release relative to healthy controls, thus weight loss intervention resulting in a 
reduction in body weight associates with a decrease in pro-inflammatory activities. The 
absence of significant changes in patient neutrophil function over the course of the three time 
points could reflect experimental time constraints and challenges associated with 
coordinating optimal patient sample collection times. 
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7.1. Summary of main findings 
The aim of this thesis was to explore novel aspects of neutrophil function in chronic 
inflammatory conditions with particular emphasis on the development and use of an assay of 
chemotactic accuracy in concert with other assays developed by members of the research 
group. Specific aims were: 
 
1. To optimise a method for the study of neutrophil chemotactic accuracy ex vivo 
2. To assess neutrophil function in acute and chronic oral disease states  
3. To assess neutrophil function in obese patients pre- and post-bariatric surgery 
 
To study neutrophil function, neutrophils were isolated from the peripheral blood of 
volunteers using discontinuous Percoll gradients. The development and optimisation of an 
efficient re-usable chemotaxis assay (Chapter 3) enabled its employment in further studies of 
neutrophil function using clinical samples. As neutrophils are relatively short-lived fast-
moving cells, the need for an assay that does not require lengthy cell preparation and is 
simple to perform were essential pre-requisites to enable measurements of neutrophil-
directed movement with several different agents in a limited time period. The Insall chamber, 
whilst originally developed for longer-term measurements of cell movement, has been 
previously shown to work with neutrophils. The assay was further optimised in this thesis to 
decipher the optimal cell numbers to track, time course of study and chemoattractant 
concentrations. This work has enabled the assay to be used by others studying neutrophil 
movement. 
 
Neutrophil ROS and NETs were measured in experimental 21-day gingivitis model (Chapter 
4) to identify any differences before and after inducing inflammation using an acute human 
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model. Gingivitis precedes chronic periodontitis, however the underlying mechanisms that 
lead to disease progression are not fully understood; moreover not all sufferers of gingivitis 
will progress to periodontitis. Identifying variations in neutrophil functionality, even during a 
localised inflammatory event, may aid in the understanding of their role in disease 
progression. Neutrophils are the dominant immune cell within the periodontal tissues and 
excessive ROS and NET production are thought to be a major driver of periodontal tissue 
damage and may aid in the acquisition of nutrients by pathogenic bacterial species colonising 
the oral tissues. The results presented in this thesis demonstrated that at the height of acute 
inflammation ROS and NETs were significantly increased and that inflammation resolution 
reversed the excessive release of both.  
 
Neutrophil chemotaxis was measured in a 21-day experimental gingivitis model, and for the 
first time, in patients with chronic periodontitis pre- and post-periodontal treatment (Chapter 
4) to explore any differences between an acute inflammatory condition (experimental 
gingivitis) and chronic periodontal inflammation (periodontitis) on peripheral blood 
neutrophil behaviour. GCF collected from gingivitis volunteers and periodontitis patients was 
assayed for cytokine release and for its chemoattractants properties when exposed to healthy 
volunteer neutrophils. At the height of gingival inflammation, chemotaxis was significantly 
different at the height of inflammation compared with baseline. For the chronic periodontitis 
patients significance was evident compared to healthy-matched controls and remained 
following non-surgical therapy, further supporting the dysfunctional behaviour of neutrophils 
in chronic periodontitis that has previously been reported, notably with regard to excessive 
ROS generation. Not surprisingly, GCF from diseased/inflamed sites in gingivitis and 
chronic periodontitis significantly induced neutrophil chemotaxis, and consistent with this 
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was the finding of increased levels of TNFα and IL-1β detected in the GCF of inflamed 
experimental gingivitis and periodontitis sites.  
 
Neutrophil function in PLS, a syndrome characterised by a severe pre-pubertal form of 
periodontitis, was investigated (Chapter 5). The expectation of attenuated NET production, 
which has been previously reported (Sorenson et al. 2014), was confirmed relative to healthy 
controls. Furthermore, specific NET analyses revealed a lack of the NET-bound NSPs NE 
and CG. ROS release was higher in PLS patients relative to controls which is consistent with 
other forms of periodontal disease. The levels of cytokines and pro-inflammatory protein 
production was also significantly higher in PLS patient neutrophils and in plasma, reflecting 
elevated local and systemic inflammation. The reduced chemotactic capabilities of PLS 
patients was also consistent with data from chronic periodontitis patients and points to a 
scenario involving increased neutrophil tissue transit times and continued neutrophil 
recruitment as a consequence of failed NSP activities, which are evidently intricately 
involved in orchestrating immune responses rather than fulfilling solely antimicrobial 
functions. 
 
The effects of the low-grade chronic inflammation, which is characteristic of obese 
individuals was also investigated (Chapter 6). Obesity is one of the greatest global health 
challenges of the 21
st
 century and interest in the link between excess adiposity and immune 
dysfunction has grown in recent years. The endocrine-like functions of adipose tissue and the 
immune cell composition of the tissue itself have attracted interest in investigating the effects 
of obesity upon immune cells. As neutrophils are key players of the innate and acquired 
immune systems, and typically reside in blood in the absence of infection, they have been 
postulated to be influenced by increased circulating levels of cytokines released (some 
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exclusively) by cells from within adipose tissue, which may prime neutrophils for a more 
robust/exaggerated behaviour during infection. This could explain the underlying cause for 
obesity as the second strongest risk factor for periodontitis as well as increased risk of obese 
individuals to other infectious disorders, such as pneumonia. Furthermore, obesity is linked 
to non-infectious diseases such as diabetes and rheumatoid arthritis making it a very complex 
disorder for which to accurately draw conclusions. Neutrophil function in obese individuals 
was measured alongside healthy controls prior to and following weight loss. The degree of 
weight loss was anticipated to be 10-15% by the post-surgical appointment, and some 
patients achieved beyond this, but several did not. As outlined, the loss of body weight does 
not directly correlate with a reduction in adipose tissue, however the reduction was 
accompanied with indicators of improved health: reduced HbA1c levels; raised HDL; and 
lower LDL and TG relative to healthy controls. Patient neutrophils displayed excessive ROS 
release, which is in accordance with other chronic inflammatory disease states, and this 
remained throughout the three time points in which blood was taken. Neutrophil chemotaxis 
was abnormal, again reflective of the systemic chronic inflammatory state, which is shared 
by other conditions including chronic periodontitis. Significant reductions in the chemotaxis 
measurements remained despite weight loss, however as stated, many of the patients 
remained severely obese, thus the chronic inflammatory state would be expected to reflect 
continued obese status. The pro-inflammatory cytokines measured were significantly higher 
relative to controls and significant differences become non-significant following weight loss.  
7.2. Overall conclusion and recommendations for future research 
The results outlined in this thesis point to various forms of dysregulated neutrophil function 
in chronic inflammatory disease states, which improve following appropriate treatment 
(periodontal treatment or weight loss). By understanding the potential contributions of 
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neutrophils to the progression of inflammation and in turn the extent of the effect of systemic 
inflammation on peripheral blood neutrophil behaviour, more effective strategies may be 
developed to prevent disease progression and identify effective therapies to reduce associated 
co-morbidities.  
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8.1. Appendix I: 2-dimensional (2-D) μ-slide chemotaxis chamber 
Cell migration assays based on microfluidic devices are becoming increasingly popular. The 
µ-slide (IBIDI, 80111) chemotaxis chamber is a 2-D microfluidic chamber that allows for 
long-term analysis of chemotaxing cells and for the observation of human leukocyte 
movement (Zengel et al. 2011). The device features two chambers connected by an internal 
channel to which cells are added via channel ports and allowed to adhere (Figure 8.1a). A 
gradient is then created by adding chemoattractant agents to either or both of the two 
chambers via the reservoir ports and migration of the cells is observed by video microscopy 
(Figure 8.1b). 
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Figure 8.1 The µ-slide chamber 
Diagrammatic representation of the chamber (a). Visualisation of the addition of 
chemoattractant showing gradient formation (b).   
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8.1.1. µ-slide chemotaxis method 
The chamber was prepared by coating the internal channel with collagen IV (10µl, 100µg/ml 
in 0.05M HCl; Sigma, C5544). The chamber ports were all sealed with provided caps and 
incubated for 24 hours at room temperature. Post-incubation the collagen was aspirated out 
and the chamber was left to dry for an hour at room temperature. Cells (6µl, 5 x 10
6
/ml) were 
introduced and the chamber was re-sealed and incubated at room temperature for 30 minutes. 
RPMI (negative control; 40µl), was added to both of the reservoirs. fMLP (10nM; 18µl) was 
added to one of the channel ports and the liquid was aspirated from the other side to allow 
diffusion through the reservoir (Figure I shows this; fMLP was dyed blue for visual 
purposes). Video microscopy was performed 40 minutes after addition of fMLP using the 
same parameters as the Insall chamber (ref. section in methods).  
8.1.2. µ-slide chemotaxis analysis 
The Manual tracking plugin (Fiji) was used to track cells using the µ-slide chamber. Ten 
cells were tracked in total and data was processed further using the Chemotaxis and 
Migration Tool (IBIDI website) which generates visual diagrams as well as qualitative 
measures.  
8.1.3. Results 
Figure 8.2a shows tracked cells and 8.2b shows the cell tracks with the same point of origin 
with the chemoattractant above, the centre of mass (blue cross) indicates the orientation of 
the cells is in an upwards fashion towards the source of the chemoattractant. Qualitative 
measurements included average speed, accumulated speed, Euclidean distance (distance in a 
particular direction) and the forward mass index (FMI) as shown in Figure 8.2c. These 
provide similar information to the analysis of chemotaxis using the Insall Chamber. An 
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additional statistical test provided by the Chemotaxis and Migration Tool and MATLAB (for 
use with the Insall chamber) is the Rayleigh test, a statistical test of the uniformity of a 
circular distribution of points, in which p < 0.05 accepts a heterogeneous spread of cells (I.e. 
cells lie more to one side of the circle than the other). In the example described here, p = 
0.0035, however use of this test with RPMI (negative control) can yield similar p values 
which can give a misleading result. The Rayleigh test strongly depends on the number of 
cells analysed and so was not selected as an additional tool for chemotaxis analysis using the 
Insall chamber.  
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Figure 8.2 Results generated from µ-slide chemotaxis assay  
Neutrophils were isolated (section 2.2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed using the Chemotaxis and Migration Tool. Cells were tracked 
using Fiji (a). Images of the cells can be generated with the same point of origin (b). 
Qualitative data of cell movements can also be calculated (c). (FMI = Forward Mass Index).  
 
 
 
 
 
 
 
 
 
 
303 
 
8.1.4. Conclusion 
The µ-slide is another chemotaxis chamber appropriate for the study of leukocyte 
chemotaxis. The level of qualitative information that can be gathered using this chamber and 
its associated software is comparable to the Insall chamber; however difficulties were 
encountered with its use making it unsuitable for using with clinical samples. One such 
drawback was the long time required to establish the chemoattractant gradient, despite the 
improved linearity of the gradient once formed. The time-consuming application of the 
chamber, used for a short window of viewing (20 minutes) makes it a less attractive option. 
Furthermore, the chamber can only be used once whereas the Insall chamber requires only 
washing with distilled water and drying with lint wipes (Kimtech), making it a more cost-
effective choice.  
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8.2. Appendix II: Periodontitis study additional information  
8.2.1. Clinical attachment loss (CAL) 
Clinical attachment loss (CAL) was calculated prior to treatment by summation of 
periodontal pocket depth and gingival recession measurements. The mean CAL and 
percentage sites with 1-2, 3-4 and >4mm CAL are shown in Table 8.1, which corresponds to 
mild, moderate and severe disease, respectively. Of the 20 patients initially recruited, one 
withdrew (patient 13) and another had a low cell count and could therefore not be used for 
measuring neutrophil chemotaxis (patient 19). Twelve patients (67%) presented with 
generalised moderate and localised severe chronic periodontitis, 3 patients (17%) presented 
with generalised mild and localised severe chronic periodontitis, and a further 3 patients also 
presented with generalised severe chronic periodontitis.   
8.2.2. Periodontal pocket depth (PPD) 
The number of periodontal probing depth (PPD) sites measuring over 4mm was significantly 
higher in patients, compared with healthy controls (unpaired t-test p < 0.0001, n = 18 pairs). 
Following treatment the difference was less compared with controls (unpaired t-test p < 
0.001, n =18 pairs). The number of sites exceeding 4mm PPD in the patients significantly 
differed pre- versus post-treatment (p = 0.0023, n = 18 pairs), demonstrating the effect of 
non-surgical therapy in reducing pocket depths (unpaired t-test p = 0.0023, n = 18 pairs) in 
patients (Table 8.2).    
 
 
305 
 
8.2.3. Bleeding on probing (BOP) 
The percentage of sites that displayed bleeding on probing (BOP) pre-treatment was 
significantly higher in patients before treatment compared with healthy controls (unpaired t-
test p < 0.0001, n = 18 pairs).  Following treatment the difference between patients and 
controls reduced but remained significant (unpaired t-test p = 0.0478, n = 18 pairs).  The 
percentage of sites that bled upon probing in periodontitis patients was reduced when 
compared with pre-treatment measurements (unpaired t-test p < 0.0001, n = 18 pairs) (Table 
8.3).
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Table 8.1 Clinical attachment loss (CAL) measurements in periodontitis patients and healthy controls  
Measurements from patients pre-treatment (n = 18).  Data is presented as percentage sites with 1-2, 3-4 and >4mm clinical attachment loss (mean 
± SD and range).     
Patient 
no. 
Clinical attachment loss 
Classification of chronic 
periodontitis 
 
Mean ± SD (mm) % sites  1-2mm % sites  3-4mm % sites  >4mm 
 
1 4.4±3.2 39.1 21.8 39.1 Generalised severe 
2 2.4±1.9 66.7 26.3 7 Generalised moderate, localised severe 
3 3.7±2.1 36.5 35.3 28.2 Generalised moderate, localised severe 
4 3.5±1.8 35.9 41 23.1 Generalised moderate, localised severe 
5 2.8±1.6 59 24.4 16.6 Generalised moderate, localised severe 
6 3.7±2.1 37 31.2 31.8 Generalised severe 
7 3.4±2.4 55.6 21.6 22.8 Generalised moderate, localised severe 
8 2.4±0.9 67.9 28.6 3.5 Generalised moderate, localised severe 
9 3.4±1.6 36.9 45.8 16.3 Generalised moderate, localised severe 
10 2.8±1.3 44.4 48.3 7.2 Generalised moderate, localised severe 
11 2.2±1.8 85.7 5.4 8.9 Generalised mild, localised severe 
12 2.9±2.6 66.1 13.3 20.6 Generalised moderate, localised severe 
14 3.3±2.0 46.4 34.5 19 Generalised moderate, localised severe 
15 3.9±1.6 20.1 50.3 29.6 Generalised moderate, localised severe 
16 3.2±2.2 55.7 25.9 18.4 Generalised moderate, localised severe 
17 5.9±3.3 25.6 11.9 62.5 Generalised severe 
18 2.2±1.5 78 16.7 5.3 Generalised mild, localised severe 
20 1.9±1.4 79 15.6 5.4 Generalised mild, localised severe 
Mean 3.4 48.7 28.2 23 
 SD 1.1 21.1 12.4 16.8 
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Table 8.2 Probing pocket depth (PPD) measurements in periodontitis patients and healthy controls 
Measurements from patients pre-treatment and post-treatment, compared with healthy matched controls (n = 18).  Data is presented as probing 
pocket depths (mean ± SD and range) and the number of sites >4mm.   
Patient 
no. Probing pocket depths 
  
Patient pre-treatment 
 
Patient post-treatment 
 
Healthy control 
 
 
Mean ± SD (mm) 
Range 
(mm) 
No. sites 
>4mm 
Mean ± SD 
(mm) 
Range 
(mm) 
No. sites 
>4mm 
Mean ± SD 
(mm) 
Range 
(mm) 
No. sites 
>4mm 
1 3.5±2.8 1-12 45 2.7±1.4 1-9 24 2.1±0.9 1-5 1 
2 2.2±1.5 1-12 7 2.2±0.9 1-7 8 2.1±0.9 1-5 1 
3 3.4±2.0 1-9 36 2.7±1.3 1-7 15 1.8±0.7 1-4 0 
4 3.4±1.7 1-9 33 1.6±0.7 0-4 0 2.0±0.8 1-5 3 
5 2.6±1.5 1-7 22 2.0±0.8 0-5 2 1.2±0.4 1-2 0 
6 3.4±2.1 1-8 45 2.5±1.0 1-7 7 1.5±0.6 1-3 0 
7 2.9±1.9 1-12 28 2.2±1.4 1-10 9 1.7±0.6 1-4 0 
8 2.3±0.9 1-7 5 1.4±0.8 0-5 1 2.2±0.9 1-5 4 
9 3.4±1.6 1-8 29 2.4±1.1 1-6 7 1.3±0.5 1-3 0 
10 2.6±1.2 1-7 10 1.8±0.9 1-4 0 1.4±0.6 1-3 0 
11 2.1±1.8 1-9 14 1.5±1.1 0-9 2 1.1±0.4 1-3 0 
12 2.8±2.4 0-12 35 2.5±2.1 1-10 23 1.1±0.4 1-3 0 
14 2.9±1.7 0-8 25 1.8±1.2 0-6 5 1.8±0.9 1-5 1 
15 2.8±1.4 1-7 23 2.4±1.5 1-8 16 1.3±0.5 1-3 0 
16 3.2±2.2 1-9 32 2.0±1.3 0-9 9 1.1±0.3 1-3 0 
17 4.8±2.7 1-12 91 3.5±2.2 1-10 52 1.4±0.5 1-3 0 
18 2.1±1.5 0-11 8 1.5±0.9 0-7 1 1.7±0.7 1-4 0 
20 1.5±1.0 1-7 5 1.5±0.8 1-7 1 1.3±0.6 1-4 0 
Mean 2.9 
  
2.2 
  
1.6 
  SD 0.66 
  
0.5 
  
0.4 
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Table 8.3 Bleeding on probing (BOP) in periodontitis patients 
Percentage of sites that bled from the pocket base after periodontal probing in periodontitis 
patients pre- and post-treatment and healthy controls (n = 18). Data is presented as 
percentage sites with bleeding on periodontal probing.   
 
% BOP 
Patient 
no. 
Patient pre-treatment Patient post-treatment Control 
1 37 23 39 
2 16 14 17 
3 87 33 0 
4 51 8 0 
5 26 5 0 
6 47 12 0 
7 44 11 16 
8 42 18 20 
9 72 15 0 
10 63 13 1 
11 21 10 0 
12 53 22 0 
14 70 14 20 
15 23 20 2 
16 21 5 0 
17 63 35 9 
18 33 5 16 
20 17 3 8 
Mean 43.7 14.8 8.2 
±SD 21.3 9.1 11.0 
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8.3. Appendix III: Chemotaxis with cathepsin G 
Cathepsin G (CG) is known to cleave MIP1α chemoattractant (Ryu et al. 2005). This was 
confirmed by pre-incubating MIP1α with a concentration of cathepsin G known to be 
effective against bacterial lysis (25μg/ml; (Edwards 2005).  Figure 8.3 shows the speed, 
velocity and chemotactic index (CI) using cathepsin G. RPMI and fMLP (10nm) were used 
as negative and positive controls to provide a reference for the other conditions, which 
included MIPα (100ng/ml) with/without GM-CSF (20pg/ml) priming and pre-incubation of 
the MIP1α with CG (25μg/ml) with/without GM-CSF priming. 
The results demonstrated that exposure of MIP1α to CG results in attenuated chemotaxis. 
MIPα with/ GM-CSF priming showed significantly greater speed, velocity and a CI above 
that of MIPα in the absence of priming and in all conditions in which CG was incubated with 
MIPα prior to use in the assay.   
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 Figure 8.3 Chemotaxis with cathepsin G 
Neutrophils were isolated (section 2.2.2) and chemotaxis was performed (section 2.6), after 
which the cells were analysed (section 2.6.2) and tracked information was used to generate 
speed (a), velocity (b) and CI (c) using MIP1α (100ng/ml) pre-incubated with/without CG 
(25μg/ml) and with/without GM-CSF priming (20pg/ml). (n = 10 different blood donors; 15 
cells tracked per chemoattractant/RPMI). Statistical test: One Way ANOVA and Tukey’s 
multiple comparisons test. * = (p < 0.05), *** = (p < 0.001). 
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8.3.1. Conclusion 
These results show the importance of CG, and therefore NSPs, in regulating immune 
responses. The inactivation of chemokines such as MIP1α by NSPs released from neutrophils 
would serve to limit the further recruitment of neutrophils to the site of infection, as would 
occur during an infection in the oral tissues. These results outline an important role of NSP 
activity in the resolution of the immune response, supporting their loss of function as a major 
contributing factor to the development of periodontal disease in PLS.  
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8.4. Appendix IV: Obesity study additional information 
Table 8.4 Bariatric patients and controls background information 
Patient no. Patient age 
Control 
age 
Gender Patient co-morbidities 
1 56 54 Male Depression, hypertension, oedema 
3 40 40 Female osteoarthritis and sleep apnoea 
5 58 56 Female 
sleep apnoea, type 2 diabetes, 
dyslipidaemia 
6 54 37 Female 
Hypertension, Hyperlipidaemia, 
Osteoarthritis 
7 38 39 Female Sleep apnoea 
8 43 38 Female N/A 
10 40 40 Female Depression, osteoarthritis 
11 42 48 Female 
Diabetes (type 2), hypothyroidism, 
asthma, eczema, 
12 50 52 Female 
Diabetes (type 2), hypertension, 
osteoarthritis 
13 58 56 Female Sleep apnoea 
14 41 41 Female N/A 
15 41 43 Female Diabetes (type 2) 
16 57 55 Female Diabetes (type 2), hypertension 
18 67 65 Female 
Hypertension, sleep apnoea, 
depression, arthritis 
19 45 43 Female Sleep apnoea 
21 61 61 Female 
Diabetes (type 2), 
hypercholesterolaemia, 
hypertension, depression 
22 24 27 Female 
Arthritis, hypertension, 2 x knee 
replacements 
23 51 51 Female Osteoarthritis, Diabetes (type 2) 
Mean ± SD 
(range) 
48 ±10.5 
(24-67) 
47 ±9.8 (27-
65) 
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Table 8.5 Patient weight loss  
Patient No. 
T1 Weight 
(kg) 
T2 Weight 
(kg)  
T3 Weight 
(kg)  
Total 
weight loss 
(kg) 
% Total weight 
loss between T1-3 
1 150 141.9 126 24 19.0 
3 162 159.8 124.4 37.6 30.2 
5 101 98 88.3 12.7 14.4 
6 148 143.5 138.6 9.4 6.8 
7 134 125 118.8 15.2 12.8 
8 106 101.6 97.4 8.6 8.8 
10 115 117.3 114.8 0.2 0.2 
11 151 143.6 132.4 18.6 14.0 
12 132 129.1 126.4 5.6 4.4 
13 149 134.6 129.8 19.2 14.8 
14 112 107.2 93.8 18.2 19.4 
15 122 118 109.1 12.9 11.8 
16 147.4 140 120.7 26.7 22.1 
18 119.2 113 107.6 11.6 10.8 
19 120.2 116 103.6 16.6 16.0 
21 145 139 119 26 21.8 
22 101 94 87.2 13.8 15.8 
23 117 110 98 19 19.4 
Mean ± SD 
(range) 
129.5 ±19.3 
(101-162) 
123.9 ±18.5 
(94-109) 
113.1 ±15.7 
(87-138) 
16.4 ±8.6 
(0.2-37.6) 
14.6 ±7.1 
(0.17-30.2) 
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8.5. Conference abstracts 
 Helen Roberts*, Phillipa White, Irundika Dias, Sarah McKaig, Ratna Veeramachaneni, Nalin 
Thakker, Melissa Grant and Iain Chapple. “Characterisation of neutrophil dysfunction in 
Papillon-Lefévre Syndrome”. Oral presentations at the British Society of Periodontology 
conference, Oxford 2016 and at the International Association of Dental Research Seoul, 
South Korea 2016.   
 Helen Roberts*, Melissa Grant, Phillipa White & Iain Chapple. “An Assessment of 
neutrophil function in children with Papillon-Lefévre Syndrome”. Oral presentation at the 
British Society for Oral and Dental Research conference in Cardiff September 14th-16th  
2015. 
 Helen Roberts*, Melissa Grant, Phillipa White & Iain Chapple. “An Assessment of 
neutrophil function in children with Papillon-Lefévre Syndrome”. Poster presentation at the 
European Congress of Immunology in Vienna September 6-9th 2015. 
 Helen Roberts*, Melissa Grant, Rishi Singhal, Paul Super & Iain Chapple. “Effect of obesity 
on innate immune function”. Poster presentation at the International Association for Dental 
Research conference in Boston 2015. 
 Helen Roberts* Phillipa White, Melissa Grant and Iain Chapple. “Neutrophil directional 
chemotaxis in children with Papillon-Lefévre Syndrome”. Leukocyte Migration Conference 
2015 
 Helen Roberts*, Melissa Grant, Rishi Singhal, Paul Super & Iain Chapple. “Effect of obesity 
on neutrophil function”. Poster presentation at Biochemical Society Meeting: Metabolic 
drivers of Immunity in Birmingham 2015 
 Helen Roberts*, Martin Ling, Melissa Grant, Robert Insall and Iain Chapple. “Neutrophil 
chemotactic accuracy in periodontitis patients pre- and post-treatment” Poster presentation at 
the International Association for Dental Research conference in Cape Town 2014. 
 Helen Roberts*, Martin Ling, Melissa Grant and Iain Chapple. “Neutrophils from 
periodontitis patients exhibit defective chemotaxis” presentation at the British Society for 
Oral and Dental Research conference in Bath September 2013. 
 Helen Roberts*, Melissa Grant, Janet Lord, Jeremy Tomlinson & Iain Chapple “Effect of 
adipokine priming upon neutrophil reactive oxygen species (ROS) & extracellular trap 
release in response to stimulation by periodontal bacteria”. Poster presentation at the Society 
for Free Radical Research in London 2012. 
 
8.6. Awards, funding and other 
 MRC-funded PhD 
 Winner of the Sir Wilfred Fish Research Prize at the British Society of Periodontology 
conference, Oxford 2016.  
 University of Birmingham Research Travel Grant 2015. Successful written grant proposal. 
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 BSODR Travel Bursary Award September 2015. Successful written grant proposal. 
 University of Birmingham Research Showcase 2013. Oral presentation, 2nd prize.  
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Abstract
Aim: To investigate the chemotactic accuracy of peripheral blood neutrophils
from patients with chronic periodontitis compared with matched healthy controls,
before and after non-surgical periodontal therapy.
Material & Methods: Neutrophils were isolated from patients and controls
(n = 18) by density centrifugation. Using the Insall chamber and video micros-
copy, neutrophils were analysed for directional chemotaxis towards N-formyl-me-
thionyl-leucyl-phenylalanine [fMLP (10 nM), or CXCL8 (200 ng/ml)]. Circular
statistics were utilized for the analysis of cell movement.
Results: Prior to treatment, neutrophils from patients with chronic periodontitis
had significantly reduced speed, velocity and chemotactic accuracy compared to
healthy controls for both chemoattractants. Following periodontal treatment,
patient neutrophils continued to display reduced speed in response to both
chemoattractants. However, velocity and accuracy were normalized for the weak
chemoattractant CXCL8 while they remained significantly reduced for fMLP.
Conclusions: Chronic periodontitis is associated with reduced neutrophil chemo-
taxis, and this is only partially restored by successful treatment. Dysfunctional
neutrophil chemotaxis may predispose patients with periodontitis to their disease
by increasing tissue transit times, thus exacerbating neutrophil-mediated collateral
host tissue damage.
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Chronic periodontitis is a disease
that is initiated by the emergence of
a pathogenic biofilm and character-
ized by non-resolving inflammation
which leads to host-mediated tissue
damage and bone loss around the
teeth (Grossi et al. 1994). Chronic
periodontitis can itself be a risk fac-
tor for other inflammatory diseases
including type 2 diabetes (Chapple
et al. 2013), rheumatoid arthritis
(RA) (de Pablo et al. 2009) and
cardiovascular diseases (Dietrich
et al. 2013). The disease is character-
ized by a strong neutrophil tissue
infiltrate (Van Dyke 2009) and
tissue damage progresses as a
result of abnormal host inflamma-
tory-immune processes, eventually
resulting in bone resorption and a
receding gingival epithelial attach-
ment (Graves & Cochran 2003).
The oral tissues are constantly
exposed to foreign and potentially
harmful microorganisms, and in
order to combat potential infections
in this vulnerable area, immune sur-
veillance involves leucocyte infiltra-
tion into the tissues from the blood
stream in response to endogenous
and exogenous chemoattractants
(Gamonal et al. 2001). Immune cells,
including neutrophils, are recruited
to the site of infection by chemokin-
es such as CXCL8 (Interleukin-8)
and CCL3 (macrophage inhibitory
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protein-1alpha-MIP1a) and other in-
flammatory stimuli including the
bacteria-derived N-formyl-methionyl-
leucyl-phenylalanine (fMLP). The
ability of neutrophils to efficiently
reach the site of inflammation is cru-
cial in order to eliminate potentially
pathogenic agents, whilst minimizing
collateral host tissue damage. Patho-
gen-associated molecular patterns
(PAMPs), damage-associated molec-
ular patterns (DAMPs) and other
molecules with chemoattractive prop-
erties, which include complement pro-
teins such as C5a, and eicosanoids
(leukotriene B4) and platelet activat-
ing factor (PAF), have different
potencies, forming a chemical hierar-
chy that serves to recruit neutrophils
to the source of inflammation. Those
that elicit the strongest migration are
molecules that emerge from the
inflammation/infection source,
including bacterial products such as
fMLP.
Chemotaxis, the directional
movement of cells in response to
chemical gradients, is a highly
conserved process occurring in a
diverse number of organisms; in
particular, there are strong similari-
ties between cell movement in the
unicellular Dictyostelium discoideum
and neutrophils, both of which are
able to navigate along shallow
chemoattractant gradients (Van
Haastert & Devreotes 2004). In the
case of neutrophils, chemotaxis
allows the cell to reach the infected/
colonized area, in order to effect
phagocytosis and subsequent
destruction of the microorganisms
by reactive oxygen species (ROS)
and proteolytic enzymes, within the
safe confines of the phagolysosome
(Cooper et al. 2013). A number of
interacting processes must occur for
effective, coordinated cell move-
ment, including recognition of the
chemoattractant, internal signalling
to reach the cells motility centre
and gradient detection to influence
movement in a persistent direction
(Kolaczkowska & Kubes 2013).
Chemoattractant binding induces
polymerization of F-actin, the for-
mation of new pseudopods at the
leading edge and retraction at the
posterior edge of the cell (Andrew
& Insall 2007). In the absence of
chemoattractants, these protrusions
occur randomly at all edges of the
cell. However, when a chemoattrac-
tant is detected, the protrusions are
directed towards the source of the
chemoattractant, determining the
direction of migration (Andrew &
Insall 2007).
To recognize the chemoattractant
signal, neutrophils employ a number
of receptors that are members of the
transmembrane G-protein-coupled
receptor (GPCR) family, activation
of which triggers various signalling
cascades that enable movement in a
direction-specific manner. Both exog-
enous agents, such as bacteria-
derived products, and endogenous
factors, such as chemokines, activate
respective GPCRs resulting in inter-
nalization, chemokine degradation
and receptor recycling back to the
cell membrane (Samanta et al. 1990).
Downstream signalling (Fig. 1)
results in the activation of the cyto-
skeleton in order for the cell to
move. Receptor–ligand binding of
chemoattractants results in the acti-
vation of phosphatidylinositol 30-
kinases (PI3Ks), protein kinases C
(PKCs), tyrosine kinases, mitogen-
activated protein kinases (MAPKs)
and GTP binding proteins (Worthen
et al. 1994). GPCR stimulation also
induces intracellular calcium release
via the inositol triphosphate and
ryanodine receptors, which has been
shown to be important for cellular
chemotaxis (Berridge et al. 2003).
Another receptor, activating intracel-
lular calcium stores in neutrophils,
stimulated by fMLP is the CD38
membrane glycoprotein (Partida-
Sanchez et al. 2001). Intracellular
calcium is released via the ryanodine
receptor as a result of CD38 binding
(Kurihara et al. 1993), and PI3K
catalyses the formation of phosphati-
dylinositol 3,4,5-triphosphate (PIP3)
Fig. 1. Neutrophil recruitment to inflamed periodontal tissues. (a) The plaque biofilm
is formed of diverse species of bacteria. (b) During infection, bacteria and their prod-
ucts penetrate the tissues surrounding the tooth and bacterial degradation products,
such as fMLP, are released. fMLP is a potent chemoattractant. (c) After exposure to
bacteria, resident macrophages and epithelial cells secrete CXCL8, another potent
chemoattractant. (d) CXCL8 and fMLP attract circulating neutrophils, which leave
the blood supply and enter the tissues to combat bacterial invasion. (e) Schematic rep-
resentation of signalling events downstream of chemoattractant–receptor ligation.
Upon binding to GPCR G-proteins dissociate and activate various proteins eventually
resulting in movement of the cell via actin polymerization. Abbreviations: fMLP, for-
myl-methionyl-leucyl-phenylalanine; CXCL8, interleukin-8; PIP3, phosphatidylinositol
3,4,5-triphosphate; PIP2, phosphatidylinositol 4,5-biphosphate; PI3K, Phosphatidyl-
inositol 3-kinase; PAK, p21-activated kinase; Prex, phosphatidylinositol-3,4,5-trisphos-
phate-dependent Rac exchange factor; RyR, ryanodine receptor located on
intracellular calcium stores (e.g. endoplasmic reticulum); PLC, phospholipase C; PKC,
protein kinase C; PTEN, phosphatase and tensin homologue.
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from phosphatidylinositol 4,5-bi-
phosphate (PIP2). PIP3 acts as a sec-
ond messenger controlling cell
adhesion and cytoskeletal reorgani-
zation (Toker & Cantley 1997). In a
cell, responding to a chemoattractant
PIP3 is found at the leading edge of
the cell (Bagorda & Parent 2008).
Downstream of receptor signalling
the MAPK signalling pathway is
also activated (Tsai et al. 2013). At
the lagging end of the cell, retraction
of the cell membrane is mediated by
the phosphatase and tensin homo-
logue (PTEN).
In addition to being a powerful
microbicidal weapon employed by
neutrophils, reactive oxygen species
(ROS) produced by NADPH oxid-
ases are also generated by chemo-
attractant stimulation and have
been shown to play a role in signal
transduction of cell movement
(Dickinson & Chang 2011). Sakai
et al. 2012 demonstrated that ROS
produced by NADPH oxidase
activity could regulate pseudopod
formation and chemotactic migra-
tion in neutrophils via actin glu-
tathionylation and polymerization.
They also showed that inhibition of
NADPH oxidase-dependent ROS
formation within healthy neutroph-
ils led to diminished chemotaxis
efficiency when exposed to a
chemoattractive gradient. Hydrogen
peroxide, a membrane-permeable
ROS, was able to direct cell move-
ment in a gradient-driven manner
(Niethammer et al. 2009), a finding
supported by another study in
which ROS were found to deacti-
vate PTEN resulting in the build-
up of PIP3 at the leading edge of
the migrating cell, necessary for
chemotaxis (Kuiper et al. 2011).
Defective neutrophil chemotaxis
features in several diseases including
actin dysfunction syndrome, Chedi-
ak–Higashi syndrome, Crohn’s dis-
ease and localized aggressive
periodontitis (LAP) (Lakshman &
Finn 2001). Although some studies
have been published on neutrophil
migratory behaviour in periodontitis
(Clark et al. 1977, Van Dyke et al.
1980, Daniel et al. 1993), very few
have been dedicated to the study of
chronic periodontitis. In LAP, previ-
ously known as localized juvenile
periodontitis (LJP) (Kantarci et al.
2003), a significant number (65–
75%) of LAP sufferers have been
shown to exhibit defective neutrophil
chemotaxis (Lavine et al. 1979, Van
Dyke et al. 1980, 1987, Page et al.
1985). Chemotaxis studies using
Boyden chambers have reported
impairment of neutrophil movement
in chronic periodontitis relative to
control subjects (Kumar & Prakash
2012). However, there is no informa-
tion on visualization of chemotaxis
in patients with chronic periodonti-
tis; this measures the cell migration
path in more detail, recording the
direction, speed, velocity and mor-
phology of the cells undergoing che-
motaxis (Sackmann et al. 2014).
We have previously shown that
peripheral blood neutrophils isolated
from patients with chronic periodon-
titis display both a hyperactive phe-
notype (i.e. excess ROS production
when unstimulated) and a hyperreac-
tive phenotype (i.e. excess ROS pro-
duction upon stimulation) relative to
age- and gender-matched controls
(Matthews et al. 2007a,b). Here, in
order to expand on these findings
and to evaluate neutrophil chemo-
taxis, we characterize the chemotac-
tic response of peripheral neutrophils
from patients with chronic periodon-
titis, compared with age- and gen-
der-matched controls, prior to and
following non-surgical periodontal
therapy using advanced time-lapse
microscopy techniques developed to
study neutrophil movement in shal-
low chemoattractant gradients.
Materials and Methods
Study populations
Thirty-six volunteers were enrolled
into this intervention study, including
18 with chronic mild–moderate peri-
odontitis (eight females; 10 males;
age mean  standard deviation
46  7 years) and 18 gender- and
age-matched periodontally healthy
controls (46  8 years). All volun-
teers were never smokers and other-
wise in good general health, as
confirmed by a detailed medical his-
tory questionnaire. Chronic peri-
odontitis was defined as the presence
of at least two non-adjacent sites per
quadrant with probing pocket depths
>4 mm, which bled on probing and
which demonstrated radiographic
bone loss ≥30% of the root length
(non-first molar or incisor sites)
(Matthews et al. 2007a). Control
patients had no evidence of attach-
ment loss, no probing pocket depths
>4 mm and whole-mouth bleeding
scores <10%. Inclusion criteria were
the complete absence of vitamin sup-
plements, no use of anti-inflamma-
tory or antibiotic medication in the
previous 3 months, no pregnancy,
mouthwash use or special dietary
needs (Brock et al. 2004). All volun-
teers provided written informed con-
sent, and ethical approval for the
study was obtained from the West
Midlands Research Ethics Commit-
tee (number 10/H1208/48). After
enrolment, all volunteers were re-
appointed for collection of baseline
blood samples and clinical measures.
Patients received oral hygiene
instruction and conventional non-
surgical therapy, in the form of scal-
ing and root surface debridement
(RSD), performed under local anaes-
thesia on a quadrant-by-quadrant
basis within a maximum of 4 weeks.
Patients were recalled 3-months post-
therapy to provide a repeat blood
sample and clinical measures. A 3-
month recall was chosen to allow for
initial healing and to reduce the risk
of re-infection/disease re-activation
(Chapple et al. 2007a,b). Neutrophil
isolation and chemotaxis data were
obtained for volunteers following
treatment along with their matched
healthy controls. Clinical data for the
patients with periodontitis pre- and
post-treatment and for the healthy
volunteers is shown in Table 1.
Collection of blood and preparation of
neutrophils
Venous blood was collected from the
ante-cubital fossa into Vacutain-
erTM lithium heparin (17 IU/ml)
tubes, and neutrophils were isolated
using Percoll density gradients (GE
Healthcare) as previously described
(Matthews et al. 2007a). Briefly, two
discontinuous gradients, 1.079 and
1.098, were used for neutrophil isola-
tion with concomitant erythrocyte
lysis (0.83% NH4Cl containing 1%
KHCO3, 0.04% EDTA and 0.25%
BSA). Isolated cells were re-sus-
pended in PBS supplemented with
glucose (1 mM) and cations (1 mM
MgCl2, 1.5 mM CaCl2) at 1 9 10
6
cells/ml. Cell viability, typically
>98%, was determined by dye
exclusion (trypan blue). Cell purity
was determined by cytospin and
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fluorescence-activated cell sorting
(FACS) using CD15 and CD66 neu-
trophil surface markers.
Chemotaxis protocol
The Insall chamber was used to visu-
alize chemotaxis (Muinonen-Martin
et al. 2010). For each sample, iso-
lated neutrophils (400 ll in RPMI,
final density 1 9 106/ml) were added
to acid washed (0.2 M HCl), dried
and blocked (7.5%, BSA 400 ll,
Sigma) coverslips (22 mm, VWR
International), which were then incu-
bated at room temperature (approxi-
mately 23°C) for 30 min. to allow
the cells to adhere. The coverslip
was then inverted and placed at the
top of the chemotaxis chamber
ensuring that the chemoattractant
loading bays were exposed (Fig. 2).
The desired chemoattractant (80 µl,
fMLP (10 nM) or CXCL8 (used at
200 ng/ml after assessing a range of
concentrations) or control (RPMI
media) was injected into the chemo-
attractant channels. Cell movement
was analysed using a Zeiss Primovert
microscope (Carl Zeiss Imaging,
Thornwood, NY, USA) and Images
captured every 30 s for up to 40
frames per condition using a Q
Imaging Retiga 2000R camera
(Qimaging, Surry, Canada).
Image analysis
The images generated by video
microscopy were processed using Q
pro-imaging software (Surrey, Can-
ada) and analysed further using Ima-
geJ 1.45SR software (National
Institutes of Health, Bethesda,
USA). The manual tracking plug-in
(MtrackJ) was employed, and for
each set of images, 15 cells were cho-
sen at random and tracked through
the frames. The numerical data gen-
erated was used to calculate cell
speed, cell velocity and chemotactic
index (CI) per experiment. The
numerical data generated were then
used to calculate cell migration,
which was defined as follows:
1 Cell speed: the average speed of a
cell in any direction over the time
course.
2 Cell velocity: the average speed of
a cell in its most prominent direc-
tion over the time course.
3 Chemotactic Index: this is a mea-
sure of the directional accuracy of
chemotaxis. It is calculated as a
change in the angle of a cell along
the Y axis according to the cosine
plot (Andrew & Insall 2007).
Statistical analysis
XY coordinates of the cells were gen-
erated using the Manual tracking Plu-
gin and ImageJ software (Rasband,
W.S., ImageJ, U. S. National Insti-
tutes of Health, Bethesda, MD, USA)
and these were further analysed with
the circular statistics (CircStat) tool-
box from MATLAB (Mathworks,
Natick, MA, USA) software to ascer-
tain the significance of the cells’
movement over the time course. The
CircStat toolbox provides statistics
for directional data, including the
mean direction, known as the resul-
tant vector, the length of which indi-
cates the strength of the direction
taken by the cells. Results are repre-
sented as circular diagrams. Two rep-
resentations are shown (Figs 3 and
4): (1) resultant vector plots showing
the distribution of the final angle of
all cells in the experiment with a vec-
tor line showing the mean angle and
vector length, illustrating the strength
of the movement; and (2) rose plots
showing the proportion of cells in each
Table 1. Age, probing pocket depths, number of sites >4 mm, percentage sites with bleeding on probing, and gingival and plaque indices of
patient and healthy control volunteers
Patients with chronic periodontitis Healthy controls (n = 18)
Pre-treatment (n = 18) Post-treatment (n = 16)
Probing pocket depths (mean  SD) 3.0  0.9 (p < 0.001)* 2.2  0.6 (p < 0.001)# 1.6  0.4
Probing pocket depths >4 mm (median; range) 26.5 (5–91) (p < 0.001)* 7.5 (0–52) (p < 0.01)# 0 (0–4)
% bleeding on probing (median; range) 41.5 (16–87) (p < 0.001)* 14 (3–35) (p < 0.001)# 1.5 (0–39)
Gingival index (median; range) 2 (1–3) (p < 0.001)* 1 (0–1) (p < 0.01)# 1 (0–1)
Plaque index (median; range) 2 (1–3) (p < 0.01)* 1 (0–2) (p < 0.01)# 1 (0–2)
*p values in parenthesis are comparisons with controls.
#p values in parenthesis are comparisons with chronic periodontitis before treatment.
Fig. 2. Photograph of the Insall chamber. Large square illustrates position of the cov-
erslip with adhered neutrophils. Arrows show the application of the chemoattractant.
Small red rectangle shows the area visualized by video microscopy.
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of 18 segments around the circle, the
larger the bar the greater proportion
of cells that moved in that direction.
Data were further summarized in box
and whisker plots, and statistical
analysis of these was performed by
Wilcoxon test using Prism 5.0 software
(GraphPad, San Diego, California
USA). Volunteer age was compared
by paired t-test and probing pocket
depths by repeated measures ANOVA
followed by Tukey–Kramer multiple
comparisons test. The number of
probing pocket depths >4 mm, per-
centage bleeding on probing, and gin-
gival and plaque indices were
compared using Friedman test fol-
lowed by Dunn’s multiple compari-
sons test.
Results
Clinical findings for patients and
their matched controls, pre- and
post-treatment, are shown in
Table 1. Figures 3 and 4 depict sum-
maries of all the data collected pre-
or post treatment, respectively. Each
dataset comprises three graphs: the
top image is a “spider plot” of indi-
vidual cell movement tracks towards
the “12.00 o’clock” position; the
lower left image is a rose plot that
clusters groups of cells according to
their direction of movement; and the
lower right image is a vector plot
that indicates the strength and angle
of movement. It is clear to see the
difference in the strength of the two
chemoattractants CXCL8 and
fMLP, with fMLP producing the
strongest response evidenced by
longer cell tracks in the spider dia-
grams. The control-treated cells
(RPMI), as anticipated, show very
little movement and no obvious
directionality of movement.
Statistical analyses of these data
(Figs 5 and 6) demonstrate that
before treatment, neutrophils from
patients with periodontitis have sig-
nificantly lower speed, velocity and
directional accuracy (chemotactic
index and resultant vector length)
than neutrophils from healthy con-
trols for both chemoattractants,
CXCL8 and fMLP. Following treat-
ment, they still display significantly
reduced speed, velocity and accu-
racy than neutrophils from healthy
Fig. 3. Summary of Pre-treatment results: arrows denote the origin of the chemoattractant, cells should be attracted towards the
arrow; spider diagrams show movement of all cells (um) from place of origin; left hand side vector plots show the proportion of
cells in each segment and the angle of the segment towards the arrow; right hand side rose plots show the strength of movement
and its directionality for the whole cohort of cells, the small red line shows the vector and the bounding dashed lines show the vari-
ation within the data. All diagrams are represented at the same scale to aid comparison.
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control volunteers for fMLP; how-
ever, with the exception of speed,
the neutrophils from patients with
periodontitis were not significantly
different in their response to
CXCL8 following therapy, in com-
parison to neutrophils from healthy
volunteers. Patient and control pre-
and post-treatment results were
analysed separately because of the
high inter-individual variation that
arises when neutrophils are analysed
on different days. Therefore, patient
and control cells were analysed syn-
chronously at both baseline and
then again simultaneously following
therapy, but no attempt was made
to compare patients’ cells pre- and
post-treatment (or controls).
Discussion
This study has demonstrated for the
first time that neutrophils from
patients with chronic periodontitis
exhibit reduced chemotactic accuracy
compared to gender- and age-
matched controls. Patient neutroph-
ils were less responsive to the widely
used chemoattractants fMLP and
CXCL8 with regard to chemokinesis
and chemotaxis when compared to
respective controls.
Direct visualization chambers,
including the Zigmond, Dunn and
the Insall chambers (the latter was
used in this study) allow cells to be
observed migrating using time-lapse
video microscopy in real time (Wells
2000). Bridge chambers provide a
visualization platform for observing
the behaviour of cells between two
wells. These chambers provide gradi-
ents for the cells to accelerate
towards rather than exposure to
absolute concentrations alone. The
majority of studies examining the
defects in neutrophil chemotaxis
over the last 30 years used the
Boyden chamber (and its derivatives)
to study chemotaxis (Clark et al.
1977, Van Dyke et al. 1980, 1987,
Offenbacher et al. 1987, Daniel et al.
1993, Yagi et al. 2009). Other studies
(Henry et al. 1984) employed the
checkerboard assay described by
Zigmond & Hirsch (1973). The use
of the Insall chamber has recently
expanded (Phillips & Gomer 2012,
Choi et al. 2013, Herlihy et al.
2013a,b, Kaul et al. 2013) and
opened up new research questions,
which informed the present study.
Here, we report on speed, velocity
and chemotactic accuracy. Chemo-
tactic accuracy has been expressed as
both chemotactic index (Sapey et al.
2011) and as resultant vector analy-
sis (Andrew & Insall 2007); however,
here, we have demonstrated that
these two factors are interchangeable
(Fig. S1, Bland-Altman analysis).
Although there are few studies
examining chemotaxis in chronic
periodontitis (Kumar & Prakash
Fig. 4. Summary of post-treatment results. The diagrams illustrate three plots per condition, as described in Fig. 3.
© 2014 The Authors Journal of Clinical Periodontology Published by John Wiley & Sons Ltd
6 Roberts et al.
2012), there is a wealth of data con-
cerning chemotaxis in patients with
localized aggressive periodontitis
(LAP). It is important to note that
LAP is distinctly different from
chronic periodontitis as it occurs in
otherwise systemically healthy ado-
lescents; the bacteria that colonize
the oral tissues in these individuals
are different in composition to
chronic periodontitis; and there is a
strong genetic pre-disposition to the
disease (Fu et al. 2002, Nibali et al.
2008). Defective LAP neutrophils,
however, offer an attractive platform
to better understand and character-
ize defects in the ability of neutroph-
ils to chemotax and the mechanism
of neutrophil movement in response
to stimuli presented as chemical gra-
dients. LAP is the best-characterized
periodontal disease showing
impaired neutrophil function.
Whether there is cross-correlation
between neutrophil abnormalities in
patients with chronic periodontitis
and patients with LAP remains to be
elucidated.
We have previously reported that
peripheral blood neutrophils from
patients with chronic periodontitis
are both hyperactive and hyperreac-
tive with respect to ROS generation
(Matthews et al. 2007a,b) and that
potential stimulants of these
responses within plasma include
GM-CSF, CXCL8 and interferon-a
(IFN-a) (Dias et al. 2011). IFN-a is
also capable of priming neutrophils
within the circulation of patients with
periodontitis and demonstrates ele-
vated plasma levels, consistent with
reported IFN-a responsive gene
expression profile in neutrophils from
patients with periodontitis (Wright
et al. 2008). However, an element of
ROS hyperactivity in periodontitis
neutrophils appears to be constitutive
(an innate property), and this may be
due to an altered intracellular redox
state in neutrophils from patients
with periodontitis (Dias et al. 2013).
Additionally, Porphyromonas gingiva-
lis-derived gingipains can cleave
CXCL8, potentially impacting upon
ROS production and chemotaxis
(Dias et al. 2008). This may be one
plausible explanation why, in the
present study, we observed a normali-
zation of patient neutrophil responses
to CXCL8 following successful treat-
ment, but not for fMLP. Of the vari-
ous neutrophil chemoattractants
reported in the literature, a number of
the host-derived chemoattractants
demonstrated a similar pattern of
activity to IL-8. We found similar
results to IL-8 for GM-CSF and mac-
rophage inhibitory protein 1alpha
(MIP1a) (data not shown) whose
receptors are all G-protein-coupled
receptor linked. The enhanced ROS
generation we have reported previ-
ously and the defective chemotactic
accuracy observed in this study of
patients with chronic periodontitis
have also been shown in individuals
with other inflammatory-driven
Fig. 5. Analysis of pre-treatment results: extracted values for each individual’s speed, velocity, chemotactic index and resultant vec-
tor length were analysed for statistical difference (Wilcoxon test). The midline of each box represents median, bounding box the
25th and 75th percentiles and the whiskers the extremities of the data sets.
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diseases, such as rheumatoid arthritis
(RA) (Biemond et al. 1986, Miesel
et al. 1996, Bostan et al. 2002, Ceder-
gren et al. 2007) and chronic obstruc-
tive pulmonary disease (COPD)
(Rahman et al. 1997, Yoshikawa
et al. 2007; Sapey at al. 2011).
Information on the mechanisms
underlying altered neutrophil chemo-
taxis in LAP neutrophils may help in
understanding aberrant chemotaxis
in chronic periodontitis neutrophils.
Several studies have reported a
diminished capacity of labelled fMLP
to bind to neutrophils in individuals
with LAP, indicating a reduction in
the number of peptide binding sites
on the surface of LAP neutrophils,
though the receptors themselves
appear to be functional (Van Dyke
et al. 1981, 1986). This would explain
the diminished responsiveness of
these neutrophils to a chemoattrac-
tive gradient. Defective LAP neu-
trophils also express lower levels of
the surface glycoprotein gp110
(ADRM1 or hRpn13) (Van Dyke
et al. 1987, 1990); the significance of
this receptor was demonstrated by
use of the monoclonal antibody to
GP110 called NCD-1, which dimin-
ished chemotaxis in healthy neu-
trophils when exposed to fMLP
(Cotter et al. 1981). LAP-defective
neutrophils also have a reduced
expression of CD38, another receptor
for the chemoattractant fMLP (Fujita
et al. 2005).
Chemoattractant–receptor bind-
ing results in the activation of
numerous signalling pathways,
including PI3K, which in turn medi-
ates the activity of phosphoinositide
dependent kinase 1 (PDK1), which
has been shown to be an essential
regulator of neutrophil chemotaxis
(Fig. 1). A study by Yagi et al.
(2009) demonstrated that neutrophils
from LAP patients had reduced
PDK-1 expression and activity.
Proteomic analysis of defective LAP
neutrophils revealed upregulation of
four proteins, of which the actin
binding protein caldesmon was con-
sidered the most significant and it
was suggested that an increase in
expression of this protein within the
cell may suppress motility by stabi-
lizing actin filaments (Mizuno et al.
2011). Other findings in defective
neutrophils include reduced influx of
extracellular calcium, lower calcium-
dependent PKC activity in unstimu-
lated defective LAP neutrophils,
accumulation of diacylglycerol
(DAG) and reduced DAG kinase
activity in defective LAP neutrophils
compared to healthy matched con-
trols (Agarwal et al. 1989, Tyagi
et al. 1992, Kurihara et al. 1993).
DAG is an activator of PKC, func-
tioning as a second messenger in a
variety of cell functions including
superoxide production and chemo-
taxis (Nishizuka 1986, Harvath et al.
Fig. 6. Analysis of post-treatment results: as described in Fig. 5.
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1987, Lambeth 1988). Elevated
DAG levels in abnormal LAP neu-
trophils support these neutrophils
being kept in a primed state for acti-
vation. The actin polymerization and
depolymerization in LAP individuals
was found to be normal, supporting
studies that show defects in the
chemotaxis signalling cascade
(Champagne et al. 1998). There is
limited data in the literature on che-
motaxis in neutrophils derived from
patients with CP and all the above
factors need to be analysed in
patients with chronic periodontitis,
such that we can further understand
the altered processes in neutrophil
chemotaxis in this disease. Indeed, it
is interesting to speculate that such
neutrophil deficiencies may represent
a common mechanistic link between
the different clinical definitions of
periodontitis (e.g. LAP and CP).
Neutrophils are one of the key
cells involved in protecting the host
from bacterial challenge. Disruption
to neutrophil functions such as che-
motaxis may pre-dispose the individ-
ual to further infection and
inflammation, exacerbating disease
pathogenesis. Impaired neutrophil
function impacts strongly on the
ability of an individual to cope with
microbial challenge as in periodonti-
tis. Reduced neutrophil chemotactic
accuracy and velocity may affect the
transit time of neutrophils that have
exited the circulation to reach the
site of infection, potentially allowing
bacteria to establish themselves in
the periodontal tissues with greater
potency. Collateral tissue damage
may also arise as a result of pro-
longed tissue transit times secondary
to defective chemotaxis, thus con-
tributing to the chronic inflamma-
tory burden.
In conclusion, we have demon-
strated for the first time that neu-
trophils from patients with chronic
periodontitis have reduced speed,
velocity and chemotactic accuracy.
Anti-infective treatment partially
restores velocity and speed of neu-
trophil movement towards CXCL8
to control levels following periodon-
tal therapy, but not for fMLP.
Coupled with our previous knowl-
edge that neutrophils from patients
with periodontitis are both hyperac-
tive and hyperreactive with respect
to extracellular ROS production,
which may drive increased tissue
destruction, these findings may help
to understand the potential role of
dysfunctional neutrophils in the
pathogenesis of periodontitis.
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Clinical Relevance
Scientific rationale for the study:
Neutrophils are the predominant
cell in the periodontal tissues. They
are essential for clearance of bacte-
ria but can also elicit host damage
by inaccurately targeted responses.
Movement of neutrophils to the epi-
thelial surface requires degradation
of tissue. Inaccurate movement can
exacerbate tissue destruction.
Principal findings: Neutrophils from
patients with chronic periodontitis
display aberrant neutrophil move-
ment that is only partially restored
to healthy levels upon treatment.
Practical implications: Understand-
ing sustained atypical neutrophil
behaviour in periodontitis may
help in the development of new
therapeutic approaches.
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Harpagophytum, Devil’s Claw, is a genus of tuberiferous xerophytic plants native to southernAfrica. Some of the taxa are appreciated
for their medicinal effects and have been traditionally used to relieve symptoms of inflammation. The objectives of this pilot study
were to investigate the antioxidant capacity and the content of total phenols, verbascoside, isoverbascoside, and selected iridoids,
as well as to investigate the capacity of various Harpagophytum taxa in suppressing respiratory burst in terms of reactive oxygen
species produced by human neutrophils challenged with phorbol myristate acetate (PMA), opsonised Staphylococcus aureus, and
Fusobacterium nucleatum. Harpagophytum plants were classified into different taxa according to morphology, and DNA analysis
was used to confirm the classification. A putative new variety ofH. procumbens showed the highest degree of antioxidative capacity.
Using PMA, three Harpagophytum taxa showed anti-inflammatory effects with regard to the PBS control. A putative hybrid
between H. procumbens and H. zeyheri in contrast showed proinflammatory effect on the response of neutrophils to F. nucleatum
in comparison with treatment with vehicle control. Harpagophytum taxa were biochemically very variable and the response in
suppressing respiratory burst differed. Further studies with larger number of subjects are needed to corroborate anti-inflammatory
effects of different taxa of Harpagophytum.
1. Introduction
Many diseases have an inflammatory pathogenesis and a
large number of plant species have for centuries been uti-
lized for their anti-inflammatory and healing effects. The
medicinal tuberiferous xerophyte Devil’s Claw (Harpago-
phytum) belongs to the family Pedaliaceae and is native
to southern Africa [1]. This genus includes two species:
Harpagophytum procumbens and H. zeyheri. There are also
a few known subspecies of both species, as well as novel
and hybrid taxa with less clear identity. Extracts made from
the tubers of H. procumbens are known to relieve symptoms
of inflammation and pain [2, 3] but there has been some
argument about whether medicinal properties of H. zeyheri
are sufficient for the acceptance of this species for use in
anti-inflammatory preparations [4–6]. The pharmacological
actions of Devil’s Claw root tubers have been attributed to
the presence of iridoid glycosides and verbascoside [4, 7,
8]. Studies have demonstrated anti-inflammatory properties
such as inhibition of COX-2, inhibition of NF-kB activation,
and downregulation of iNOS [9–11]. However, the effects of
Devil’s Claw have also been associated with the presence of
other compounds such as flavonoids [11].
Neutrophil-mediated oxidant injury is a feature of many
inflammatory diseases [12, 13]. The initial response to infec-
tion is often mediated by neutrophils because of their rapid
chemotactic response towards bacteria [14]. Neutrophils
inhibit infection activity by ingestion of microorganisms,
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synthesis of reactive oxygen species (ROS), and release of
cytokines. Neutrophils are important in both the innate
and the acquired immune responses and microorganisms
are recognized through receptor-mediated mechanisms, for
example, by the antibody-antigen complex mediated Fc
receptor (FcR) and bacterial product mediated Toll-like
receptors (TLR) [15, 16]. These receptors represent specific,
adaptive immune responses and nonspecific, innate immune
responses, respectively, and activate intracellular signal trans-
duction such as protein kinase C, MAPK cascades, and the
NADPH-oxidase enzyme complex [17].TheNADPH-oxidase
enzyme complex produces ROS at the expense of NADPH.
In resting cells from healthy donors little ROS is produced,
limiting potential bystander damage to adjacent tissues.Upon
stimulation ROS are produced in the local environment
where they react rapidly with proximal molecules. In chronic
inflammatory disease, such as severe gum disease (periodon-
titis), both resting and stimulated neutrophils are hyperac-
tive [18]. Therapeutic strategies are continuously sought to
decrease these characteristics and prevent excessive collateral
tissue damage in infectious situations without preventing
the primary infection fighting capacity. Neutrophils may
therefore be used as a model to explore mechanisms and
possible therapeutic modulation of inflammation.
The specific objective of this paper was (1) to identify and
to select genetically diverse Harpagophytum plant material
that adequately represents the pharmacological capability of
the genus and (2) to determine the potential of root tuber
ethanol extracts of various taxa to suppress the production of
ROS in human neutrophils. We also investigated the antiox-
idant capacity and the content of ascorbate, verbascoside,
isoverbascoside, major iridoids, and total phenols in the
extracts.
2. Materials and Methods
2.1. DNA Studies and Plant Material Selection. Seed capsules
(for taxonomic and DNA-based species determination) and
secondary root tubers (for analysis of chemical content and in
vitro studies) of 24 Harpagophytum accessions were sampled
in Botswana (Table 1, Figure 1).
To select genetically diverse samples and to corroborate
the taxonomical classification based on morphological char-
acters DNA analyses were performed. One seed capsule was
collected from each of the Harpagophytum accessions; seeds
were germinated and one seedling per accession was used for
extraction of DNA. DNA was extracted with the E.Z.N.A.
SPDNAmini kit (OmegaBio-Tek,Norcross,GA,USA).DNA
quality was determined in 2% agarose gel. The DNA samples
were analyzed with 2 inter-simple sequence repeat (ISSR)
and 6 random amplified polymorphicDNA (RAPD) primers,
using previously described methodology [19]. RAPD and
ISSR bands were scored as present or absent, and a total of
107 polymorphic DNA bands were obtained. Based on the
DNA studies 6 accessions representing 5 taxa were selected
for use in the subsequent neutrophil and biochemical study:
H. procumbens ssp. transvaalense (Accession 17; O1APT),
a putative new variety of H. procumbens ssp. transvaalense
0 100
(km)
N
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Kumakwane (Accessions 3–5)
Leshibitse (Accession 6)
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Figure 1: Sampling sites in Botswana for accessions used in theDNA
marker, biochemical and neutrophil studies.
(Accession 3; K1APN), H. zeyheri ssp. zeyheri (Accession
24; T1AZZ), and H. zeyheri ssp. sublobatum (Accession 14;
MP3AZS) and two samples with unclear taxonomic identity
but most likely interspecific hybrids between H. procumbens
and H. zeyheri (Accession 16; O1APH and Accession 11;
MP1APH) according to morphological characters of the
tuber-bearing plants [20].
2.2. Root Sample Preparation. Samples of the root tuberswere
obtained by sectioning the specimen into halves, and the peel
and pulp were separated, weighed, and freeze-dried at the
Department of Plant Breeding, Balsga˚rd, Swedish University
of Agricultural Sciences. Vacuum was applied at <0.2mbar
and the condenser temperature was set at −70∘C during
the freeze-drying process. The initial temperature of the
sample tray was −5∘C, and after 16 h a temperature gradient
was applied from −35∘C to 10∘C. The temperature was then
maintained at 10∘Cuntil the extracts were completely dry.The
dry extracts were ground to a fine powder in a laboratorymill
(Yellow line, A10, IKA-Werke, Staufen, Germany).
2.3. Extract Preparation. Extracts were made fresh before
each experiment by adding 1mL of 50% ethanol containing
0.05M H
3
PO
4
to 250 𝜇g (for in vitro studies) or 50mg (for
biochemical studies) of finely ground Harpagophytum tuber
powder. The extracts were kept in an ultrasonic bath for
15min before centrifugation at 16000 g for 10min and the
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Table 1: Accessions of Harpagophytum subjected to DNA analysis.
Accession Taxon Location
(1) B1AZZ H. zeyheri ssp. zeyheri Bela-Bela (24∘30.7󸀠S, 26∘2.27󸀠E) introgression zone
(2) B1APH Putative hybrid (between H. procumbens and H.zeyheri) Bela-Bela (24
∘30.7󸀠S, 26∘2.27󸀠E) introgression zone
(3) K1APN∗ Putative new variety of H. procumbens ssp.transvaalense Kumakwane (24
∘37.9󸀠S, 25∘41.1󸀠E) introgression zone
(4) K1APH Putative hybrid (between H. procumbens and H.zeyheri) Kumakwane (24
∘37.9󸀠S, 25∘41.1󸀠E) introgression zone
(5) K1AZZ H. zeyheri ssp. zeyheri Kumakwane (24∘37.9󸀠S, 25∘41.1󸀠E) introgression zone
(6) L1APT H. procumbens ssp. transvaalense Leshibitse (24∘16.9󸀠S, 26∘9.41󸀠E) introgression zone
(7) ML1APN Putative new variety of H. procumbens ssp.transvaalense Malotwana (24
∘17.5󸀠S, 26∘09.27󸀠E) introgression zone
(8) ML1BPN Putative new variety of H. procumbens ssp.transvaalense Malotwana (24
∘17.5󸀠S, 26∘09.27󸀠E) introgression zone
(9) ML2APN Putative new variety of H. procumbens ssp.transvaalense Malotwana (24
∘17.5󸀠S, 26∘09.27󸀠E) introgression zone
(10) ML3APN Putative new variety of H. procumbens ssp.transvaalense Malotwana (24
∘17.5󸀠S, 26∘09.27󸀠E) introgression zone
(11) MP1APH∗ Putative hybrid (between H. procumbens and H.zeyheri)
Matlapaneng (19∘55.4󸀠S, 23∘32.9󸀠E) H. zeyheri ssp.
sublobatum allopatric zone
(12) MP1AZS H. zeyheri ssp. sublobatum Matlapaneng (19
∘55.4󸀠S, 23∘32.9󸀠E) H. zeyheri ssp.
sublobatum allopatric zone
(13) MP2AZS H. zeyheri ssp. sublobatum Matlapaneng (19
∘55.4󸀠S, 23∘32.9󸀠E) H. zeyheri ssp.
sublobatum allopatric zone
(14) MP3AZS∗ H. zeyheri ssp. sublobatum Matlapaneng (19
∘55.4󸀠S, 23∘32.9󸀠E) H. zeyheri ssp.
sublobatum allopatric zone
(15) MT1APT H. procumbens ssp. transvaalense Mmathethe H. procumbens ssp. transvaalense allopatriczone
(16) O1APH∗ Putative hybrid (between H. procumbens and H.zeyheri) Oodi (24
∘28.1󸀠S, 26∘2.83󸀠E) introgression zone
(17) O1APT∗ H. procumbens ssp. transvaalense Oodi (24∘28.1󸀠S, 26∘2.83󸀠E) introgression zone
(18) O2APT H. procumbens ssp. transvaalense Oodi (24∘28.1󸀠S, 26∘2.83󸀠E) introgression zone
(19) S1APP H. procumbens ssp. procumbens Sekoma (24
∘24.8󸀠S, 23∘47.8󸀠E) H. procumbens ssp.
procumbens allopatric zone
(20) S2APP H. procumbens ssp. procumbens Sekoma (24
∘24.8󸀠S, 23∘47.8󸀠E) H. procumbens ssp.
procumbens allopatric zone
(21) T1APT H. procumbens ssp. transvaalense Tlokweng (24∘37.8󸀠S, 25∘59.1󸀠E) introgression zone
(22) T1BPT H. procumbens ssp. transvaalense Tlokweng (24∘37.8󸀠S, 25∘59.1󸀠E) introgression zone
(23) T2APT H. procumbens ssp. transvaalense Tlokweng (24∘37.8󸀠S, 25∘59.1󸀠E) introgression zone
(24) T1AZZ∗ H. zeyheri ssp. zeyheri Tlokweng (24∘37.8󸀠S, 25∘59.1󸀠E) introgression zone
∗Accessions used in the neutrophil and biochemical study.
supernatant was collected. This resulted in a 100% stock with
a concentration of 250 𝜇g/mL. This stock was then diluted
(v/v) with phosphate-buffered saline (PBS) to produce final
concentrations of 50%, 10%, and 5%.
2.4. Determination of Total Phenolics. To measure the total
phenolic content according to the Folin-Ciocalteu method
[21] the sample was mixed with Folin-Ciocalteu reagent
(Merck, Darmstadt, Germany), H
2
O, and 15% Na
2
CO
3
and
the absorbance measured at 765 nm after 1 h incubation at
room temperature. Gallic acid was used as a standard and
the total content of phenols was expressed as mg gallic acid
equivalents (GAE) per g dry weight (dw). For comparison,
total phenolic content was analyzed also in commercially
obtained, external standards of 8-O-p-coumaroyl-harpagide,
harpagoside, and verbascoside.
2.5. Determination of Ferric Reducing Ability of Plasma. The
ferric reducing ability of plasma (FRAP) of the extracts was
measured according to the method developed by Benzie and
Strain [22] but modified to fit a 96-well format [23]. The
different extracts were diluted 20–100-fold. Ten 𝜇L of these
extracts was incubated at 37∘C and then mixed with 260𝜇L
of ferric-TPTZ reagent (prepared by mixing 300mM acetate
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buffer, pH 3.6; 10mM of 2,4,6-tripyridyl-s-triazine in 40mM
HCl; and 20mM FeCl
3
in the ratio of 4 : 1 : 1; the solution was
kept at 37∘C). The absorbance was measured at 595 nm after
4min on a plate reader (Sunrise, Tecan Nordic AB, Sweden).
Fe2+ was used as a standard and L-ascorbic acid was used
as a control where one mole of ascorbic acid corresponds
approximately to two moles of FRAP (we obtained the value
2.09).
2.6. HPLC Analysis of Ascorbate, Verbascoside, Isoverbasco-
side, and Iridoids. For ascorbate analysis samples were placed
in ultrasonic bath for 10min and centrifuged for 10min at
2000 g (Beckham, USA). The supernatant was filtered with
a syringe particle filter (glass/nylon 0.45𝜇m, 30mm Cameo,
Sorbent AB, Sweden) directly into anHPLC-vial.The analysis
was made on a Shimadzu HPLC system consisting of a
communication bus module (SCL 10A-VP) and a pump (LC
10AD) using an ACE (5𝜇m) for separation. For detection a
variable SPD-10A UV-VIS detector set to 254 nm was used.
The mobile phase consisted of a 50mM sodium phosphate
(Fluka, Switzerland) buffer set to pH 2.8. The flow rate
was 1mLmin−1 and 20𝜇L sample was injected into the
HPLC system. The peak was identified by retention time of
an ascorbate standard (Sigma-Aldrich, USA). Quantification
was carried by peak area.
Contents of verbascoside, isoverbascoside, and the iri-
doids acetylacteoside, 8-O-p-coumaroyl-harpagide, harpa-
goside, and pagoside were analyzed in Harpagophytum
extracts on a ShimadzuHPLC system equipped with a diode-
array detector according to a method slightly modified from
Karioti et al. [24]. The eluent consisted of solvent A (H
2
O
at pH 3.2 by formic acid) and solvent B (acetonitrile).
The binary gradient was as follows: 95% A (0–5min), 85%
A (5–8min), 76% A (8–15min), 75% A (15–19min), 73%
A (19–24min), 71% A (24–29min), and 50% A (29min).
A Phenomenex Synergi 4l Hydro-RP 80A column (250 ×
4.6mm) and a guard C18 precolumn were used. Evaluation
of data was carried out with Shimadzu Class-VP software
(version 6.13 SP2). Retention times and spectral data were
obtained and compared with those of the external standards
verbascoside, 8-O-p-coumaroyl-harpagide, and harpagoside.
The peaks of acetylacteoside, pagoside, and isoverbascoside
were verified by HPLC MS. Acetylacteoside and pagoside
were quantified against harpagoside, and isoverbascoside was
quantified against verbascoside. Detection was carried out
at 280 nm with a total run time of 35 minutes. Example
chromatograms of accessions are provided as Supplementary
Material (Supplementary File, Figure S1, available online at
http://dx.doi.org/10.1155/2016/3841803).
2.7. Collection of Venous Blood and Preparation of Neutrophils.
West Midlands Research Ethics Committee in Birmingham,
UK, in compliancewith theDeclaration ofHelsinki, approved
the study (Institutional Review Board approval number
10/H1208/48). The study was based on periodontally and
systemically healthy individual volunteers (𝑛 = 10; mean age:
29 years, range 21–61 years, all female) who consented to par-
ticipate in the study. Exclusion criteria included pregnancy,
use of nonsteroidal anti-inflammatory drugs, mouth-washes,
antimicrobial drugs, or vitamin supplements within the past
three months.
Venous blood was drawn from each participant. A dis-
continuous Percoll gradient (𝛿 = 1.079 : 1.098) was used to
isolate neutrophils, followed by erythrocyte lysis using a
solution containing 0.83%NH
4
Cl, 1% KHCO
3
, 0.04% EDTA,
and 0.25% bovine serum albumin (BSA) for 20 minutes.
Isolated cells were then washed and resuspended at 1 ×
106 cells/mL in solution grade phosphate-buffered saline
(GPBS) containing 1mM glucose and cations (1mM MgCl
2
and 1.5mM CaCl
2
). Trypan blue was used to determine cell
viability and only samples with more than 98% viability were
retained for further analysis.
2.8. Cell ViabilityAssay. Cell viabilitywasmeasured using the
CellTiter-Glo Reagent (Promega). The luciferase present in
the reagent uses luciferin, oxygen, and ATP as substrates in
a reaction that produces oxyluciferin and releases energy in
the form of light. Because the luciferase reaction requires
ATP, conditions have been created such that the amount
of light produced is proportional to the amount of ATP
present, reflecting the number of viable cells [25, 26]. 100 𝜇L
of neutrophils in GPBS (1 × 105 cells/mL) and 10𝜇L of PBS,
the vehicle control, or theHarpagophytum extracts (5%) were
added to preblocked (PBS containing 1% BSA overnight, 4∘C)
white microwells (Microlite 2, VWR, UK). The plate was
placed in the microplate reader and incubated at 30∘C for
30min before the addition of 100𝜇L of CellTiter-Glo to each
well.The contents of the wells weremixed and returned to the
plate reader before reading the luminescence levels at 10min.
2.9. Detection of Reactive Oxygen Species (ROS) by Chemi-
luminescence Assay. Chemiluminescence assays were per-
formed using luminol to detect total oxygen radical (HOCl
and H
2
O
2
) generation (intra- and extracellular) as described
in Matthews et al. [27]. All assays were performed at
37∘C using a Berthold microplate luminometer (LB96v).
Supplemented PBS (35 𝜇L, PBS supplemented with glucose,
Ca+, and Mg+) and luminol (30 𝜇L, 3mM) were added to
preblocked (PBS containing 1% BSA overnight, 4∘C) white
microwells (Microlite 2, VWR, UK). The plate was then
placed into the microplate reader and 100𝜇L of the isolated
neutrophils (1 × 105) was added to each well. Cells were
allowed to settle for 30min at 37∘C prior to priming by addi-
tion of the extracts (only 5%) or controls for 30min at 37∘C.
Neutrophils were then stimulated with either PMA (Phorbol
12-myristate 13-acetate, 25 nM), Fusobacterium nucleatum
(MOI 1 : 100), opsonised S. aureus (MOI 1 : 300), or PBS
(control). S. aureus (NCTC 6571) had been grown aerobically
on mannitol salt agar and inoculated into tryptone soy broth;
opsonised S. aureus was prepared according to Bergstro¨m
and A˚sman [28] and stored as cell suspension of 1.2 × 109
cells/mL at −80∘C. The anaerobic bacteria F. nucleatum (Fn;
ATCC 10953) were grown at 37∘C according to Roberts et
al. [29]. The bacteria were washed three times in sterile
PBS, heat-treated at 100∘C for 10min, and then diluted to a
suspension of 5 × 109 cells/mL and stored at −80∘C. PMAwas
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resuspended intoDMSOanddiluted in PBS. For each subject,
all samples were analyzed in triplicate and light emission
in relative light units (RLUs) was recorded throughout the
experiment.
2.10. Statistical Analysis. Based on the total of 107 poly-
morphic RAPD and ISSR bands, a matrix of standardized
covariates was calculated for the 24 samples (6 samples
investigated in this study and 18 control samples for taxo-
nomic classification) and used as input variable in a principal
component analysis (PCA) conducted with GenAlEx.
Associations between the content of chemical com-
pounds in the six chemically analyzed samples were similarly
investigated with PCA. Based on the scree-plot, three PCA
components were selected for illustration of between-sample
similarity. This analysis was performed using the Minitab 16
software (Minitab, State College, PA, USA).
Descriptive statistics for mean values and standard devi-
ations were calculated on data for the enhanced chemilumi-
nescence assays, and mean values, standardized to the total
relative light units (RLUs) for each test subject, respectively,
were compared using theWilcoxon signed-rank test. SPSS 20
for Windows was used for these calculations.
3. Results and Discussion
3.1. Accession Identification, Diversity, and Selection. The first
step in this investigation was to ascertain the taxonomic
identity of the selected plant material by DNA analysis of
seedlings from the field-collected seed capsules. The clus-
tering of the 24 studied accessions in a DNA marker-based
PCA (Figure 2) in general supported the morphology-based
species classification. Material from six of these accessions
(Table 2) was selected to determine the ability to suppress
respiratory burst in human neutrophils and to investigate
the antioxidant capacity and phenol content. The selected
samples of H. procumbens ssp. transvaalense (Accession 17;
O1APT) and of a putative new variety of H. procumbens
ssp. transvaalense (Accession 3; K1APN) grouped with other
H. procumbens accessions. Similarly, the two samples of H.
zeyheri ssp. zeyheri (Accession 24; T1AZZ) andH. zeyheri ssp.
sublobatum (Accession 14; MP3AZS), respectively, grouped
with other accessions ofH. zeyheri. One of the two samples of
putative interspecific hybrids (Accession 11; MP1APH) took
an intermediary position while the other sample (Accession
16; O1APH) showed somewhat stronger affinity to the H.
zeyheri accessions.
3.2. Content of Total Phenols. Using the Folin-Ciocalteu assay
the highest content of total phenols was found in the putative
new variety of H. procumbens (Accession 3, 28.9mg GAE/g
dw) and in H. zeyheri ssp. sublobatum (Accession 14, 25.1mg
GAE/g dw) whereas considerably lower content was revealed
for the other samples investigated (Table 2). The external
standards of harpagide, harpagoside, and verbascoside were
also subjected to this analysis. Low phenolic content was
identified for the iridoids and high phenolic content for the
verbascoside standard (Table 2).
Table 2: Content of total phenols (TP) and antioxidant capacity
(FRAP) of Harpagophytum extracts, presented as mean with stan-
dard deviation per dryweight (dw) of the plantmaterial (GAE: gallic
acid equivalents).
Accession
Total phenols
(mg GAE/g dw)
FRAP (𝜇mol
Fe2+/g dw)
Mean SD Mean SD
3 28.9 0.4 596.7 25.2
11 13.5 0.6 204.8 0.1
14 25.1 1.3 444.3 13.0
16 5.1 0.3 80.8 13.2
17 2.1 0.4 33.8 0.2
24 3.5 0.5 54.5 5.6
Standard: harpagide 16.7 1.1 149.2 0.0
Standard: harpagoside 0.0 0.0 612.3 3.2
Standard: verbascoside 359.9 9.8 5854.2 52.7
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Figure 2: Principal component analysis showing ISSR and RAPD
marker-based similarity between 24 Harpagophytum accessions
used in the DNA and neutrophil study (the 6 accessions within
circles). Samples are plotted on the first two components, explaining
29 and 13% of the total variation, respectively.The numbers indicate
accession codes, whereas the symbols for the taxa are abbreviated
as follows: PP: H. procumbens ssp. procumbens; PT: H. procumbens
ssp. transvaalense; PN: putative new variety of H. procumbens ssp.
transvaalense; ZS: H. zeyheri ssp. sublobatum; ZZ: H. zeyheri ssp.
zeyheri; HH: putative interspecific hybrids (betweenH. procumbens
and H. zeyheri).
3.3. Antioxidant Capacity of Harpagophytum Extracts: Ferric
Reducing Activity of Plasma (FRAP). Using the chemical
FRAP assay as a measure of antioxidant capacity, Accession
3 had the highest value (596.7 𝜇mol Fe2+/g dw), followed by
Accession 14 (444.3 𝜇mol Fe2+/g dw), and more than double
that of Accession 11 (204.8𝜇mol Fe2+/g dw) (Table 2).
The standards harpagide, harpagoside, and verbascoside
were also analyzed and verbascoside was the most potent
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Table 3: Composition of verbascosides and iridoids in each Harpagophytum tuber extract presented as mean value with standard deviation
(SD) as mg per g dry weight of the plant material.
Accession Verbascoside Isoverbascoside Acetylacteoside Pagoside Harpagoside
8-O-p-
Coumaroyl-harpagide
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
3 3.04 0.11 21.75 1.16 4.49 0.16 0.11 0.01 4.09 0.34 0.04 0.00
11 1.28 0.11 6.02 0.50 3.30 0.45 0.68 0.08 9.08 0.97 4.04 0.41
14 4.22 0.33 15.62 1.32 1.29 0.15 0.48 0.05 7.07 0.60 3.29 0.35
16 0.64 0.09 2.47 0.27 0.84 0.03 0.17 0.01 0.96 0.15 0.07 0.01
17 0.33 0.05 0.62 0.08 0.23 0.03 0.02 0.00 1.71 0.24 0.09 0.01
24 0.39 0.08 0.64 0.14 0.41 0.11 0.00 0.00 0.16 0.01 0.01 0.00
(5854.2𝜇mol Fe2+/g dw)with approximately 10× the capacity
of harpagoside and 40 × the capacity of harpagide (Table 2).
Thus, there was a very large difference among samples in
antioxidant capacity and also the antioxidant capacity of the
different standards varied largely.
3.4. Content of Verbascoside, Isoverbascoside, Iridoids, and
Ascorbate. The content of verbascoside was highest in Acces-
sion 14 (mean 4.2mg/g dw) followed by Accession 3 (mean
3.0mg/g dw) (Table 3). The content of isoverbascoside was
highest in Accession 3 (mean 21.8mg/g dw). Significant
amounts of harpagoside and 8-O-p-coumaroyl harpagide
were identified in Accession 11 as well as in Accession
14 (Table 3). The extracts from Accessions 16, 17, and 24
contained low levels of verbascoside, isoverbascoside, and
iridoid compounds. HPLC analysis revealed that there was
no ascorbate in the samples (Supplementary File, Figure S2).
Thus, the phytochemical analysis revealed substantial
differences in chemical composition between the analyzed
taxa but whether these differences are taxon-specific must
be ascertained in future studies using a much larger material
with several samples of each taxon.
3.5. Cell Viability Assay. Therewere no significant differences
among the effects of different extracts on neutrophil cell
viability, and none of the extracts showed lethal/suppressive
effects on neutrophils (Supplementary File, Figure S3).
3.6. Effect on Neutrophil Reactive Oxygen Species (ROS)
Production. To assess the effects of the extracts on neutrophil
ROS production, neutrophils from healthy volunteers were
preincubated with extracts (5% solutions, including 2.5%
ethanol) or controls (PBS or vehicle control 2.5% ethanol) for
30min prior to stimulation.
For unstimulated cells (PBS, Figure 3(a)), there were sig-
nificant differences in response among some of the samples.
Accession 3 responded significantly stronger (lower RLUs
recorded) than Accessions 16 (𝑝 = 0.028) and 24 (𝑝 = 0.037),
and Accession 14 was significantly stronger than Accessions
16 (𝑝 = 0.022), 17 (𝑝 = 0.028), and 24 (𝑝 = 0.047)
in protecting the cells. However, none of the samples were
significantly different from the PBS or vehicle ethanol control.
For stimulated cells, Staphylococcus aureus treatment
(Figure 3(b)), there was a significant proinflammatory effect
of Accession 11 in comparison to Accession 16 (𝑝 = 0.028).
A significant proinflammatory response was also detected
for Accession 14 with regard to Accession 17 (𝑝 = 0.017).
However, none of the samples were significantly different
from the PBS or vehicle ethanol control.
With the Toll-like receptor ligand F. nucleatum treatment
(Figure 3(c)), a significant proinflammatory response was
detected for Accession 11 in comparison with the vehicle
control (𝑝 = 0.037) and also in comparison with Accession
17 (𝑝 = 0.017).
With PMA treatment (Figure 3(d)), Accessions 14, 16, and
17 showed significant anti-inflammatory activity in compari-
son to the PBS control (𝑝 = 0.038, 𝑝 = 0.028, and 𝑝 = 0.049)
but no significant difference was detected in comparisonwith
the vehicle control. There was also a significant difference
in anti-inflammatory effects among samples. Accessions 14
(𝑝 = 0.029) and 17 (𝑝 = 0.037) had significantly higher
activity than Accession 3, and Accessions 14 (𝑝 = 0.015)
and 17 (𝑝 = 0.031) had significantly higher activity than
Accession 11.
Neutrophils were also preincubated with standard solu-
tions (0.5 𝜇g/mL verbascoside and 0.5 𝜇g/mL harpagoside).
For unstimulated cells (PBS, Figure 4(a)), significant effects
against ROS production were observed for harpagoside and
verbascoside in comparison to PBS control (𝑝 = 0.043
and 𝑝 = 0.043, resp.). Verbascoside was also significantly
different to the vehicle control (𝑝 = 0.043) and to harpagoside
(𝑝 = 0.043). For stimulated cells, Staphylococcus aureus
and F. nucleatum treatments only identified a significant
difference between PBS and vehicle control (𝑝 = 0.043).
PMA treatment (Figure 4(b)) revealed a significant difference
between PBS and vehicle control (𝑝 = 0.043) and also
between verbascoside and PBS control and harpagoside (𝑝 =
0.043 and 𝑝 = 0.043, resp.).
Accessions 3 and 14 contained highest levels of verbasco-
side and isoverbascoside. Accession 11 contained the high-
est levels of harpagoside, pagoside, and 8-O-p-coumaroyl-
harpagide. Ouitas and Heard [30] have previously examined
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Figure 3: Luminol-detected total ROS production by neutrophils stimulated with (a) PBS (no stimulus), (b) opsonised Staphylococcus aureus,
(c) Fusobacterium nucleatum, and (d) PMA (25 nM) in the presence of PBS, ethanol, and Accessions 3, 11, 14, 16, 17, and 24 (𝑛 = 10). Error
bars: 95% CI. All sample results were compared by Wilcoxon two related samples tests.
a number of H. procumbens extracts for anti-inflammatory
activity and, in broad agreement with our study, have
shown some proinflammatory responses. The reported anti-
inflammatory effect by Qi et al. [31] was not replicated in
our report, which may be due to cell specific responses
and/or the differing properties of the various compounds
available in the extracts. In a previous study by Matthews et
al. [18] it was demonstrated that ascorbate may significantly
decrease the amount of ROS produced by healthy neutrophils
stimulated by PMA; however ascorbate was not detected in
our samples. Ethanol is known to decrease ROS production
by neutrophils [32] and can increase superoxide production
during PMA treatment of neutrophils [33]. In our studies
the PMA-mediated respiratory burst was clearly affected by
ethanol as shown by the vehicle control.
Bivariate Pearson rank correlation analysis identified
significant correlations between total phenols and FRAP (𝑅 =
0.991, 𝑝 = 0.000) as well as between total phenols, FRAP, and
PBS control (luminol-detected total ROS production) with
verbascoside (𝑅 = 0.934, 𝑝 = 0.006; 𝑅 = 0.903, 𝑝 = 0.014;
𝑅 = −0.931, 𝑝 = 0.007) and with isoverbascoside (𝑅 = 0.985,
𝑝 = 0.000; 𝑅 = 0.999, 𝑝 = 0.000; 𝑅 = −0.846, 𝑝 = 0.034).
We also noted significant correlation between total phenols
and FRAP with PBS control (luminol-detected total ROS
production) (𝑅 = −0.888, 𝑝 = 0.018; 𝑅 = −0.847, 𝑝 =
0.033). The high positive correlations between the content of
total phenols and verbascoside as well as with isoverbascoside
and the high negative correlation between total phenols and
FRAP as well as with the PBS control show that verbascoside
really is an important antioxidant phenol in Harpagophytum
and verifies the antioxidant activity of samples as revealed in
the unstimulated cell PBS control treatment.
The present pilot study revealed a tentative anti-
inflammatory effect of three Harpagophytum taxa using a
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Figure 4: Luminol-detected total ROS production by neutrophils stimulated with (a) PBS or (b) PMA (25 nM) in the presence of PBS,
ethanol, harpagoside (0.5 𝜇g/mL), and verbascoside (0.5 𝜇g/mL) (𝑛 = 5). Error bars: 95% CI. All sample results were compared by Wilcoxon
two related samples tests.
modest number of subjects. Future verifying studies using a
larger number of subjects should take into account gender
and age of volunteers, as well as the impact of single purified
constituents of the extracts on respiratory burst process in
vitro.
4. Conclusions
The accessions of different Harpagophytum taxa were shown
to be biochemically very variable with regard to content
of verbascoside, isoverbascoside, and analyzed iridoids, and
some accessions had very high antioxidant capacity.However,
we were unable to corroborate a general anti-inflammatory
effect forH. procumbens with the neutrophil model although
evidence of anti-inflammatory activity was noticed for three
taxa. In addition, the proinflammatory effect noticed for one
taxon needs further verification.
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